Alcon (ALC) 20-F 27 Feb 23 2022 FY Annual report (foreign) Financial data

Cover Page

Cover Page	12 Months Ended
	Dec. 31, 2022 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Current Fiscal Year End Date	--12-31
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-31269
Entity Registrant Name	Alcon Inc.
Entity Incorporation, State or Country Code	V8
Entity Address, Address Line One	Rue Louis-d'Affry 6
Entity Address, Postal Zip Code	1701
Entity Address, City or Town	Fribourg
Entity Address, Country	CH
Title of 12(b) Security	Ordinary Shares, nominal value CHF 0.04 per share
Trading Symbol	ALC
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding	490,086,981
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Central Index Key	0001167379
Business Contact
Document Information [Line Items]
Contact Personnel Name	Royce Bedward
Entity Address, Address Line One	Chemin de Blandonnet 8
Entity Address, Postal Zip Code	1214
Entity Address, Address Line Two	Vernier
Entity Address, City or Town	Geneva
Entity Address, Country	CH
City Area Code	817
Local Phone Number	293 0450
Contact Personnel Fax Number	1 817 916 2652

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Firm ID	238
Auditor Location	Fort Worth, Texas

Consolidated Income Statement

Consolidated Income Statement - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Profit or loss [abstract]
Net sales to third parties	$ 8,654	$ 8,222	$ 6,763
Other revenues	63	69	70
Net sales and other revenues	8,717	8,291	6,833
Cost of net sales	(3,910)	(3,577)	(3,830)
Cost of other revenues	(59)	(62)	(63)
Gross profit	4,748	4,652	2,940
Selling, general & administration	(3,068)	(3,076)	(2,694)
Research & development	(702)	(842)	(673)
Other income	36	43	235
Other expense	(342)	(197)	(290)
Operating income/(loss)	672	580	(482)
Interest expense	(134)	(120)	(124)
Other financial income & expense	(75)	(42)	(29)
Income/(loss) before taxes	463	418	(635)
Taxes	(128)	(42)	104
Net income/(loss)	$ 335	$ 376	$ (531)
Earnings/(loss) per share
Basic (in dollars per share)	$ 0.68	$ 0.77	$ (1.09)
Diluted (in dollars per share)	$ 0.68	$ 0.76	$ (1.09)
Weighted average number of shares outstanding
Basic (in shares)	491.4	490	489
Diluted (in shares)	494.4	493.4	489

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income/(Loss) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of comprehensive income [abstract]
Net income/(loss)		$ 335	$ 376	$ (531)
Other comprehensive income to be eventually recycled into the Consolidated Income Statement:
Currency translation effects, net of taxes	[1]	(36)	(58)	19
Total of items to eventually recycle		(36)	(58)	19
Other comprehensive income never to be recycled into the Consolidated Income Statement:
Actuarial gains/(losses) from defined benefit plans, net of taxes	[2]	141	26	(14)
Fair value adjustments on equity securities, net of taxes	[3]	(1)	0	(7)
Total of items never to be recycled		140	26	(21)
Total comprehensive income/(loss)		$ 439	$ 344	$ (533)
[1]Amounts are net of tax expense of $0.4 million in 2022 and net of tax benefit of $6 million in 2021.[2] Amounts are net of tax expense of $40 million and $11 million in 2022 and 2021, respectively, and net of tax benefit of $13 million in 2020.

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income/(Loss) (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of comprehensive income [abstract]
Currency translation effects, tax expense (benefit)	$ 0.4	$ (6)
Actuarial gains/(losses) from defined benefit plans, tax expense (benefit)	40	$ 11	$ (13)
Fair value adjustments on equity securities, tax expense (benefit)	$ (1)		$ (3)

Consolidated Balance Sheet

Consolidated Balance Sheet SFr in Millions, $ in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Non-current assets
Property, plant & equipment	$ 4,025	$ 3,711
Right-of-use assets	391	372
Goodwill	8,970	8,905
Intangible assets other than goodwill	9,689	8,765
Deferred tax assets	411	409
Financial assets	287	217
Other non-current assets	243	234
Total non-current assets	24,016	22,613
Current assets
Inventories	2,109	1,899
Trade receivables	1,673	1,496
Income tax receivables	13	9
Cash and cash equivalents	980	1,575
Other current assets	418	407
Total current assets	5,193	5,386
Total assets	29,209	27,999
Equity
Share capital	20	20
Reserves	19,657	19,236
Total equity	19,677	19,256
Non-current liabilities
Financial debts	4,541	3,966
Lease liabilities	359	339
Deferred tax liabilities	1,064	1,026
Provisions & other non-current liabilities	786	940
Total non-current liabilities	6,750	6,271
Current liabilities
Trade payables	861	903
Financial debts	107	114
Lease liabilities	71	67
Current income tax liabilities	219	187
Provisions & other current liabilities	1,524	1,201
Total current liabilities	2,782	2,472
Total liabilities	9,532	8,743
Total equity and liabilities	$ 29,209	$ 27,999

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Millions		Total	Share capital	Other reserves	Fair value adjustments on equity securities	Actuarial gains/(losses) from defined benefit plans	Cumulative currency translation effects	Total value adjustments	[1]
Beginning balance at Dec. 31, 2019		$ 19,303	$ 20	$ 19,355	$ (25)	$ (72)	$ 25	$ (72)
Net income/(loss)		(531)		(531)
Other comprehensive income/(loss)		(2)			(7)	(14)	19	(2)
Total comprehensive income/(loss)		(533)		(531)	(7)	(14)	19	(2)
Equity-based compensation		70		70
Other movements	[2]	(18)		5		(23)		(23)
Total other movements		52		75		(23)		(23)
Ending balance at Dec. 31, 2020		18,822	20	18,899	(32)	(109)	44	(97)
Net income/(loss)		376		376
Other comprehensive income/(loss)		(32)			0	26	(58)	(32)
Total comprehensive income/(loss)		344		376	0	26	(58)	(32)
Dividends		(53)		(53)
Equity-based compensation		124		124
Other movements	[2]	19		10		9		9
Total other movements		90		81		9		9
Ending balance at Dec. 31, 2021		19,256	20	19,356	(32)	(74)	(14)	(120)
Net income/(loss)		335		335
Other comprehensive income/(loss)		104			(1)	141	(36)	104
Total comprehensive income/(loss)		439		335	(1)	141	(36)	104
Dividends		(102)		(102)
Equity-based compensation		68		68
Other movements	[2]	16		16				0
Total other movements		(18)		(18)		0		0
Ending balance at Dec. 31, 2022		$ 19,677	$ 20	$ 19,673	$ (33)	$ 67	$ (50)	$ (16)
[1]"Total value adjustments" are presented net of the corresponding tax effects.[2]    Activity includes hyperinflationary accounting (see Note 2 to the Consolidated Financial Statements). The prior year primarily includes an adjustment to actuarial gains to recognize plan assets related to the separation of a pension plan in the spin-off from Novartis but which were not previously recorded. The year ended December 31, 2020 includes an adjustment to actuarial (losses) for other post-employment benefit obligation assumption changes directly related to the spin-off on April 9, 2019 but which was not recorded at that time.

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of cash flows [abstract]
Net income/(loss)	$ 335	$ 376	$ (531)
Adjustments to reconcile net income/(loss) to net cash flows from operating activities
Depreciation, amortization, impairments and fair value adjustments	1,111	1,220	1,626
Equity-based compensation expense	140	138	105
Non-cash change in current and non-current provisions and other non-current liabilities	187	57	(106)
Losses on disposal and other adjustments on property, plant & equipment and other non-current assets, net	10	13	42
Interest expense	134	120	124
Other financial income & expense	75	42	29
Taxes	128	42	(104)
Interest received	14	3	5
Interest paid	(111)	(108)	(105)
Other financial payments	(7)	(7)	(5)
Taxes paid	(178)	(175)	(97)
Net cash flows before working capital changes and net payments out of provisions and other non-current liabilities	1,838	1,721	983
Net payments out of provisions and other cash movements in non-current liabilities	(99)	(62)	(115)
Change in net current assets and other operating cash flow items	(522)	(314)	(45)
Net cash flows from operating activities	1,217	1,345	823
Purchase of property, plant & equipment	(636)	(700)	(479)
Proceeds from sale of property, plant & equipment	0	0	6
Purchase of intangible assets	(109)	(480)	(88)
Purchase of financial assets	(50)	(19)	(11)
Proceeds from financial assets	2	1	0
Proceeds from sale of short-term investments	79	0	0
Acquisitions of assets, net of cash acquired	(485)	0	0
Acquisition of business, net of cash acquired	(666)	0	0
Net cash flows used in investing activities	(1,865)	(1,198)	(572)
Dividends paid to shareholders of Alcon Inc.	(100)	(54)	0
Proceeds from non-current financial debts, net of issuance costs	1,815	52	744
Proceeds from 2022 Bridge Loan Facility, net of issuance costs	771	0	0
Repayment of non-current financial debts	(1,176)	0	0
Repayment of 2022 Bridge Loan Facility	(775)	0	0
Repayment of financial debts assumed in acquisition of business	(316)	0	0
Change in current financial debts	(42)	(43)	(139)
Lease payments	(69)	(72)	(69)
Payment of withholding taxes related to equity-based compensation	(50)	(22)	(16)
Other financing cash flows	(66)	16	(54)
Net cash flows (used in)/from financing activities	(8)	(123)	466
Effect of exchange rate changes on cash and cash equivalents	61	(6)	18
Net change in cash and cash equivalents	(595)	18	735
Cash and cash equivalents at January 1	1,575	1,557	822
Cash and cash equivalents at December 31	$ 980	$ 1,575	$ 1,557

Description of business

Description of business	12 Months Ended
	Dec. 31, 2022
Corporate Information And Statement Of IFRS Compliance [Abstract]
Description of business	Description of business Alcon Inc. (the "Company") and the subsidiaries it controls (collectively "Alcon") is a leading eye care company. Alcon is a multinational company specializing in the research, development, manufacturing and marketing of a broad range of eye care products within two businesses: Surgical and Vision Care. Alcon is a stock corporation organized under the laws of Switzerland, domiciled in Fribourg, Switzerland, with global headquarters located in Geneva, Switzerland. The shares of the Company are listed on the SIX Swiss Stock Exchange ("SIX") and on the New York Stock Exchange ("NYSE") under the symbol “ALC”. The Consolidated Financial Statements of Alcon are comprised of the Consolidated Balance Sheet as of December 31, 2022 and 2021 and the Consolidated Income Statement, Consolidated Statement of Comprehensive Income/(Loss), Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows for each of the years ended December 31, 2022, 2021 and 2020.

Selected accounting policies

Selected accounting policies	12 Months Ended
	Dec. 31, 2022
Corporate Information And Statement Of IFRS Compliance [Abstract]
Selected accounting policies	Selected accounting policies Basis of preparation The accompanying Consolidated Financial Statements present our historical financial position, results of operations, comprehensive income/(loss), and cash flows in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Alcon's principal accounting policies are described in this Note. Principles of consolidation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. In the event that the Company has an interest in another entity that is not wholly owned, the assets, liabilities, results of operations and cash flows of such entity are included in the Company's Consolidated Financial Statements, if the Company is exposed or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Consolidated Financial Statements of the Company are prepared in accordance with IFRS as issued by the IASB. They are prepared in accordance with the historical cost convention except for items that are required to be accounted for at fair value. All intercompany transactions and accounts within Alcon were eliminated. The Company's financial year-end is December 31, which is also the annual closing date of the individual entities' financial statements incorporated into the Consolidated Financial Statements. Use of estimates and assumptions The preparation of Consolidated Financial Statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year that affect the reported amounts of assets and liabilities as well as revenues and expenses. Alcon has analyzed the impact of the war on Ukraine, economic sanctions and export controls on Russia and the COVID-19 pandemic on the Consolidated Financial Statements for the years ended December 31, 2022, 2021 and 2020. Alcon has assessed various accounting estimates and other matters, including those that require consideration of forecasted financial information, in the context of the unknown future impacts of these and other events using information reasonably available to us at this time. The accounting estimates and other matters assessed included, but were not limited to, provisions for expected credit losses, goodwill and other intangible assets, financial instruments, inventory provisions, associate benefits, income taxes and revenue recognition. Based on the assessment performed, the resulting provisions recorded were not material to the Consolidated Financial Statements. However, because of the inherent uncertainties of the continuation of the war on Ukraine, COVID-19 or other items, actual outcomes and results may differ materially from management's current assumptions and estimates. Foreign currencies The Consolidated Financial Statements are presented in US dollars ("USD"). The functional currency of individual entities incorporated into the Consolidated Financial Statements is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. For entities not operating in hyperinflationary economies, the entities results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: • Income, expense and cash flows using for each month the average exchange rate with the USD values for each month being aggregated during the year. • Balance sheet using year-end exchange rates. • Resulting exchange rate differences are recognized in other comprehensive income/(loss). The hyperinflationary economies in which Alcon operates are Argentina, Turkey and Venezuela. Argentina and Venezuela were hyperinflationary for all years presented. Turkey became hyperinflationary effective April 1, 2022, requiring retroactive implementation from January 1, 2022 of hyperinflationary accounting. The impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period an economy becomes hyperinflationary is recorded in "Other reserves" in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets and liabilities are recorded in "Other financial income & expense" in the Consolidated Income Statement. Acquisition of assets Assets separately acquired are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. The capitalized cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost. Property, plant and equipment Property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset or "Cost of net sales" in the Consolidated Income Statement. Property, plant and equipment are assessed for impairment at the cash generating unit ("CGU") level whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. The following table shows the respective useful lives for property, plant and equipment: Useful life Buildings and improvements 10 to 40 years Machinery and other equipment Machinery and equipment 5 to 20 years Furniture and vehicles 5 to 10 years Computer hardware 3 to 7 years Business combinations Effective January 1, 2020, Alcon adopted Amendments to IFRS 3, Business Combinations . The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary may include: • Fair values of the assets transferred; • Liabilities incurred to the former owners of the acquired business; • Equity interests issued by the Company; • Fair value of an asset or liability resulting from a contingent consideration arrangement; and • Fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The excess of the consideration transferred over the fair value of the net identifiable assets acquired is recorded as goodwill, or directly in the income statement if it is a bargain purchase. Alcon primarily uses net present value techniques, utilizing post-tax cash flows and discount rates in estimating the fair value of identifiable assets acquired when allocating the purchase consideration paid for the acquisition. The estimates of the fair values involve significant judgment by management and include assumptions with measurement uncertainty such as, the amount and timing of projected cash flows, long-term sales forecasts, the timing and probability of regulatory and commercial success, and the discount rate. Acquisition related costs are expensed as incurred. Alcon may elect on a transaction-by-transaction basis to apply the optional concentration test to assess whether a transaction qualifies as a business. Under the test, when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, Alcon will account for the transaction as an asset purchase and not a business combination. If the concentration test is not met, or Alcon elects not to apply this optional test, Alcon will perform an assessment focusing on the existence of inputs and processes that have the ability to create outputs to determine whether the transaction is an asset purchase or a business combination. Goodwill and intangible assets The annual impairment testing date is Alcon's financial year-end, December 31. Goodwill Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of CGUs which are usually represented by the reportable segments, which are the same as Alcon's operating segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under "Other expense" in the Consolidated Income Statement. Intangible assets available for use Alcon has the following classes of available-for-use intangible assets: Currently marketed products, Marketing know-how, Technologies, Other intangible assets (including computer software) and the Alcon brand name. Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names. Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. Technologies represent identified and separable acquired know-how used in the research, development and production processes. Significant investments in internally developed and acquired software are capitalized and included in the "Other" category and amortized once available for use. The Alcon brand name is shown separately as it is the only Alcon intangible asset that is available for use with an indefinite useful life. Alcon considers it appropriate that the brand name has an indefinite life since the branded products have a history of strong revenue and cash flow performance, and Alcon has the intent and ability to support the brand with spending to maintain its value for the foreseeable future. Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually. The following table shows the respective useful lives for available-for-use intangible assets and the location in the Consolidated Income Statement in which the respective amortization and any potential impairment charge is recognized: Useful life Income statement location for Currently marketed products 5 to 20 years "Cost of net sales" Marketing know-how 25 years "Cost of net sales" Technologies 10 to 20 years "Cost of net sales" or "Research and Development" Other (including software) 3 to 10 years In the respective functional expense Alcon brand name Not amortized, indefinite useful life "Other expense" Acquired In-Process Research & Development ("IPR&D") Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as IPR&D. IPR&D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. IPR&D is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal ("FVLCOD") and its value in use ("VIU"). Usually, Alcon applies the FVLCOD method for its impairment assessments. Under this approach when evaluating IPR&D for potential impairment, FVLCOD is estimated using net present value techniques utilizing post-tax cash flows and discount rates as there are no direct or indirect observable prices in active markets for identical or similar assets. The estimates used in calculating the net present values involve significant judgment by management and include assumptions with measurement uncertainty such as, the amount and timing of projected cash flows, long-term sales forecasts, discount rate, and the timing and probability of regulatory and commercial success. In the limited cases where the VIU method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. Any impairment charge is recorded in the Consolidated Income Statement under "Research & development". Once a project included in IPR&D has been successfully developed it is transferred to the "Currently marketed products" category. Impairment of goodwill, Alcon brand name and definite lived intangible assets A CGU to which goodwill has been allocated (reportable segments) is considered impaired when its carrying amount, including the goodwill, exceeds its recoverable amount, which is defined as the higher of its FVLCOD and its VIU. If the recoverable amount of the reportable segment is less than its carrying amount, an impairment loss shall be recognized. The impairment loss shall be allocated to reduce the carrying amount of any goodwill allocated to the reportable segment first, with any remaining impairment loss allocated to other assets of the reportable segment on a pro-rata basis of their carrying amount. An intangible asset other than goodwill is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its FVLCOD and its VIU. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset shall be reduced to its recoverable amount. That reduction is an impairment loss. Usually, Alcon applies the FVLCOD method for its impairment assessment. In most cases, no direct or indirect observable market prices for identical or similar assets are available to measure the FVLCOD. Therefore, an estimate of FVLCOD is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the VIU method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. FVLCOD reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. The estimates used in calculating the net present values involve significant judgment by management and include assumptions with measurement uncertainty, such as the following: • Amount and timing of projected cash flows; • Long-term sales forecasts for periods of up to 25 years including sales growth rates; • Royalty rate for the Alcon brand name; • Terminal growth rate; and • Discount rate. Other assumptions used in the net present values calculation include: • Future tax rate; • Actions of competitors (launch of competing products, marketing initiatives, etc.); and • Outcome of R&D activities and forecast of related costs (future product developments). Generally, for intangible assets with a definite useful life Alcon uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Alcon generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections considering the long-term expected growth rates and impact of demographic trends of the population to which Alcon products are prescribed, for later periods. Probability-weighted scenarios are typically used. Discount rates used consider Alcon estimated weighted average cost of capital adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant. Actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using net present value techniques. Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, and other short-term and highly liquid investments. Other short-term and highly liquid investments are classified as cash and cash equivalents when original or weighted-average maturities are three months or less and amounts are readily convertible to known amounts of cash which are subject to an insignificant risk of changes in value. Bank overdrafts are usually presented within current financial debts on the Consolidated Balance Sheet except in cases where a right of offset has been agreed with a bank which then allows for presentation on a net basis. Financial assets Non-current financial assets such as loans and long-term receivables from customers, primarily related to surgical equipment sales arrangements, advances and other deposits, are carried at amortized cost, which reflects the time value of money, less any allowances for uncollectable amounts. Alcon assesses on a forward-looking basis the expected credit losses associated with its non-current financial assets valued at amortized cost. For loans, advances and other deposits valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in "Other expense" in the Consolidated Income Statement and exchange rate gains and interest income, using the effective interest rate method, are included in "Other income" in the Consolidated Income Statement. For long-term receivables from customers, provisions for uncollectable amounts, which are based on their expected credit losses, are recorded as marketing and selling costs recognized in the Consolidated Income Statement within "Selling, general & administration" expenses. Fund investments are valued at fair value through profit and loss ("FVPL"). Unrealized gains and losses, including exchange gains and losses, are recognized in the Consolidated Income Statement in "Other income" for gains and "Other expense" for losses. Equity securities and convertible notes receivable held as strategic investments are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income ("FVOCI") with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the Consolidated Statement of Comprehensive Income/(Loss). They are reclassified to "Other reserves" when the equity security is sold. If these equity securities and convertible notes receivable are not designated at the date of acquisition as financial assets valued at FVOCI, they are valued at FVPL, as described above for fund investments. Changes in fair value of options to acquire development stage companies are charged to research and development expense. Derivative financial instruments are initially recognized in the Consolidated Balance Sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of forward exchange rate contracts and foreign exchange swaps are based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. Unsettled forward contracts and swaps are measured at fair value at quarter-end with changes in fair value recorded to the Consolidated Income Statement as unrealized gains or losses in "Other financial income & expense". Settled forward contracts and swaps are measured at maturity date at fair value with corresponding realized gains or losses recognized in the Consolidated Income Statement in "Other financial income & expense". No hedge accounting is applied for these arrangements. Inventories Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the "Cost of net sales" and "Cost of other revenues" in the Consolidated Income Statement. Unsalable inventory is fully written off in the Consolidated Income Statement under "Cost of net sales" and "Cost of other revenues". Trade receivables Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as chargebacks and cash discounts. Provisions for expected credit losses are established using an expected credit loss model ("ECL"). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable's carrying amount and the estimated net collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the Consolidated Income Statement within "Selling, general & administration" expenses. Leases As lessee, Alcon assesses whether a contract contains a lease at inception of a contract based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Alcon recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases for which Alcon has elected the recognition exemptions allowed under IFRS 16. Right-of-use assets Right-of-use assets are initially recognized at cost, which is comprised of the amount of the initial measurement of the corresponding lease liabilities, adjusted for any lease payments made at or prior to the commencement date of the lease, lease incentives received and initial direct costs incurred, as well as any expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. Right-of-use assets are depreciated on a straight-line basis over the shorter of the useful life of the right-of-use asset or the end of the lease term. Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. Lease liabilities Lease liabilities are accounted for at amortized cost and are initially measured at the present value of future lease payments and are classified as current or non-current based on the due dates of the underlying principal payments. In determining the lease term, Alcon evaluates the renewal options and termination options reasonably certain to be exercised. Lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the incremental borrowing rate Alcon would be expected to pay within the respective markets, on a borrowing with a similar term and security. Interest in the period is recorded within "Interest expense" in the Consolidated Income Statement. Lease liabilities are remeasured for changes in estimated lease term, future lease payments arising from a change in an index or rate, amounts expected to be payable under a residual value guarantee, or in assessment of whether Alcon will exercise a purchase, extension or termination option. Changes to initial lease contract terms are assessed to determine their impact on the scope of lease, and any modifications increasing the scope of the lease are treated as new contracts under the initial measurement principles, while modifications that do not increase or that decrease the scope of the lease result in an adjustment to the right-of-use asset which is remeasured as of the date of the modification. Principal payments made on lease liabilities and any initial direct costs paid are classified as financing cash outflows, while interest payments are classified as operating cash outflows. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the Consolidated Income Statement and are classified as cash flows from operating activities. Legal liabilities Alcon is subject to contingencies arising in the ordinary course of business such as patent litigation and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes. Contingent consideration In a business combination, it is necessary to recognize contingent future payments to previous owners representing contractually defined potential amounts as a liability. Usually for Alcon, these are linked to development or commercial milestones related to certain assets and are recognized as a financial liability at their fair value, which is then re-measured at each subsequent reporting date. For the determination of the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the timing and probability of regulatory and commercial success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, appropriately discounted to reflect the impact of time. Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the Consolidated Income Statement in "Cost of net sales" for currently marketed products and in "Research & development" for IPR&D. The effect of unwinding the discount over time is recognized in "Interest expense" in the Consolidated Income Statement. Alcon accounts for variable or contingent consideration associated with asset acquisitions using the cost accumulation model. At the date of the asset acquisition, the intangible asset is initially recognized at the amount paid. Variable payments are subsequently capitalized as part of the cost of the asset when paid, on the basis that such payments represent the direct cost of acquisition. Defined benefit pension plans and other post-employment benefits The liability or asset recognized in the balance sheet in respect of defined benefit pension plans and other post-employment benefits is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating the terms of the related obligation. In countries where there is no sufficient market for such bonds, the market rates on government bonds are used. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed. The net interest on the net defined benefit liability is recognized as "Other expense" or "Other income". The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. Past service cost is recognized as "Other expense" or "Other income" in the Consolidated Income Statement for the change in the present value of a defined benefit obligation for employee service in prior periods resulting from a plan amendment or a curtailment. Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income/(loss). Defined contribution plans For defined contribution plans, Alcon contributes to publicly or privately administered plans. Alcon has no further payment obligations once the contributions have been paid. The contributions are included in the personnel expenses of the various functions where the associates are employed. Financial debts Financial debts are initially recognized at fair value, net of transaction costs incurred. Financial debts are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs and discounts) and the redemption amount is recognized in the Consolidated Income Statement over the period of the financial debts using the effective interest method. Fees paid on the establishment of credit facilities are recognized as transaction costs of the financial debt to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent that there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalized as a prepayment for liquidity services and amortized over the period of the facility to which it relates, and is recognized in "Other financial income & expense" in the Consolidated Income Statement. Financial debts are derecognized from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial debt that has been extinguished and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in "Other financial income & expense" in the Consolidated Income Statement. Interest paid on financial debts is classified as operating activities in the Consolidated Statement of Cash Flows. Financial debts are classified as current liabilities unless Alcon has an unconditional right and intent to defer the settlement of the liability for at least twelve months after the reporting period. Revenue Net sales to third parties Revenue on the sale of Alcon products and services, which is recorded as "Net sales to third parties" in the Consolidated Income Statement, is recognized when a contractual promise to a customer (i.e., a performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue would be recognized upon the satisfaction of acceptance criteria. The amount of revenue to be recognized is based on the consideration Alcon expects to receive in exchange for its goods and services. If a contract contains more than one performance obligation, the consideration is allocated based on the relative standalone selling price of each performance obligation. Surgical equipment may be sold together with other products and services under a single contract and may be structured as an outright cash sale, an installment sale, or lease. Surgical equipment installment sales and leases have a fixed payment amount which the customer may pay either in fixed intervals or as the customer purchases consumables and/or implantables. Revenues are recognized upon satisfaction of each of the performance obligations in the contract and the consideration is allocated based on the relative standalone selling price of each performance obligation. • Surgical equipment revenue from outright cash sales and installment sales arrangements is recognized at the point in time when control is transferred to the customer. The current portion of long-term receivables from customers and long-term receivables from customers for installment sales arrangements are recorded in "Other current assets" (see "Current portion of long-term receivables from customers" in Note 14 of these Consolidated Financial Statements) and "Financial assets" (see "Long-term receivables from customers" in Note 11 of these Consolidated Financial Statements), respectively. Financing income for installment sales arrangements longer than twelve months is recognized over the term of the arrangement in "Other income". Alcon applies the practical expedien

Significant transactions

Significant transactions	12 Months Ended
	Dec. 31, 2022
Significant Transactions [Abstract]
Significant transactions	Significant transactions Significant transactions in 2022 Vision Care - Acquisition of Aerie Pharmaceuticals, Inc. On November 21, 2022, Alcon acquired 100% of the outstanding shares and equity of Aerie Pharmaceuticals, Inc. ("Aerie"), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies. Pursuant to the terms of the Agreement and Plan of Merger, Alcon paid $15.25 per share to acquire all outstanding shares of Aerie's common stock. The total purchase consideration amounted to $744 million and total cash paid for the net identifiable assets recognized, net of cash acquired, was $666 million. Alcon also assumed debt of $316 million. This transaction was accounted for as a business combination that resulted in goodwill of $65 million. Refer to Note 21.1 to these Consolidated Financial Statements for additional information regarding the acquisition. The total purchase consideration was funded with proceeds from a bridge loan facility agreement (the "2022 Bridge Loan Facility") on November 21, 2022. Refer to Note 16 to these Consolidated Financial Statements for additional information regarding the 2022 Bridge Loan Facility. Series 2032 Notes and Series 2052 Notes issuance On December 6, 2022, Alcon, through its wholly owned subsidiary Alcon Finance Corporation (“AFC”), completed a private offering of non-current financial debt consisting of $700 million of 5.375% senior notes due 2032 and $600 million of 5.750% senior notes due 2052. The funds borrowed through the issuance, together with cash, were used to repay the remaining $640 million Facility B term loan and the $775 million 2022 Bridge Loan Facility. Refer to Note 16 to these Consolidated Financial Statements for additional information. Vision Care - Acquisition of Eysuvis and Inveltys products On July 8, 2022, Alcon acquired two pharmaceutical ophthalmic eye drops, Eysuvis and Inveltys , from Kala Pharmaceuticals, Inc. The acquisition complements Alcon’s existing portfolio in the large and fast-growing dry eye category. Pursuant to the terms of the Asset Purchase Agreement, Alcon paid total upfront consideration of $60 million for Eysuvis and Inveltys, paid an additional amount to purchase certain related inventory and assumed certain liabilities of approximately $14 million for a purchase consideration of $79 million. In addition, Alcon agreed to potentially pay additional amounts upon achievement of certain commercial milestones if annual sales exceed defined targets that expire after 2029. The purchase consideration was allocated using the relative fair value approach primarily to currently marketed product intangible assets within the Vision Care reportable segment of $71 million and assumed liabilities of $14 million. Series 2028 Notes issuance On May 31, 2022, Alcon, through its wholly owned subsidiary Alcon Finance B.V. (“AFBV”), completed a public offering of $537 million (EUR500 million) of non-current EUR denominated financial debt consisting of 2.375% senior notes due 2028. The funds borrowed through the issuance were used to repay the $376 million (EUR350 million) Facility C term loan in full and partially repay $160 million of the Facility B term loan. Refer to Note 16 to these Consolidated Financial Statements for additional information. Surgical - Acquisition of Ivantis, Inc. On January 7, 2022, Alcon acquired 100% of the outstanding shares and equity of Ivantis, Inc., a privately-held, US-based company and manufacturer of the Hydrus Microstent, a minimally-invasive glaucoma surgery (“MIGS”) device designed to lower intraocular pressure for open-angle glaucoma patients, for total upfront consideration of $479 million and additional amounts to be potentially paid upon achievement of development and commercial milestones. The acquisition expands Alcon’s surgical portfolio and is expected to help provide a platform for more growth in the glaucoma space. Refer to Note 21.2 to these Consolidated Financial Statements for additional information regarding this transaction which was accounted for as an asset acquisition. Significant transactions in 2021 Vision Care - Acquisition of Simbrinza US commercialization rights On April 28, 2021, Alcon executed an Asset Purchase Agreement (“Agreement”) to acquire exclusive US commercialization rights to a pharmaceutical ophthalmic eye drop, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under the terms of the Agreement, Alcon paid $355 million at closing on June 8, 2021 and recognized the intangible asset acquisition as currently marketed products within the Vision Care reportable segment. After closing, Alcon and Novartis immediately began a transition period during which Novartis sold Simbrinza on Alcon's behalf. The transition period concluded during the third quarter of 2021 and Alcon began to fully commercialize Simbrinza for the US market. Novartis retains all rights to Simbrinza® outside of the US. Significant transactions in 2020 Series 2030 Notes issuance On May 27, 2020, Alcon, through its wholly owned subsidiary AFC, completed an offering of $750 million of non-current financial debt consisting of 2.600% senior notes due 2030. The senior notes are described in Note 16 of these Consolidated Financial Statements.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Operating Segments [Abstract]
Segment information	Segment information The segment information disclosed in these Consolidated Financial Statements reflects historical results consistent with the identifiable reportable segments of Alcon and financial information that the Chief Operating Decision Maker ("CODM") reviews to evaluate segmental performance and allocate resources among the segments. The CODM is the Executive Committee of Alcon. The businesses of Alcon are divided operationally on a worldwide basis into two identified reportable segments, Surgical and Vision Care. Alcon's reportable segments are the same as its operating segments as Alcon does not aggregate any operating segments in arriving at its reportable segments. As indicated below, certain income and expenses are not allocated to segments. Reportable segments are presented in a manner consistent with the internal reporting to the CODM. The reportable segments are managed separately due to their distinct needs and activities for research, development, manufacturing, distribution and commercial execution. The Executive Committee of Alcon is responsible for allocating resources and assessing the performance of the reportable segments. In Surgical, Alcon researches, develops, manufactures, distributes and sells ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio also includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end procedure needs of the ophthalmic surgeon. In Vision Care, Alcon researches, develops, manufactures, distributes and sells daily disposable, reusable, and color-enhancing contact lenses and a comprehensive portfolio of ocular health products, including products for dry eye, glaucoma, contact lens care and ocular allergies, as well as ocular vitamins and redness relievers. Alcon also provides services, training, education and technical support for both the Surgical and Vision Care businesses. The basis of preparation and the selected accounting policies mentioned in Note 2 of these Consolidated Financial Statements are used in the reporting of segment results. The Executive Committee of Alcon evaluates segmental performance and allocates resources among the segments primarily based on net sales and segment contribution. Net identifiable assets are not assigned to the segments in the internal reporting to the CODM, and are not considered in evaluating the performance of the business segments by the Executive Committee of Alcon. Segment contribution excludes amortization and impairment charges for acquired product rights or other intangibles, general and administrative expenses for corporate activities, separation costs, transformation costs, fair value adjustments to contingent consideration liabilities, past service costs primarily for post-employment benefit plan amendments, acquisition and integration related costs and certain other income and expense items. General & administration (corporate) includes the costs of the Alcon corporate headquarters, including all related corporate function costs. Other income and expense items excluded from segment contribution include fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, net gains and losses on fund investments and equity securities valued at FVPL, restructuring costs, legal provisions and settlements and other income and expense items not attributed to a specific segment. Net sales and other revenues by segment ($ millions) 2022 2021 2020 Surgical Implantables 1,725 1,522 1,126 Consumables 2,499 2,388 1,952 Equipment/other 821 793 632 Total Surgical net sales to third parties 5,045 4,703 3,710 Vision Care Contact lenses 2,192 2,139 1,838 Ocular health 1,417 1,380 1,215 Total Vision Care net sales to third parties 3,609 3,519 3,053 Total net sales to third parties 8,654 8,222 6,763 Vision Care other revenues 63 69 70 Total net sales and other revenues 8,717 8,291 6,833 Segment contribution and reconciliation to income/(loss) before taxes ($ millions) 2022 2021 2020 Segment contribution Surgical 1,336 1,184 672 Vision Care 600 604 419 Total segment contribution 1,936 1,788 1,091 Not allocated to segments: Amortization of intangible assets (653) (590) (1,078) Impairment charges on intangible assets (62) (225) (167) General & administration (corporate) (255) (251) (232) Separation costs — (36) (217) Transformation costs (119) (68) (49) Fair value adjustments to contingent consideration liabilities 23 42 63 Past service costs for post-employment benefit plan amendments — 18 154 Acquisition and integration related costs (64) — — Other (134) (98) (47) Operating income/(loss) 672 580 (482) Interest expense (134) (120) (124) Other financial income & expense (75) (42) (29) Income/(loss) before taxes 463 418 (635) Included in segment contribution are: ($ millions) 2022 2021 2020 Depreciation of property, plant & equipment: Surgical (131) (129) (122) Vision Care (198) (194) (171) Not allocated to segments (1) — — Total depreciation of property, plant & equipment (330) (323) (293) Depreciation of right-of-use assets: Surgical (46) (50) (47) Vision Care (30) (31) (32) Total depreciation of right-of-use assets (76) (81) (79) Impairment charges on property, plant & equipment, net: Surgical (2) — (6) Vision Care — — — Total impairment charges on property, plant & equipment, net (2) — (6) Equity-based compensation: Surgical (74) (74) (55) Vision Care (61) (60) (45) Not allocated to segments (17) (17) (13) Total equity-based compensation (152) (151) (113) Geographical information The following table shows the United States, International and countries that accounted for more than 5% of at least one of the respective Alcon totals, for net sales for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets at December 31, 2022 and 2021: Net sales (2) Total of selected non-current assets (3) ($ millions unless indicated otherwise) (1) 2022 2021 2020 2022 2021 Country United States 3,897 45 % 3,651 44 % 2,975 44 % 11,739 51 % 10,200 47 % International 4,757 55 % 4,571 56 % 3,788 56 % 11,336 49 % 11,553 53 % thereof: Switzerland (country of domicile) 59 1 % 60 1 % 55 1 % 9,462 41 % 9,762 45 % Japan 568 7 % 621 8 % 650 10 % 44 — % 46 — % China 474 5 % 486 6 % 383 6 % 9 — % 16 — % Other 3,656 42 % 3,404 41 % 2,700 40 % 1,821 8 % 1,729 8 % Company total 8,654 100 % 8,222 100 % 6,763 100 % 23,075 100 % 21,753 100 % (1) International percentages may not sum due to rounding. (2) Net sales from operations by location of third-party customer. (3) Includes property, plant & equipment, right-of-use assets, goodwill and other intangible assets. No customer accounted for 10% or more of Alcon's net sales.

Interest expense and other fina

Interest expense and other financial income & expense	12 Months Ended
	Dec. 31, 2022
Analysis of income and expense [abstract]
Interest expense and other financial income & expense	Interest expense and other financial income & expense Interest expense ($ millions) 2022 2021 2020 Interest expense on financial debts (110) (95) (94) Interest expense from discounting long-term liabilities (9) (12) (17) Interest expense on lease liabilities (15) (13) (13) Total interest expense (134) (120) (124) Other financial income & expense ($ millions) 2022 2021 2020 Interest income 16 3 6 Loss on extinguishment of financial debt (5) — — Other financial expense (12) (10) (9) Monetary loss from hyperinflation accounting (16) (6) (4) Currency result, net (58) (29) (22) Total other financial income & expense (75) (42) (29)

Taxes

Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Taxes	Taxes Income/(loss) before taxes ($ millions) 2022 2021 2020 Switzerland 234 680 (585) Foreign 229 (262) (50) Total income/(loss) before taxes 463 418 (635) Current and deferred income tax (expense)/income ($ millions) 2022 2021 2020 Switzerland (17) (118) (14) Foreign (146) (116) (105) Current income tax expense (163) (234) (119) Switzerland 53 45 96 Foreign (18) 147 127 Deferred tax income 35 192 223 Total income tax (expense)/income (128) (42) 104 Analysis of tax rate Alcon's overall applicable tax rate can change each year since it is calculated as the weighted average tax rate based on pre-tax income/(loss) of each subsidiary. The main elements contributing to the difference between Alcon's overall applicable tax rate and the effective tax rate are summarized in the below table. 2022 2021 2020 ($ millions unless indicated otherwise) (1) % % % Applicable tax rate (104) 22.5 % (39) 9.3 % 98 15.4 % Effect of disallowed expenditures (13) 2.8 % (10) 2.4 % (20) (3.1) % Effect of equity-based compensation (13) 2.8 % (7) 1.7 % (5) (0.8) % Effect of income taxed at reduced rates 4 (0.9) % 1 (0.2) % 4 0.6 % Effect of tax credits and allowances 11 (2.4) % 9 (2.2) % 9 1.4 % Effect of deductibility of a statutory expense in Switzerland (2) 23 (5.0) % 38 (9.1) % — — % Effect of adjustments to contingent consideration and other liabilities 3 (0.6) % 7 (1.7) % 17 2.7 % Effect of option payments — — % (2) 0.5 % (6) (0.9) % Effect of tax rate changes — — % (3) 0.7 % 10 1.6 % Effect of changes in uncertain tax positions (3) 10 (2.2) % (39) 9.3 % (8) (1.3) % Effect of 2022 APA on prior years (37) 8.0 % — — % — — % Effect of non-deductible amortization (7) 1.5 % — — % — — % Effect of other items (2) 0.4 % (3) 0.7 % (10) (1.6) % Effect of prior year items (3) 0.6 % 6 (1.4) % 15 2.4 % Effective tax rate (128) 27.6 % (42) 10.0 % 104 16.4 % (1) Percentages may not sum due to rounding. (2) Effect of deductibility of statutory expense in Switzerland relates to agreements for fiscal years 2022 and 2021. It is uncertain whether Alcon will obtain a similar benefit in future years. (3) Effect of changes in uncertain tax positions in 2022 primarily relate to recognition of the benefit of the effect of deductibility of a statutory expense in Switzerland for 2021, partially offset by a reserve for the deductibility of a statutory expense in Switzerland for 2022. Effect of changes in uncertain tax positions in 2021 primarily relate to international transfer pricing and a partial reserve for the deductibility of a statutory expense in Switzerland. Alcon has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or are taxed at different rates in those tax jurisdictions. This results in a difference between Alcon's applicable tax rate and effective tax rate as shown in the table above. During the fourth quarter of 2022, Alcon recognized the impact of an Advanced Pricing Agreement between US and Switzerland tax authorities (the "2022 APA") related to the allocation and taxation of relevant Alcon profits between the US and Switzerland retroactive to 2019. The 2022 APA results in more profit being taxable at the rate applicable in the US compared to Alcon's historical filing position. As a result, in the fourth quarter of 2022 Alcon recorded a discrete item of $37 million of tax expense related to the 2019 through 2021 tax years and an increase of $64 million of tax expense for the current year, which is included in Alcon's effective tax rate. The 2022 APA was agreed upon in the first quarter of 2023 and is expected to be valid through 2027. The increase in the applicable tax rate for 2022 was primarily driven by more profit being taxable at the rate applicable in the US compared to Alcon’s historical filing position as a result of the 2022 APA. The applicable tax rate in 2021 and 2020 was impacted by pre-tax losses in certain tax jurisdictions. The fluctuation in taxes and effective tax rates is primarily due to the geographical pre-tax income and loss mix across certain tax jurisdictions relative to Alcon's consolidated income/(loss) before taxes, changes in uncertain tax positions and certain non-recurring items. Tax returns are subject to examination by competent taxing authorities, which may result in assessments being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.

Share capital, dividends and ea

Share capital, dividends and earnings/(loss) per share	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
Share capital, dividends and earnings/(loss) per share	Share capital, dividends and earnings/(loss) per share 7.1 Share capital The share capital of the Company as of December 31, 2022 is CHF 20 million, which is comprised of 499.7 million registered shares, nominal value of CHF 0.04 per share. The following table shows the movement in the shares: (shares in millions) Common stock shares outstanding Treasury stock shares Total shares January 1, 2020 488.3 3.4 491.7 Issuance of additional registered shares — 8.0 8.0 Settlement of equity-based awards 0.9 (0.9) — December 31, 2020 489.2 10.5 499.7 Settlement of equity-based awards 0.9 (0.9) — December 31, 2021 490.1 9.6 499.7 Settlement of equity-based awards 1.7 (1.7) — December 31, 2022 491.8 7.9 499.7 On November 10, 2020, the Company's Board of Directors approved an increase of CHF 320,000 out of the Company’s authorized share capital through the issuance of 8.0 million additional registered shares, nominal value CHF 0.04 per share, to fulfill the future vesting of existing and future equity-based awards. These additional shares were issued as treasury shares as part of the Company's authorized share capital according to the authority granted by the shareholders at the Company’s Annual General Meeting held on January 29, 2019 and reflected in the Company’s Articles of Incorporation as amended. While the transaction increased the number of shares available for issuance under the Company’s equity-based compensation plans, there was no immediate impact on the number of shares outstanding or earnings per share calculations at the time of the transaction. To the extent award settlement occurs through the use of treasury shares, the number of shares outstanding and earnings per share calculations will be impacted as shares are delivered to plan participants over the course of the next several years. All of the Company's 7.9 million shares held in treasury may only be used to fulfill the future vesting of existing and future equity-based awards. The authority to issue additional registered shares under the authorized share capital expired on January 29, 2021. 7.2 Dividends On February 15, 2022, the Company's Board of Directors proposed a dividend of CHF 0.20 per share, which was subsequently approved by the shareholders at the Annual General Meeting on April 27, 2022 and paid in May 2022 for an amount of $100 million. On February 23, 2021, the Company's Board of Directors proposed a dividend of CHF 0.10 per share, which was subsequently approved by the shareholders at the Annual General Meeting on April 28, 2021 and paid in May 2021 for an amount of $54 million. 7.3 Earnings/(loss) per share Basic earnings/(loss) per share is computed by dividing net income/(loss) for the period by the weighted average number of common shares outstanding during the period. For the years ended December 31, 2022, 2021 and 2020, the weighted average number of shares outstanding was 491.4 million, 490.0 million and 489.0 million shares, respectively. The only potentially dilutive securities are the outstanding unvested equity-based awards under the Company's equity-based incentive plans, as described in Note 23 to these Consolidated Financial Statements. Except when the effect would be anti-dilutive, the calculation of diluted earnings per common share includes the weighted average net impact of unvested equity-based awards. For the years ended December 31, 2022 and 2021, the weighted average diluted number of shares outstanding was 494.4 million and 493.4 million, respectively, which includes the potential conversion of 3.0 million and 3.4 million unvested equity-based awards, respectively. For the year ended December 31, 2020, 2.8 million unvested equity-based awards have been excluded from the calculation of diluted loss per share as their effect would be anti-dilutive.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Property, plant and equipment	Property, plant & equipment The following table summarizes the movements of property, plant & equipment in 2022: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2022 36 1,987 790 3,547 6,360 Additions — 10 554 123 687 Impact of business combination — 10 2 15 27 Disposals and derecognitions (1) — (13) (3) (172) (188) Reclassifications for assets placed in service — 127 (389) 262 — Currency translation effects (1) (30) 1 (81) (111) December 31, 2022 35 2,091 955 3,694 6,775 Accumulated depreciation January 1, 2022 — (802) (1) (1,846) (2,649) Depreciation charge — (92) — (238) (330) Impairment charge — — (2) — (2) Disposals and derecognitions (1) — 13 1 165 179 Currency translation effects — 11 — 41 52 December 31, 2022 — (870) (2) (1,878) (2,750) Net book value at December 31, 2022 35 1,221 953 1,816 4,025 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. As of December 31, 2022, commitments for purchases of property, plant & equipment were $248 million. The following table summarizes the movements of property, plant & equipment in 2021: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2021 35 1,884 573 3,425 5,917 Additions 2 8 654 57 721 Disposals and derecognitions (1) — (7) (8) (93) (108) Reclassifications for assets placed in service — 146 (410) 264 — Currency translation effects (1) (44) (19) (106) (170) December 31, 2021 36 1,987 790 3,547 6,360 Accumulated depreciation January 1, 2021 — (716) (8) (1,768) (2,492) Depreciation charge — (107) — (216) (323) Disposals and derecognitions (1) — 5 7 83 95 Currency translation effects — 16 — 55 71 December 31, 2021 — (802) (1) (1,846) (2,649) Net book value at December 31, 2021 36 1,185 789 1,701 3,711 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets [Abstract]
Goodwill and intangible assets	Goodwill and other intangible assets The following table summarizes the movements of goodwill and other intangible assets in 2022: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Cost January 1, 2022 8,905 2,980 737 5,369 4,803 5,960 658 20,507 Impact of business combination 65 — 175 — 850 — — 1,025 Impact of asset acquisitions — — 10 — 385 — 12 407 Additions — — — — 151 — 57 208 Disposals and derecognitions (1) — — (2) — — — (7) (9) December 31, 2022 8,970 2,980 920 5,369 6,189 5,960 720 22,138 Accumulated amortization January 1, 2022 — — (180) (5,238) (3,471) (2,622) (231) (11,742) Amortization charge — — — (40) (279) (239) (95) (653) Disposals and derecognitions (1) — — 2 — — — 6 8 Impairment charges — — (3) — (59) — — (62) December 31, 2022 — — (181) (5,278) (3,809) (2,861) (320) (12,449) Net book value at December 31, 2022 8,970 2,980 739 91 2,380 3,099 400 9,689 (1) Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. The following table summarizes the allocation of the net book values of goodwill and other intangible assets by reportable segment at December 31, 2022: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Surgical 4,544 — 564 91 583 3,099 240 4,577 Vision Care 4,426 — 175 — 1,797 — 160 2,132 Not allocated to segments — 2,980 — — — — — 2,980 Net book value at December 31, 2022 8,970 2,980 739 91 2,380 3,099 400 9,689 The Surgical and Vision Care reportable segments' CGUs, to which goodwill is allocated, are comprised of a group of smaller CGUs. The valuation method of the recoverable amount of the CGUs, to which goodwill is allocated, is based on the FVLCOD. The Alcon brand name is an intangible asset with an indefinite life. The intangible asset is not allocated to the reportable segments as it is used to market the Alcon-branded products of both the Surgical and Vision Care businesses. Net sales of these products together are the grouping of CGUs, which is used to determine the recoverable amount. The valuation method is based on the FVLCOD. The following assumptions were used in the calculations for the recoverable amounts of goodwill and the Alcon brand name at December 31, 2022 and 2021: 2022 2021 (As a percentage) Surgical Vision Care Surgical Vision Care Terminal growth rate 3.0 3.0 3.0 3.0 Discount rate (post-tax) 9.0 8.75 7.0 6.5 The Surgical and Vision Care reportable segments' terminal growth rate assumption of 3.0% takes into consideration how the industry is expected to grow, analysis of industry expert reports, and expected relevant changes in demographics for various markets. The discount rates for both Surgical and Vision Care reportable segments consider Alcon's weighted average cost of capital, adjusted to approximate the weighted average cost of capital of comparable market participants. Both the terminal growth rates and the discount rates are consistent with external sources of information. The FVLCOD, for all groupings of CGUs containing goodwill or indefinite life intangible assets, is reviewed for the impact of reasonably possible changes in key assumptions. In particular Alcon considered an increase in the discount rate, a decrease in the terminal growth rate and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment. Refer to "Impairment of goodwill, Alcon brand name and definite lived intangible assets" and "Acquired In-Process Research & Development ("IPR&D")" in Note 2 in these Consolidated Financial Statements for additional disclosures on how Alcon performs goodwill and intangible asset impairment testing. The following table summarizes the movements of goodwill and other intangible assets in 2021: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Cost January 1, 2021 8,905 2,980 727 5,369 4,440 5,960 556 20,032 Additions — — 20 — 359 — 104 483 Reclassifications — — (10) — 10 — — — Disposals and derecognitions (1) — — — — (6) — (2) (8) December 31, 2021 8,905 2,980 737 5,369 4,803 5,960 658 20,507 Accumulated amortization January 1, 2021 — — — (5,199) (3,197) (2,384) (155) (10,935) Amortization charge — — — (39) (235) (238) (78) (590) Disposals and derecognitions (1) — — — — 6 — 2 8 Impairment charges — — (180) — (45) — — (225) December 31, 2021 — — (180) (5,238) (3,471) (2,622) (231) (11,742) Net book value at December 31, 2021 8,905 2,980 557 131 1,332 3,338 427 8,765 (1) Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. The following table summarizes the allocation of the net book values of goodwill and other intangible assets by reportable segment at December 31, 2021: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Surgical 4,544 — 555 131 229 3,338 251 4,504 Vision Care 4,361 — 2 — 1,103 — 176 1,281 Not allocated to segments — 2,980 — — — — — 2,980 Net book value at December 31, 2021 8,905 2,980 557 131 1,332 3,338 427 8,765 Intangible asset impairment charges The following table shows the intangible asset impairment charges in 2022, 2021 and 2020: ($ millions) 2022 2021 2020 Surgical (60) (178) (66) Vision Care (2) (47) (101) Total (62) (225) (167) For the year ended December 31, 2022, impairment charges recognized in the Consolidated Income Statement amounted to $62 million, primarily due to impairments of $61 million recognized in the second quarter. An impairment charge of $59 million was recognized in Cost of net sales for a currently marketed product CGU in the Surgical reportable segment due to higher forecasted research and development costs associated with product redesign and delayed launch date of the next generation product. The CGU was reduced to its recoverable amount of $15 million determined based on the VIU method at the time of impairment. VIU was estimated using net present value techniques utilizing pre-tax cash flows and a discount rate of 7.8%. The remaining impairment charge of $2 million in the second quarter was recognized in Research & development to fully impair an acquired research & development intangible asset in the Vision Care reportable segment which will no longer be used. For the year ended December 31, 2021, impairment charges recognized in the Consolidated Income Statement amounted to $225 million. Impairments of $180 million were recognized in Research & development in 2021. Of that amount, an impairment charge of $178 million was recognized in the third quarter of 2021 in Research & development to fully impair a CGU in the Surgical reportable segment upon a decision to suspend research and development efforts and commercialization of the product as Alcon prioritizes other products in the portfolio. An additional impairment charge of $2 million was recognized in the fourth quarter of 2021 in Research & development to fully impair a licensed technology in the Vision Care reportable segment, which will no longer be used in any future research and development activities. The remaining amount of $45 million relates to an impairment charge recognized in the first quarter of 2021 in Cost of net sales for a currently marketed product CGU in the Vision Care reportable segment due to lower expected sales. The CGU was reduced to its recoverable amount of $48 million determined based on the FVLCOD method at the time of impairment. FVLCOD was estimated using net present value techniques utilizing post-tax cash flows and a discount rate as there are no direct or indirect observable prices in active markets for identical or similar assets. The discount rate was consistent with the rate used in the annual goodwill impairment assessment. For the year ended December 31, 2020, impairments amounted to $167 million. An impairment of $61 million was recognized in the third quarter of 2020, primarily to fully impair a CGU within the Vision Care reportable segment upon termination of the associated licensing agreement. The impairment was recognized in Research & development in the Consolidated Income Statement. The remaining amount relates to additional impairments of $106 million, which were recognized in Cost of net sales in the Consolidated Income Statement in 2020. Of that amount, an impairment of $41 million was recorded for a currently marketed product CGU within the Vision Care reportable segment due to lower expected sales. The CGU was reduced to its recoverable amount of $88 million at the time of impairment in the second quarter of 2020. An additional $65 million relates to impairments of a currently marketed product CGU in the Surgical reportable segment recognized in the first and fourth quarters of 2020 due to lower expected sales. This CGU was also reduced to its recoverable amount of $65 million at the time of impairment at December 31, 2020. The recoverable amount of each CGU was determined based on the FVLCOD method. FVLCOD was estimated using net present value techniques utilizing post-tax cash flows and discount rates as there are no direct or indirect observable prices in active markets for identical or similar assets. The discount rates of 7.5% and 7.0% for Surgical and Vision Care reportable segments, respectively, were consistent with the rates used in the annual goodwill impairment assessment. The estimates used in calculating net present values involve significant judgement by management and include assumptions with measurement uncertainty. The estimates include cash flow projections for a five-year period based on management forecasts, sales forecasts beyond the five-year period extrapolated using long-term expected growth rates, discount rates, and future tax rates. Actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using net present value techniques. For FVLCOD, the estimates used are considered to be consistent with market participant assumptions. Since the cash flow projections are a significant unobservable input, the fair value of the CGUs were classified as Level 3 in the fair value hierarchy.

Deferred tax assets and liabili

Deferred tax assets and liabilities	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Deferred tax assets and liabilities	Deferred tax assets and liabilities ($ millions) Property, plant & equipment Intangible assets Pensions and other benefit obligations of associates Inventories Tax loss carry-forwards Other assets, provisions and accruals Total Gross deferred tax assets at December 31, 2021 28 5 116 372 188 452 1,161 Gross deferred tax liabilities at December 31, 2021 (246) (1,382) — (23) — (127) (1,778) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617) At December 31, 2021 (218) (1,377) 116 349 188 325 (617) (Charged)/credited to income (57) 102 1 (23) (168) 180 35 (Charged)/credited to equity — — — — 12 (31) (19) (Charged) to other comprehensive income — — (38) — — (5) (43) Impact of business combination (1) (250) — — 142 43 (66) Impact of asset acquisitions — — — — 57 — 57 Net deferred tax balance at December 31, 2022 (276) (1,525) 79 326 231 512 (653) Gross deferred tax assets at December 31, 2022 31 4 79 352 231 642 1,339 Gross deferred tax liabilities at December 31, 2022 (307) (1,529) — (26) — (130) (1,992) Net deferred tax balance at December 31, 2022 (276) (1,525) 79 326 231 512 (653) The below table presents the Net deferred tax balance as of December 31, 2022 after offsetting $928 million of deferred tax assets and liabilities within the same tax jurisdiction. ($ millions) At December 31, 2022 Deferred tax assets 411 Deferred tax liabilities (1,064) Net deferred tax liabilities (653) ($ millions) Property, plant & equipment Intangible assets Pensions and other benefit obligations of associates Inventories Tax loss carry-forwards Other assets, provisions and accruals Total Gross deferred tax assets at December 31, 2020 24 5 128 381 174 314 1,026 Gross deferred tax liabilities at December 31, 2020 (215) (1,519) — (23) — (66) (1,823) Net deferred tax balance at December 31, 2020 (191) (1,514) 128 358 174 248 (797) At December 31, 2020 (191) (1,514) 128 358 174 248 (797) (Charged)/credited to income (27) 137 1 (9) 4 86 192 (Charged)/credited to equity — — (2) — 7 3 8 (Charged)/credited to other comprehensive income — — (11) — 3 (12) (20) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617) Gross deferred tax assets at December 31, 2021 28 5 116 372 188 452 1,161 Gross deferred tax liabilities at December 31, 2021 (246) (1,382) — (23) — (127) (1,778) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617) The below table presents the Net deferred tax balance as of December 31, 2021 after offsetting $752 million of deferred tax assets and liabilities within the same tax jurisdiction. ($ millions) At December 31, 2021 Deferred tax assets 409 Deferred tax liabilities (1,026) Net deferred tax liabilities (617) The below table presents deferred tax assets and deferred tax liabilities expected to have an impact on current taxes payable after more than twelve months. ($ billions) At December 31, 2022 At December 31, 2021 Deferred tax assets 1.0 0.8 Deferred tax liabilities 1.9 1.7 For foreign unremitted earnings retained by consolidated entities for reinvestment, which amounted to $9 billion as of December 31, 2022 and December 31, 2021, no provision is made for income taxes that would be payable upon the distribution of these earnings. If these earnings were remitted, an income tax charge could result based on the tax statutes currently in effect. IFRS exceptions to recognizing taxable temporary differences include an exception to recognizing a deferred tax liability arising on the initial recognition of goodwill from acquisitions. As such, we have not provided a deferred tax for goodwill from acquisitions which amounted to $9 billion as of December 31, 2022 and 2021. The gross value of capital loss carryforwards for which no deferred tax assets were recognized amounted to $120 million at December 31, 2022 ($103 million at December 31, 2021) and will expire in four years. The gross value of tax loss carryforwards capitalized as deferred tax assets amounted to $1,429 million at December 31, 2022 ($1,047 million at December 31, 2021), of which $45 million will expire in five years. Of the remaining $1,384 million, approximately $776 million have an indefinite carryforward period, and approximately $608 million have a carryforward period that ranges from six to twenty years. The gross value of tax loss carryforwards for which no deferred tax assets were recognized amounted to $438 million. All other tax loss carryforwards have been capitalized as deferred tax assets in 2022 as it is probable that sufficient taxable income will be available for the foreseeable future.

Financial and other non-current

Financial and other non-current assets	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Financial and other non-current assets	Financial and other non-current assets The below tables provide details related to Financial assets and Other non-current assets as of December 31, 2022 and 2021. Financial assets ($ millions) 2022 2021 Long-term financial investments measured at FVOCI 88 46 Long-term financial investments measured at FVPL 20 6 Long-term receivables from customers 119 110 Non-current minimum lease payments from finance lease agreements 38 35 Long-term loans, advances and security deposits 22 20 Total financial assets 287 217 Minimum lease payments from finance lease agreements The following table shows the receivables of the gross investments in finance leases and the net present value of the minimum lease payments, as well as unearned finance income, related to surgical equipment lease arrangements. The finance income is recorded in "Other income". 2022 2021 ($ millions) Total future payments Unearned interest income Present Provision Net Total future payments Unearned interest income Present Provision Net Not later than one year (1) 28 (2) 26 (1) 25 32 (2) 30 (2) 28 Between one and five years 49 (2) 47 (10) 37 47 (2) 45 (12) 33 Later than five years 1 — 1 — 1 2 — 2 — 2 Total 78 (4) 74 (11) 63 81 (4) 77 (14) 63 (1) The current portion of the minimum lease payments is recorded in Trade receivables or Other current assets (to the extent not yet invoiced). Other non-current assets ($ millions) 2022 2021 Deferred compensation plans 139 155 Prepaid post-employment benefit plans 8 25 Other non-current assets 96 54 Total other non-current assets 243 234

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventories [Abstract]
Inventories	Inventories The amount of inventory recognized as an expense in "Cost of net sales" in the Consolidated Income Statement during 2022 amounted to $2.7 billion (2021: $2.5 billion, 2020: $2.1 billion). The amount of inventory recognized as an expense in "Cost of other revenues" in the Consolidated Income Statement during 2022 amounted to $59 million (2021: $62 million, 2020: $63 million). ($ millions) 2022 2021 Raw material, consumables 433 336 Work in progress 201 169 Finished products 1,475 1,394 Total inventories 2,109 1,899 Alcon recognized inventory provisions and write-downs amounting to $200 million in 2022 (2021: $220 million, 2020: $304 million) and reversed inventory provisions amounting to $72 million in 2022 (2021: $83 million, 2020: $91 million). Inventory provisions mainly relate to the adjustment of inventory balances to their net realizable value based on the forecasted sales. Reversals are made when the products become salable.

Trade receivables

Trade receivables	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables	Trade receivables Trade receivable balances include sales to wholesalers, retailers, doctor groups, private health systems, government agencies, pharmacy benefit managers, managed health-care organizations and government-supported healthcare systems. The following tables provide details related to Trade receivables as of December 31, 2022 and 2021, including trade receivables that are not overdue as specified in the payment terms and conditions established with Alcon's customers, as well as an analysis of overdue amounts, expected credit loss rates and related provisions for doubtful trade receivables: 2022 ($ millions) Gross trade receivables Provision Trade receivables, net Expected credit loss rates Not overdue 1,390 (2) 1,388 0.1 % Past due for not more than one month 125 (1) 124 0.8 % Past due for more than one month but less than three months 93 (2) 91 2.2 % Past due for more than three months but less than six months 56 (4) 52 7.1 % Past due for more than six months but less than one year 28 (16) 12 57.1 % Past due for more than one year 38 (32) 6 84.2 % Total 1,730 (57) 1,673 2021 ($ millions) Gross trade receivables Provision Trade receivables, net Expected credit loss rates Not overdue 1,273 (2) 1,271 0.2 % Past due for not more than one month 96 (1) 95 1.0 % Past due for more than one month but less than three months 74 (1) 73 1.4 % Past due for more than three months but less than six months 43 (2) 41 4.7 % Past due for more than six months but less than one year 23 (13) 10 56.5 % Past due for more than one year 42 (36) 6 85.7 % Total 1,551 (55) 1,496 The following table summarizes the movement in the provision for doubtful trade receivables: ($ millions) 2022 2021 2020 January 1 (55) (68) (48) Provisions for doubtful trade receivables charged to the Consolidated Income Statement (40) (20) (48) Utilization of provisions for doubtful trade receivables 7 8 15 Reversal of provisions for doubtful trade receivables 28 23 14 Currency translation effects 3 2 (1) December 31 (57) (55) (68) Closely monitored countries include Greece, Italy, Portugal, Spain, Brazil, Russia, Turkey, Saudi Arabia, and Argentina. The majority of the outstanding trade receivables from Greece, Italy, Spain, Saudi Arabia and Argentina are due directly from local governments or from government-funded entities. We evaluate trade receivables in these countries for potential collection risk. Should there be a substantial deterioration in our economic exposure with respect to those countries, we may increase our level of provisions by updating our expected loss provision or may change the terms of trade on which we operate. The following table shows the gross trade receivables balance from these closely monitored countries as of December 31, 2022 and 2021, the amounts that are past due for more than one year and the related amount of the provisions for doubtful trade receivables that have been recorded: ($ millions) 2022 2021 Total balance of gross trade receivables from closely monitored countries 280 252 Past due for more than one year 8 10 Provisions for doubtful trade receivables (10) (11) Trade receivables include amounts denominated in the following major currencies: ($ millions) 2022 2021 US dollar (USD) 701 526 Euro (EUR) 256 243 Japanese yen (JPY) 154 160 Chinese yuan (CNY) 102 122 Brazilian real (BRL) 55 44 Indian rupee (INR) 33 36 Canadian dollar (CAD) 35 39 Australian dollar (AUD) 29 24 British pound (GBP) 31 29 Russian ruble (RUB) 28 35 South Korean won (KRW) 37 38 Mexican peso (MXN) 26 25 Other currencies 186 175 Total trade receivables, net 1,673 1,496

Other current assets

Other current assets	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Other current assets	Other current assets The following table provides details related to Other current assets as of December 31, 2022 and 2021: ($ millions) 2022 2021 Current portion of long-term receivables from customers 102 97 Current portion of minimum lease payments from finance lease agreements 25 28 Prepaid expenses 107 92 VAT receivables 99 105 Other receivables, security deposits and current assets 77 79 Derivative financial instruments 8 3 Equity securities in public companies — 3 Total other current assets 418 407

Right-of-use assets and Lease l

Right-of-use assets and Lease liabilities	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Right-of-use assets and Lease liabilities	Right-of-use assets and Lease liabilities Right-of-use assets Right-of-use assets as of December 31, 2022 and 2021 were comprised of the following: ($ millions) 2022 2021 Land 15 17 Buildings 347 326 Machinery & equipment and other assets 29 29 Total right-of-use assets 391 372 Depreciation charges of $76 million and $81 million for the years ended December 31, 2022 and 2021, respectively, are shown in the table below by underlying class of asset: ($ millions) 2022 2021 Land 1 1 Buildings 58 60 Machinery & equipment and other assets 17 20 Total depreciation of right-of-use assets 76 81 Lease liabilities Lease liabilities totaled $430 million as of December 31, 2022, including $71 million in current Lease liabilities and $359 million in non-current Lease liabilities. The contractual maturities of the undiscounted lease liabilities as of December 31, 2022 and 2021, are as follows: Lease liabilities undiscounted ($ millions) 2022 2021 Not later than one year 85 80 Between one and five years 226 197 Later than five years 233 237 Total lease liabilities undiscounted 544 514 Lease liabilities ($ millions) 2022 2021 Not later than one year 71 67 Between one and five years 180 157 Later than five years 179 182 Total lease liabilities 430 406 Additional disclosures The following table provides additional disclosures related to Right-of-use assets and Lease liabilities: ($ millions) 2022 2021 Interest expense on lease liabilities 15 13 Expense on short-term, low value and variable leases 3 7 Total cash outflows for leases 87 92 Thereof: Lease liability payments (1) 69 72 Interest payments (2) 15 13 Short-term, low value and variable lease payments (2) 3 7 (1) Reported as cash outflows from financing activities net of lease incentives received (2) Included within total net cash flows from operating activities

Non-current and current financi

Non-current and current financial debts	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Non-current and current financial debts	Non-current and current financial debts The below table summarizes non-current and current Financial debts outstanding as of December 31, 2022 and 2021. ($ millions) 2022 2021 Non-current financial debts Facility B, floating rate debt due 2024 — 796 Facility C, floating rate debt due 2024 — 395 Local facilities (Japan), floating rate debt due 2023 — 47 2.750% Series 2026 Notes 497 496 2.375% Series 2028 Notes 527 — 3.000% Series 2029 Notes 994 993 2.600% Series 2030 Notes 746 745 5.375% Series 2032 Notes 692 — 3.800% Series 2049 Notes 494 494 5.750% Series 2052 Notes 591 — Revolving facility, floating rate due 2026 — — Total non-current financial debts 4,541 3,966 Current financial debts Local facilities, floating rate: Japan 69 84 All others 2 17 Other short-term financial debts, floating rate 26 6 Derivatives 10 7 Total current financial debts 107 114 Total financial debts 4,648 4,080 Interest expense recognized for Financial debts, excluding lease liabilities, was $110 million, $95 million and $94 million for the years ended December 31, 2022, 2021 and 2020, respectively. The weighted average interest rate on Financial debts was 2.7% and 2.3% in 2022 and 2021, respectively. Series 2028 Notes issuance On May 31, 2022, AFBV issued EUR denominated senior notes due in 2028 ("Series 2028 Notes"). The Series 2028 Notes are unsecured senior obligations of AFBV issued and closed in a public offering and rank equally in right of payment with the Series 2026, Series 2029, Series 2030 and Series 2049 notes. The total principal of the Series 2028 Notes is $533 million (EUR500 million) as of December 31, 2022. The Series 2028 Notes were issued at 99.476% with 2.375% interest payable annually in May, beginning in May 2023. The Series 2028 Notes were issued at a discount totaling $3 million, which was recorded as a reduction to the carrying value of the Series 2028 Notes and will be amortized to Interest expense over the term of the Series 2028 Notes. AFBV incurred $3 million of debt issuance costs, which were recorded as a reduction to the carrying value of the Series 2028 Notes and will be amortized to Other financial income & expense over the term of the Series 2028 Notes. On May 31, 2022, the funds borrowed through the issuance of the Series 2028 Notes were used to fully repay the $376 million (EUR350 million) Facility C term loan maturing in 2024 and repay $160 million of the $800 million Facility B term loan maturing in 2024. The transactions were accounted for as an extinguishment and partial extinguishment of a liability, respectively. Alcon recognized losses on extinguishment of $1 million associated with the write-off of unamortized deferred financing costs in Other financial income & expense during the second quarter of 2022. 2022 Bridge Loan Facility On September 14, 2022, AFC executed a $900 million 2022 Bridge Loan Facility with J.P. Morgan Chase Bank, N.A. London Branch. The 2022 Bridge Loan Facility was fully guaranteed by the Company and was restricted for use in funding the acquisition of Aerie. On September 27, 2022, a Syndication Agreement was executed to add more financial institutions as new lenders, effective from September 28, 2022. On November 21, 2022, in connection with the consummation of the Aerie acquisition, $775 million of the financing commitments were drawn with net proceeds of $771 million used for the acquisition of Aerie. AFC incurred $4 million of debt issuance costs, which were recorded as a reduction to the carrying value of the 2022 Bridge Loan Facility. Series 2032 Notes and Series 2052 Notes issuance On December 6, 2022, AFC issued senior notes due in 2032 ("Series 2032 Notes") and 2052 ("Series 2052 Notes"). The Series 2032 Notes and Series 2052 Notes are unsecured senior obligations of AFC issued and closed in a private offering and rank equally in right of payment with the Series 2026, Series 2028, Series 2029, Series 2030 and Series 2049 notes. The principal amounts of the Series 2032 Notes and Series 2052 Notes are $700 million and $600 million, respectively. The Series 2032 Notes and Series 2052 Notes were issued at a discount of $4 million and $2 million, respectively, which were recorded as a reduction to the carrying values of the Series 2032 Notes and Series 2052 Notes and will be amortized to Interest expense over the term of the notes. AFC incurred debt issuance costs of $4 million and $7 million for the Series 2032 Notes and Series 2052 Notes, respectively, which were recorded as a reduction to the carrying values of the Series 2032 Notes and Series 2052 Notes and will be amortized to Other financial income & expense over the term of the notes. The Notes consist of the following: • Series 2032 Notes - $700 million due in 2032 issued at 99.458%, 5.375% interest is payable twice per year in December and June, beginning in June 2023. • Series 2052 Notes - $600 million due in 2052 issued at 99.674%, 5.750% interest is payable twice per year in December and June, beginning in June 2023. Using the funds borrowed through the issuance of the Series 2032 Notes and Series 2052 Notes together with cash, the Company exercised its early redemption rights to fully repay the remaining $640 million Facility B term loan and to fully repay the drawn amount of $775 million under the 2022 Bridge Loan Facility, as required by the mandatory prepayment clause. Consequently, the undrawn commitment of the 2022 Bridge Loan Facility was cancelled. The transactions were accounted for as extinguishment of liabilities. Alcon recognized losses on extinguishment of $4 million associated with the write-off of unamortized deferred financing costs in Other financial income & expense during the fourth quarter of 2022. Senior notes assumed in Aerie acquisition As part of the Aerie acquisition, Alcon assumed Aerie's $316.2 million convertible senior notes due on October 1, 2024. The convertible notes were issued at 1.500% interest payable semi-annually on April 1 and October 1 of each year. Following the delisting of Aerie on November 21, 2022, the senior notes were no longer convertible to equity. On December 20, 2022, Alcon made payments of $316.0 million to note holders and $0.2 million remained outstanding as of December 31, 2022. Series 2030 Notes issuance On May 27, 2020, AFC issued senior notes due in 2030 (“Series 2030 Notes”). The Series 2030 Notes are unsecured senior obligations of AFC issued in a private placement and rank equally in right of payment with the Series 2026, Series 2029, and Series 2049 notes. The total principal amount of the Senior 2030 Notes is $750 million. The Senior 2030 Notes were issued at 99.843% with 2.600% interest payable twice per year in May and November, beginning in November 2020. The Series 2030 Notes were issued at a discount totaling $1 million, which was recorded as a reduction to the carrying value of the Series 2030 notes and will be amortized to Interest expense over the term of the Series 2030 Notes. AFC incurred $5 million of debt issuance costs, which were recorded as a reduction to the carrying value of the Series 2030 Notes and will be amortized to Other financial income & expense over the term of the Series 2030 Notes. Revolving Facility In February 2021, the $1.0 billion Revolving Facility was extended to March 2026. The Revolving Facility remained undrawn as of December 31, 2022. Local bilateral facilities Alcon holds a number of local bilateral facilities in different countries with the largest share of borrowings in Japan. Two local bilateral facilities in Japan matured in February 2021 and were refinanced by three facilities with one hanges in financial debts for local bilateral facilities primarily included the movement of balances from non-current to current and payment of certain local bilateral facilities in Japan. In addition, o ne local bilateral facility in Japan matured in February 2022 and was renewed for another one year term. As of December 31, 2022, a total of $69 million was drawn in Japan and is classified as current with a maturity date of one year or less. There was $101 million undrawn on the facilities in Japan as of December 31, 2022. Guarantees The Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes, the three local bilateral facilities in Japan and the undrawn Revolving Facility are guaranteed by the Company. Maturity of contractual undiscounted cash flows and interest payment commitments The following table provides details on the maturity of the contractual undiscounted cash flows for Alcon's borrowings as of December 31, 2022 and 2021: 2022 2021 ($ millions) Nominal amount - Current and non-current financial debt Derivatives Total Nominal amount - Current and non-current financial debt Derivatives Total Not later than one year 97 10 107 107 7 114 Between one and five years 500 — 500 1,743 — 1,743 Later than five years 4,083 — 4,083 2,250 — 2,250 Total contractual undiscounted cash flows 4,680 10 4,690 4,100 7 4,107 Unamortized debt discount and issuance costs (42) — (42) (27) — (27) Total carrying value 4,638 10 4,648 4,073 7 4,080 The following table provides details on the maturity of the future contractual interest payments commitments as of December 31, 2022 and 2021: ($ millions) 2022 2021 Not later than one year 169 94 Between one and five years 651 340 Later than five years 1,563 583 Total cash flows 2,383 1,017

Financial instruments - additio

Financial instruments - additional disclosures	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Financial instruments - additional disclosures	Financial instruments - additional disclosures The below table provides detail related to financial instruments as of December 31, 2022 and December 31, 2021. ($ millions) Note 2022 2021 Cash and cash equivalents Cash in current accounts 281 246 Cash held in time deposits and money market funds 699 1,329 Total cash and cash equivalents 980 1,575 Financial assets - measured at fair value through other comprehensive income ("FVOCI") Long-term financial investments 11 88 46 Total financial assets - measured at FVOCI 88 46 Financial assets - measured at amortized costs (1) Trade receivables 13 1,673 1,496 Income tax receivables 13 9 Other current assets (excluding prepaid expenses and other current assets measured at FVPL) 14 303 309 Long-term receivables from customers 11 119 110 Non-current minimum lease payments from finance lease agreements 11 38 35 Long-term loans, advances and security deposits 11 22 20 Total financial assets - measured at amortized costs 2,168 1,979 Financial assets - measured at fair value through profit and loss ("FVPL") Equity securities of public companies 14 — 3 Deferred compensation assets 11 139 155 Derivative financial instruments 14 8 3 Long-term financial investments 11 20 6 Total financial assets - measured at FVPL 167 167 Total financial assets 3,403 3,767 Financial liabilities - measured at amortized cost or cost (1) Current financial liabilities Financial debts 16 97 107 Lease liabilities 15 71 67 Trade payables 861 903 Total current financial liabilities - measured at amortized cost or cost 1,029 1,077 Non-current financial liabilities Financial debts 16 4,541 3,966 Lease liabilities 15 359 339 Total non-current financial liabilities - measured at amortized cost or cost 4,900 4,305 Total financial liabilities - measured at amortized cost or cost 5,929 5,382 Financial liabilities - measured at FVPL Contingent consideration liabilities 18 98 112 Derivative financial instruments 16 10 7 Total financial liabilities - measured at FVPL 108 119 Total financial liabilities 6,037 5,501 Net financial assets and financial liabilities (2,634) (1,734) (1) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debts with a fair value of $4,145 million and carrying value of $4,541 million as of December 31, 2022. As of December 31, 2021, the Series 2026, 2029, 2030 and 2049 Notes recorded in Non-current financial debts had a fair value of $2,891 million and carrying value of $2,728 million. The fair value of notes was determined using Level 2 inputs. The notes were valued using a quoted market price for such notes, which have low trading volumes. Fair value by hierarchy As required by IFRS, financial assets and liabilities recorded at fair value in the Consolidated Financial Statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of judgment associated with the inputs to derive fair value for these financial assets and liabilities, which are as follows: Financial assets and liabilities carried at Level 1 fair value hierarchy are listed in active markets. Financial assets and liabilities carried at Level 2 fair value hierarchy are valued using corroborated market data. Level 1 financial assets include money market funds, equity securities of public companies and deferred compensation assets. There were no financial liabilities carried at Level 1 fair value, and Level 2 financial assets and liabilities include derivative financial instruments. Investments in money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The investments are classified as Cash & cash equivalents within the Consolidated Balance Sheet. Investments in equity securities of public companies are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Deferred compensation investments for certain employee benefit plans are held in a rabbi trust and dedicated to pay the benefits under the associated plans but are not considered plan assets as the assets remain available to creditors of Alcon in certain events, including bankruptcy. Rabbi trust assets primarily consist of investments in mutual funds. These assets are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Level 3 inputs are unobservable for the financial asset or liability. The financial assets and liabilities generally included in the Level 3 fair value hierarchy are equity securities and convertible notes receivable of private companies measured at FVOCI, fund investments, options to acquire private companies, and contingent consideration liabilities measured at FVPL. The following tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of December 31, 2022 and December 31, 2021. December 31, 2022 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 88 — 88 Long-term financial investments measured at FVPL — — 20 — 20 Long-term receivables from customers — — — 119 119 Deferred compensation assets (1) 139 — — — 139 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, advances and security deposits — — — 22 22 Non-current financial assets 139 — 108 179 426 Current financial assets Money market funds 229 — — — 229 Current portion of long-term receivables from customers (2) — — — 102 102 Current portion of minimum lease payments from finance lease agreements (2) — — — 25 25 VAT receivables (2) — — — 99 99 Other receivables, security deposits and current assets (2) — — — 77 77 Derivative financial instruments (2) — 8 — — 8 Current financial assets 229 8 — 303 540 Financial assets at fair value and amortized cost or cost 368 8 108 482 966 Financial liabilities Contingent consideration liabilities — — (98) — (98) Non-current financial debt — — — (4,541) (4,541) Current financial debt — — — (97) (97) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (98) (4,638) (4,746) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets. December 31, 2021 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 46 — 46 Long-term financial investments measured at FVPL — — 6 — 6 Long-term receivables from customers — — — 110 110 Deferred compensation assets (1) 155 — — — 155 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, advances and security deposits — — — 20 20 Non-current financial assets 155 — 52 165 372 Current financial assets Money market funds 624 — — — 624 Equity securities of public companies (2) 3 — — — 3 Current portion of long-term receivables from customers (2) — — — 97 97 Current portion of minimum lease payments from finance lease agreements (2) — — — 28 28 VAT receivables (2) — — — 105 105 Other receivables, security deposits and current assets (2) — — — 79 79 Derivative financial instruments (2) — 3 — — 3 Current financial assets 627 3 — 309 939 Financial assets at fair value and amortized cost or cost 782 3 52 474 1,311 Financial liabilities Contingent consideration liabilities — — (112) — (112) Non-current financial debt — — — (3,966) (3,966) Current financial debt — — — (107) (107) Derivative financial instruments — (7) — — (7) Financial liabilities at fair value and amortized cost — (7) (112) (4,073) (4,192) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets There were no transfers of financial instruments between levels in the fair value hierarchy during the years ended December 31, 2022 and December 31, 2021. Level 3 financial instruments measured at fair value on a recurring basis Financial assets Long-term financial investments measured Financial investments ($ millions) 2022 2021 2022 2021 Balance as of January 1 46 28 6 24 Additions 45 18 — — (Loss) recognized in Consolidated Statement of Comprehensive Income/(Loss) (2) — — — Unrealized gain/(loss) in Consolidated Income Statement — — 14 (3) Amortization — — — (12) Settlement (1) — — (3) Balance as of December 31 88 46 20 6 If the pricing parameters for the Level 3 inputs were to change for Long-term financial investments measured at FVOCI and Financial investments measurement at FVPL by 10% positively or negatively, this would change the amount recorded in the 2022 Consolidated Statement of Comprehensive Income/(Loss) by $11 million. Financial liabilities Contingent consideration liabilities ($ millions) 2022 2021 Balance as of January 1 (112) (157) Accretion for passage of time (9) (12) Adjustments for changes in assumptions 23 42 Payments — 15 Balance as of December 31 (98) (112) Changes in contingent consideration liabilities in the current year include adjustments for changes in assumptions of $23 million, primarily due to revised expectations for achievement and timing of settlement for development and commercial milestones. As of December 31, 2022, the probability of success for various development and commercial milestones ranges from 55% to 57% and the maximum remaining potential payments related to contingent consideration from business combinations is $395 million, plus other amounts calculated as a percentage of commercial sales in cases where there is not a specified maximum contractual payment amount. The estimation of probability typically depends on factors such as technical milestones or market performance and is adjusted for the probability of payment. If material, probable payments are appropriately discounted to reflect the impact of time. Changes in contingent consideration liabilities in the prior year included adjustments for changes in assumptions of $42 million, primarily due to revised expectations for achievement of commercial milestones related to the fully impaired CGU in the Surgical reportable segment discussed in Note 9 and timing of settlement for development and commercial milestones. The prior year also included a payment of $15 million related to achievement of a development milestone. As of December 31, 2021, the probability of success for various development and commercial milestones ranged from 55% to 80% and the maximum remaining potential payments related to contingent consideration from business combinations was $395 million, plus other amounts calculated as a percentage of commercial sales in cases where there is not a specified maximum contractual payment amount. Contingent consideration liabilities are reported in “Provisions & other non-current liabilities" based on the projected timing of settlement which is estimated to range from 2028 through 2034 for contingent consideration obligations as of December 31, 2022. For the determination of the fair value of a contingent consideration various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. As the most significant Level 3 input, if the probability of success were to change by 10% positively or negatively, this would change the amount recorded for contingent consideration payables in the 2022 Consolidated Income Statement by $18 million. Derivatives As of December 31, 2022, the net value of unsettled positions for derivative forward contracts and swaps was $2 million, including $8 million of unrealized gains in Other current assets and $10 million of unrealized losses in Current financial debts. As of December 31, 2021, the net value of unsettled positions for derivative forward contracts and swaps was $4 million, including $3 million of unrealized gains in Other current assets and $7 million of unrealized losses in Current financial debts. There are master agreements with several banking counterparties for derivatives financial instruments; however, there were no derivative financial instruments meeting the offsetting criteria under IFRS as of December 31, 2022 or December 31, 2021. Nature and extent of risks arising from financial instruments Market risk Alcon is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of investments of liquid funds. Alcon actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is Alcon policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. Alcon does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, Alcon does not sell short assets it does not have, or does not know it will have, in the future. Alcon only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, Alcon may write call options on assets it has, or write put options on positions it wants to acquire and has the liquidity to acquire. Alcon expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions. Foreign currency exchange rate risk Alcon uses the US Dollar as its reporting currency and is therefore exposed to foreign currency exchange movements, primarily in Euros, Japanese Yen, Chinese Renminbi, Canadian Dollars, Korean Won, Swiss Francs, Russian Rubles and emerging market currencies. Fluctuations in the exchange rate between the US Dollar and other currencies can have a significant effect on both Alcon’s results of operations, including reported sales and earnings, as well as on the reported value of Alcon's assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations. Alcon manages its global currency exposure by engaging in hedging transactions where management deems appropriate (forward contracts and swaps). Specifically, Alcon enters into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets. Refer to Note 2 to these Consolidated Financial Statements for information regarding the hyperinflationary economies in which Alcon operates. Interest rate risk Alcon's exposure to cash flow interest rate risks arises from the portion of financial debts at variable rates. Alcon may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable rate interests. If the interest rates had been higher / lower by 1% in 2022, the income before taxes would have been lower / higher by $9 million from the impacts of interest expense based on the change in the interest rate. As of December 31, 2022, 98% of Alcon's financial debt is at fixed interest rates materially reducing future exposure to cash flow interest rate risk. Commodity price risk Alcon is currently experiencing inflation and supply chain challenges due to global economic challenges to procure certain components and has exposure to price risk related to anticipated purchases of certain commodities used as raw materials by Alcon's businesses. A change in those prices may alter the gross margin of a specific business, but generally not by more than 10% of the gross margin and thus below Alcon's risk management tolerance levels. Alcon primarily manages inflationary pressures through pricing actions and productivity initiatives. Based on historical and anticipated price fluctuations, Alcon does not enter into significant forward and option contracts to manage fluctuations in prices of anticipated purchases. Credit risk Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, Alcon periodically assesses credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate. For further information, refer to Note 13 of these Consolidated Financial Statements. No customer accounted for 10% or more of Alcon's net sales in 2022, 2021 or 2020. Liquidity risk

Provisions and other non-curren

Provisions and other non-current liabilities	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Provisions and other non-current liabilities	Provisions and other non-current liabilities The below table provides details related to Provisions and other non-current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accrued liability for employee benefits: Defined benefit pension plans 22 175 295 Other long-term employee benefits and deferred compensation 160 177 Other post-employment benefits 22 221 300 Provisions for litigation and other legal matters — — Contingent consideration 17 98 112 Other non-current liabilities 132 56 Total provisions and other non-current liabilities 786 940 Alcon believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Alcon may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to Alcon's financial condition but could be material to the results of operations or cash flows in a given period. Provisions for litigation and other legal matters Alcon has established provisions for certain litigation and other legal matters, where a potential cash outflow is probable and a reliable estimate can be made of the amount of the outflow. These provisions represent the current best estimate of the total financial effect for these matters. Potential cash outflows reflected in a provision may be fully or partially offset by insurance in certain circumstances. Alcon has not established provisions for potential damage awards for certain additional legal claims if Alcon currently believes that a payment is either not probable or cannot be reliably estimated. A number of other legal matters are in such early stages or the issues presented are such that Alcon has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, Alcon generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. There might also be cases for which Alcon was able to make a reliable estimate of the possible loss or the range of possible loss, but Alcon believes that publication of such information on a case-by-case basis would prejudice Alcon's position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information would be disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. Note 25 contains additional information on contingencies. Summary of significant legal proceedings A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property, including under the Hatch-Waxman Act, and anti-bribery matters such as those under the Foreign Corrupt Practices Act of 1977 ("FCPA"), as amended. As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. The following is a summary as of February 27, 2023 of significant legal proceedings to which Alcon or its subsidiaries were or are currently a party. Contact lenses class actions Beginning in the first quarter of 2015, more than 50 class action complaints were filed in several courts across the US naming as defendants contact lens manufacturers, including Alcon, and alleging violations of federal antitrust law, as well as the antitrust, consumer protection and unfair competition laws of various states, in connection with the implementation of unilateral price policies by the defendants in the sale of contact lenses. The cases were consolidated in the Middle District of Florida by the Judicial Panel on Multidistrict Litigation. On March 23, 2022, Alcon entered a settlement agreement under which it admitted no liability and subsequently paid $20 million into a common fund for eligible members of a class consisting of retail purchasers of contact lenses that were subject to a unilateral price policy. In exchange, Alcon obtained a release of all claims asserted against it by the class during the third quarter of 2022. On October 12, 2022, the court approved Alcon's settlement of this matter and the case is now concluded. Hatch-Waxman patent litigation From time to time, Alcon is a party to certain patent infringement proceedings in the US in connection with Notices of Paragraph IV Certification under the Hatch-Waxman Act received from third-party generic manufacturers respecting their applications for generic versions of certain products sold by or on behalf of Alcon, including Simbrinza, Pataday, Rhopressa and Rocklatan, or other similar suits. During the third quarter of 2022, Alcon received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying Alcon that a generic drug company filed an application with the FDA seeking pre-patent expiry approval to sell a generic version of Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%. In October 2022, Alcon filed a patent infringement lawsuit in the US District Court for the District of Delaware against that generic drug company. The lawsuit, which asserts two patents, automatically stays FDA approval of the generic drug application for up to 30 months from receipt of the Paragraph IV Certification Letter (or earlier if the court renders a decision adverse to Alcon). The court has entered a schedule that sets trial for October 2024. Alcon intends to defend its patents in this case vigorously. On January 31, 2022, prior to Alcon's acquisition of Aerie, Aerie received three Paragraph IV Certification Letters under the Hatch-Waxman Act notifying Aerie that three generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Rhopressa and/or Rocklatan . On March 14, 2022, Aerie filed patent infringement lawsuits in the US District Court for the District of New Jersey against those generic drug companies. These lawsuits automatically stay FDA approval of the generic drug applications for up to 30 months from receipt of the respective Paragraph IV Certification Letters (or earlier if a court renders a decision adverse to Alcon). The lawsuits have been consolidated into a single case with a trial scheduled for January 2025. Alcon intends to defend its patents in this case vigorously. JJSVI patent dispute On June 23, 2020, Johnson & Johnson Surgical Vision, Inc. ("JJSVI"), acting through its subsidiaries, filed a patent infringement action in the US District Court in Delaware alleging that the manufacture, use, sale, offer for sale, and/or importation of Alcon’s LenSx Laser System willfully infringes, directly and/or indirectly, one or more claims of 12 US patents. JJSVI subsequently amended its complaint to include copyright infringement claims relating to, among other things, source code used in the LenSx Laser System as well as additional claims of patent infringement. Also beginning on June 23, 2020, JJSVI filed claims in Mannheim, Germany, alleging that Alcon directly infringes certain European patents through its manufacture and sale of LenSx . In these cases, JJSVI sought monetary and injunctive relief. Alcon defended all of these cases vigorously and asserted various patent infringement and invalidity claims against JJSVI in Europe and the US. Prior to the trial on the copyright claims in the Delaware action set for February 2023, the parties entered into a confidential settlement agreement to resolve all of the pending legal proceedings described above. As part of that resolution, the parties exchanged cross-licenses of certain intellectual property and other mutually agreed covenants and releases, and Alcon agreed to make a one-time payment to JJSVI of $199 million, which was accrued as of December 31, 2022, for those rights and to resolve the parties’ various worldwide intellectual property disputes concerning such devices. Hoya patent dispute On December 11, 2020, Hoya Corporation and one of its affiliates filed suit against Alcon in the US District Court for the Northern District of Texas alleging that Alcon's UltraSert Pre-Loaded Delivery System infringes six of Hoya's US patents. The court denied in part Alcon’s motion to dismiss Hoya’s complaint on September 20, 2021. Trial is set for February 2024. Alcon intends to defend the case vigorously. Asia / Russia investigation In 2017 and 2018, Alcon and Novartis Group companies, as well as certain present and former executives and associates of Alcon and Novartis, received document requests and subpoenas from the US Department of Justice (“DoJ”) and the SEC requesting information concerning Alcon accounting, internal controls and business practices in Asia and Russia, including revenue recognition for surgical equipment and related products and services and relationships with third party distributors, both before and after Alcon became part of the Novartis Group. The Investigations by the DoJ and the SEC have concluded. On June 25, 2020, Alcon entered into a three-year Deferred Prosecution Agreement with the DoJ regarding a charge that Alcon Pte Ltd. conspired to falsify financial books and records in violation of the US FCPA. The charge relates to payments made by a former distributor to health care providers in Vietnam between 2007 and 2014. Alcon agreed to pay the DoJ a penalty of $8.925 million, for which Novartis has indemnified Alcon. Litigation and other legal matters provision movements ($ millions) 2022 2021 2020 January 1 53 — — Additions to provisions 175 54 9 Cash payments (21) (1) (9) Releases of provisions (1) — — December 31 206 53 — Less current portion (206) (53) — Non-current provisions for litigation and other legal matters at December 31 — — — Alcon believes that its total provisions for litigation and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, additional liabilities and costs may be incurred beyond the amounts provided. The following table provides details related to Provisions and other current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accruals for compensation and benefits including social security 465 489 Accruals for deductions from revenue 386 264 Deferred income 89 108 Taxes other than income taxes 98 93 Restructuring provisions 64 17 Accrued expenses for goods and services received but not invoiced 95 76 Accruals for royalties 12 10 Provisions for litigation and other legal matters 18 206 53 Accrued equity-based payments 12 14 Accrued interest on financial debts 31 19 Other payables 66 58 Total provisions and other current liabilities 1,524 1,201 Provisions and accruals are based upon management's best estimate and adjusted for actual experience. Such adjustments to the historical estimates have not been material. Accruals for deductions from revenue The following table shows the movement of accruals for deductions from revenue: ($ millions) 2022 2021 2020 January 1 264 217 212 Additions 878 677 540 Impact of business combination 86 — — Payments/utilizations (829) (619) (537) Changes in offset against gross trade receivables (3) (5) (2) Currency translation effects (10) (6) 4 December 31 386 264 217 Restructuring provisions The following table shows the movement of restructuring provisions: ($ millions) 2022 2021 2020 January 1 17 10 28 Additions 72 21 22 Cash payments (24) (14) (40) Releases (1) — — December 31 64 17 10 In 2022, 2021 and 2020, additions to restructuring provisions of $72 million, $21 million and $22 million, respectively, were primarily related to the multi-year transformation program initially announced by Alcon on November 19, 2019 and subsequently expanded as announced on November 15, 2022. The costs

Provisions and other current li

Provisions and other current liabilities	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Provisions and other current liabilities	Provisions and other non-current liabilities The below table provides details related to Provisions and other non-current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accrued liability for employee benefits: Defined benefit pension plans 22 175 295 Other long-term employee benefits and deferred compensation 160 177 Other post-employment benefits 22 221 300 Provisions for litigation and other legal matters — — Contingent consideration 17 98 112 Other non-current liabilities 132 56 Total provisions and other non-current liabilities 786 940 Alcon believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Alcon may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to Alcon's financial condition but could be material to the results of operations or cash flows in a given period. Provisions for litigation and other legal matters Alcon has established provisions for certain litigation and other legal matters, where a potential cash outflow is probable and a reliable estimate can be made of the amount of the outflow. These provisions represent the current best estimate of the total financial effect for these matters. Potential cash outflows reflected in a provision may be fully or partially offset by insurance in certain circumstances. Alcon has not established provisions for potential damage awards for certain additional legal claims if Alcon currently believes that a payment is either not probable or cannot be reliably estimated. A number of other legal matters are in such early stages or the issues presented are such that Alcon has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, Alcon generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. There might also be cases for which Alcon was able to make a reliable estimate of the possible loss or the range of possible loss, but Alcon believes that publication of such information on a case-by-case basis would prejudice Alcon's position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information would be disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. Note 25 contains additional information on contingencies. Summary of significant legal proceedings A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property, including under the Hatch-Waxman Act, and anti-bribery matters such as those under the Foreign Corrupt Practices Act of 1977 ("FCPA"), as amended. As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. The following is a summary as of February 27, 2023 of significant legal proceedings to which Alcon or its subsidiaries were or are currently a party. Contact lenses class actions Beginning in the first quarter of 2015, more than 50 class action complaints were filed in several courts across the US naming as defendants contact lens manufacturers, including Alcon, and alleging violations of federal antitrust law, as well as the antitrust, consumer protection and unfair competition laws of various states, in connection with the implementation of unilateral price policies by the defendants in the sale of contact lenses. The cases were consolidated in the Middle District of Florida by the Judicial Panel on Multidistrict Litigation. On March 23, 2022, Alcon entered a settlement agreement under which it admitted no liability and subsequently paid $20 million into a common fund for eligible members of a class consisting of retail purchasers of contact lenses that were subject to a unilateral price policy. In exchange, Alcon obtained a release of all claims asserted against it by the class during the third quarter of 2022. On October 12, 2022, the court approved Alcon's settlement of this matter and the case is now concluded. Hatch-Waxman patent litigation From time to time, Alcon is a party to certain patent infringement proceedings in the US in connection with Notices of Paragraph IV Certification under the Hatch-Waxman Act received from third-party generic manufacturers respecting their applications for generic versions of certain products sold by or on behalf of Alcon, including Simbrinza, Pataday, Rhopressa and Rocklatan, or other similar suits. During the third quarter of 2022, Alcon received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying Alcon that a generic drug company filed an application with the FDA seeking pre-patent expiry approval to sell a generic version of Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%. In October 2022, Alcon filed a patent infringement lawsuit in the US District Court for the District of Delaware against that generic drug company. The lawsuit, which asserts two patents, automatically stays FDA approval of the generic drug application for up to 30 months from receipt of the Paragraph IV Certification Letter (or earlier if the court renders a decision adverse to Alcon). The court has entered a schedule that sets trial for October 2024. Alcon intends to defend its patents in this case vigorously. On January 31, 2022, prior to Alcon's acquisition of Aerie, Aerie received three Paragraph IV Certification Letters under the Hatch-Waxman Act notifying Aerie that three generic drug companies had filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Rhopressa and/or Rocklatan . On March 14, 2022, Aerie filed patent infringement lawsuits in the US District Court for the District of New Jersey against those generic drug companies. These lawsuits automatically stay FDA approval of the generic drug applications for up to 30 months from receipt of the respective Paragraph IV Certification Letters (or earlier if a court renders a decision adverse to Alcon). The lawsuits have been consolidated into a single case with a trial scheduled for January 2025. Alcon intends to defend its patents in this case vigorously. JJSVI patent dispute On June 23, 2020, Johnson & Johnson Surgical Vision, Inc. ("JJSVI"), acting through its subsidiaries, filed a patent infringement action in the US District Court in Delaware alleging that the manufacture, use, sale, offer for sale, and/or importation of Alcon’s LenSx Laser System willfully infringes, directly and/or indirectly, one or more claims of 12 US patents. JJSVI subsequently amended its complaint to include copyright infringement claims relating to, among other things, source code used in the LenSx Laser System as well as additional claims of patent infringement. Also beginning on June 23, 2020, JJSVI filed claims in Mannheim, Germany, alleging that Alcon directly infringes certain European patents through its manufacture and sale of LenSx . In these cases, JJSVI sought monetary and injunctive relief. Alcon defended all of these cases vigorously and asserted various patent infringement and invalidity claims against JJSVI in Europe and the US. Prior to the trial on the copyright claims in the Delaware action set for February 2023, the parties entered into a confidential settlement agreement to resolve all of the pending legal proceedings described above. As part of that resolution, the parties exchanged cross-licenses of certain intellectual property and other mutually agreed covenants and releases, and Alcon agreed to make a one-time payment to JJSVI of $199 million, which was accrued as of December 31, 2022, for those rights and to resolve the parties’ various worldwide intellectual property disputes concerning such devices. Hoya patent dispute On December 11, 2020, Hoya Corporation and one of its affiliates filed suit against Alcon in the US District Court for the Northern District of Texas alleging that Alcon's UltraSert Pre-Loaded Delivery System infringes six of Hoya's US patents. The court denied in part Alcon’s motion to dismiss Hoya’s complaint on September 20, 2021. Trial is set for February 2024. Alcon intends to defend the case vigorously. Asia / Russia investigation In 2017 and 2018, Alcon and Novartis Group companies, as well as certain present and former executives and associates of Alcon and Novartis, received document requests and subpoenas from the US Department of Justice (“DoJ”) and the SEC requesting information concerning Alcon accounting, internal controls and business practices in Asia and Russia, including revenue recognition for surgical equipment and related products and services and relationships with third party distributors, both before and after Alcon became part of the Novartis Group. The Investigations by the DoJ and the SEC have concluded. On June 25, 2020, Alcon entered into a three-year Deferred Prosecution Agreement with the DoJ regarding a charge that Alcon Pte Ltd. conspired to falsify financial books and records in violation of the US FCPA. The charge relates to payments made by a former distributor to health care providers in Vietnam between 2007 and 2014. Alcon agreed to pay the DoJ a penalty of $8.925 million, for which Novartis has indemnified Alcon. Litigation and other legal matters provision movements ($ millions) 2022 2021 2020 January 1 53 — — Additions to provisions 175 54 9 Cash payments (21) (1) (9) Releases of provisions (1) — — December 31 206 53 — Less current portion (206) (53) — Non-current provisions for litigation and other legal matters at December 31 — — — Alcon believes that its total provisions for litigation and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, additional liabilities and costs may be incurred beyond the amounts provided. The following table provides details related to Provisions and other current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accruals for compensation and benefits including social security 465 489 Accruals for deductions from revenue 386 264 Deferred income 89 108 Taxes other than income taxes 98 93 Restructuring provisions 64 17 Accrued expenses for goods and services received but not invoiced 95 76 Accruals for royalties 12 10 Provisions for litigation and other legal matters 18 206 53 Accrued equity-based payments 12 14 Accrued interest on financial debts 31 19 Other payables 66 58 Total provisions and other current liabilities 1,524 1,201 Provisions and accruals are based upon management's best estimate and adjusted for actual experience. Such adjustments to the historical estimates have not been material. Accruals for deductions from revenue The following table shows the movement of accruals for deductions from revenue: ($ millions) 2022 2021 2020 January 1 264 217 212 Additions 878 677 540 Impact of business combination 86 — — Payments/utilizations (829) (619) (537) Changes in offset against gross trade receivables (3) (5) (2) Currency translation effects (10) (6) 4 December 31 386 264 217 Restructuring provisions The following table shows the movement of restructuring provisions: ($ millions) 2022 2021 2020 January 1 17 10 28 Additions 72 21 22 Cash payments (24) (14) (40) Releases (1) — — December 31 64 17 10 In 2022, 2021 and 2020, additions to restructuring provisions of $72 million, $21 million and $22 million, respectively, were primarily related to the multi-year transformation program initially announced by Alcon on November 19, 2019 and subsequently expanded as announced on November 15, 2022. The costs

Consolidated statement of cas_2

Consolidated statement of cash flows - additional details	12 Months Ended
	Dec. 31, 2022
Cash Flow Statement [Abstract]
Consolidated statements of cash flows - additional details	Consolidated Statement of Cash Flows - additional details The Consolidated Statement of Cash Flows was prepared in accordance with IAS 7, Statement of Cash Flows. The below tables provide additional detail supporting select line items in the Consolidated Statement of Cash Flows. 20.1 Depreciation, amortization, impairments and fair value adjustments ($ millions) 2022 2021 2020 Property, plant & equipment 332 323 299 Right-of-use assets 76 81 79 Intangible assets 715 815 1,245 Financial assets (14) 3 5 Other non-current assets 2 (2) (2) Total 1,111 1,220 1,626 20.2 Change in net current assets and other operating cash flow items ($ millions) 2022 2021 2020 (Increase) in inventories (217) (326) (159) (Increase)/decrease in trade receivables (164) (198) 43 (Decrease)/increase in trade payables (48) 60 (21) Net change in other operating assets (63) (24) 127 Net change in other operating liabilities (30) 174 (35) Total (522) (314) (45) 20.3 Reconciliation of assets and liabilities arising from financing activities Financial Liabilities ($ millions) Non-current financial debts Current financial debts Non-current lease liabilities Current lease liabilities January 1, 2022 3,966 114 339 67 Proceeds from non-current financial debts, net of issuance costs 1,815 — Repayment of non-current financial debts (1,176) — Proceeds from 2022 Bridge Loan Facility, net of issuance costs — 771 Repayment of 2022 Bridge Loan Facility — (775) Impact from business combination — 316 22 5 Repayment of financial debts assumed in acquisition of business — (316) Additions to leases 68 13 Impact of asset acquisitions 2 1 Change in current financial debts — (42) Amortization of discounts on financial debts 1 — Payments of lease liabilities, net — (69) Interest payments for amounts included in lease liabilities classified as cash flows from operating activities — (15) Changes in fair values and other non-cash changes, net 5 8 (2) 13 Currency translation effects (23) (16) (10) (4) Reclassification from non-current to current (47) 47 (60) 60 December 31, 2022 4,541 107 359 71 Financial Liabilities ($ millions) Non-current financial debts Current financial debts Non-current lease liabilities Current lease liabilities January 1, 2021 3,949 169 315 70 Proceeds from non-current financial debts, net of issuance costs 52 — Additions to leases 106 9 Change in current financial debts — (43) Amortization of discounts on financial debts 1 — Payments of lease liabilities, net — (72) Interest payments for amounts included in lease liabilities classified as cash flows from operating activities — (13) Changes in fair values and other non-cash changes, net 4 — (2) 8 Currency translation effects (40) (12) (10) (5) Reclassification from non-current to current — — (70) 70 December 31, 2021 3,966 114 339 67 20.4 Additional disclosure of non-cash investing and financing activity ($ millions) 2022 2021 2020 Treasury stock issued for settlement of equity-based compensation plan, net of withholding taxes 128 63 54 Non-cash additions of right-of-use assets in exchange for a lease liability 81 115 107 Non-cash additions of property, plant & equipment 62 52 83 Non-cash additions of intangible assets 105 6 33

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2022
Asset Acquisitions [Abstract]
Acquisitions	Acquisitions 21.1 Acquisition of business Fair value of assets and liabilities arising from acquisition of business The below table summarizes the preliminary purchase price allocation for business combinations for the years ended December 31, 2022, 2021 and 2020. ($ millions) 2022 2021 2020 Property, plant and equipment 27 — — Right-of-use assets 29 — — Currently marketed products 850 — — Acquired in-process research & development 175 — — Deferred tax assets 189 — — Inventories 49 — — Trade receivables 70 — — Short-term investments 79 — — Cash and cash equivalents 78 — — Other assets 15 — — Lease liabilities (27) — — Deferred tax liabilities (255) — — Provisions and other non-current and current liabilities (235) — — Current income tax liabilities (46) — — Trade payables (3) — — Financial debts (316) — — Net identifiable assets acquired 679 — — Goodwill 65 — — Total purchase consideration 744 — — Acquired liquidity (78) — — Net assets recognized as a result of business combinations 666 — — Vision care - Acquisition of Aerie Pharmaceuticals, Inc. On November 21, 2022, Alcon acquired 100% of the outstanding shares and equity of Aerie, a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies. The acquisition includes with the business among other assets, two commercial pharmaceutical ophthalmic eye drop products, Rocklatan and Rhopressa, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several ophthalmic pharmaceutical product candidates. This transaction helps bolster Alcon’s presence in the ocular health space with its portfolio of commercial products and development pipeline within the Vision Care reportable segment. Pursuant to the terms of the Agreement and Plan of Merger, Alcon paid $15.25 per share to acquire all outstanding shares of Aerie. The total purchase consideration amounted to $744 million and total cash paid for the net identifiable assets recognized, net of cash acquired, was $666 million. The fair values of the acquired assets and assumed liabilities are provisional pending final measurement of the purchase consideration. The short-term investments were liquidated subsequent to the acquisition. Provisions and other non-current liabilities include a contingent liability of $57 million recognized upon the acquisition of Aerie in 2022 related to uncertainty associated with potential contractual payment obligations in the event patents are issued in certain international markets, which may prevent commercialization of Rocklatan and Rhopressa in those markets. The estimated potential undiscounted amount and timing of all future payments that Alcon could be required to make is $71 million in 2027. As of December 31, 2022, there has been no change in the amount recognized for the liability, except for the unwinding of the discount of $0.3 million, as there has been no change in the assumptions. The goodwill is attributable to assembled workforce and pharmaceutical research and development capabilities, including early stage compounds under development. The goodwill is not deductible for tax purposes. Direct acquisition costs of $20 million were recognized in Other expense in the Consolidated Income Statement during 2022 and were reported in operating cash flows in the Consolidated Statement of Cash Flows. Post-acquisition net sales and net loss attributable to Aerie For the period from the date of the Aerie acquisition, November 21, 2022, through December 31, 2022, the acquired business increased Alcon's 2022 net sales by $16 million and reduced Alcon's 2022 net income by $32 million. Unaudited Alcon consolidated pro forma net sales and net income If the Aerie acquisition had occurred on January 1, 2022, unaudited consolidated pro forma net sales and net income for the twelve months ended December 31, 2022 would have been approximately $8,776 million and $192 million, respectively. This pro forma information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro forma information. These estimated amounts have been calculated using Aerie's results of operation beginning January 1, 2022 and adjusting them for: • alignment of the accounting policies between Alcon and Aerie; • additional amortization that would have been charged assuming the fair value adjustments to inventories and intangible assets had been applied from January 1, 2022; • add back of interest expense from Aerie's convertible senior notes to pro forma net income assuming senior notes would have been repaid on January 1, 2022; • additional interest expense that would have been recorded assuming the Series 2032 Notes and Series 2052 Notes were issued on January 1, 2022 to the extent the proceeds were used to refinance the 2022 Bridge Loan Facility; • exclusion of Aerie's pre-acquisition transaction costs; and • tax effects of the above adjustments. 21.2 Acquisitions of assets The below table summarizes the purchase price allocation for asset acquisitions for the years ended December 31, 2022, 2021 and 2020. ($ millions) 2022 2021 2020 Currently marketed products 385 — — Acquired in-process research & development 10 — — Other intangible assets (including software) 12 — — Deferred tax assets 57 — — Trade receivables 10 — — Inventory 16 — — Cash and cash equivalents 4 — — Other assets 6 — — Trade payables and other liabilities (11) — — Net identifiable assets acquired 489 — — Acquired liquidity (4) — — Net assets recognized as a result of asset acquisitions 485 — — During 2022, cash paid for acquisitions, net of cash acquired, was $485 million, the most significant of which was $477 million paid for Ivantis, Inc., described below. Surgical - Acquisition of Ivantis, Inc. On January 7, 2022, Alcon acquired 100% of the outstanding shares and equity of Ivantis, Inc., a privately-held, US-based company and manufacturer of the Hydrus Microstent, a minimally-invasive glaucoma surgery (“MIGS”) device designed to lower intraocular pressure for open-angle glaucoma patients. The acquisition expands Alcon’s surgical portfolio and is expected to help provide a platform for more growth in the glaucoma space. Pursuant to the terms and subject to the conditions of the Option Agreement and Plan of Merger, as amended, Alcon agreed to pay total upfront consideration of $479 million and additional amounts to be potentially paid upon achievement of a development milestone and commercial milestones calculated as a percentage of sales in excess of defined targets that expire in calendar year 2024. The acquisition was accounted for as an asset acquisition rather than a business combination as substantially all of the fair value of the gross assets acquired is concentrated in the value of the Hydrus Microstent commercially marketed product intangible assets, being a group of identifiable assets. Consequently, a relative fair value approach was taken for allocating the consideration to the acquired assets and liabilities with no goodwill recognized.

Post-employment benefits for as

Post-employment benefits for associates	12 Months Ended
	Dec. 31, 2022
Employee Benefits [Abstract]
Post-employment benefits for associates	Post-employment benefits for associates Defined benefit plans In addition to the legally required social security schemes, Alcon has sponsored numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from Alcon. For certain subsidiaries, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases the related unfunded liability is included in the Consolidated Balance Sheet. The value of the post-employment benefits promised under the pension and other post-employment benefit plans is represented by the defined benefit obligation ("DBO"), which is measured based on the projected unit credit method ("PUC"). Independent actuaries reappraise the DBOs of all major pension and other post-employment benefit plans annually. Plan assets are recognized at fair value. The major pension and other post-employment benefit plans are based in Switzerland, the United States, Germany, and the United Kingdom. As of December 31, 2022, these plans represent 88% of Alcon's total DBO and are independently sponsored by Alcon. Details of the plans in those significant countries are provided below. The pension plans in Switzerland represent the most significant portion of Alcon's total pension DBO and the largest component of Alcon's total plan assets. The principal plan in Switzerland is funded and open for new joiners. For the Swiss pension plan, active insured members' benefits are partially linked to the contributions paid into the plan. Certain features of the Swiss pension plan required by law preclude the plan from being categorized as a defined contribution plan. These factors include a minimum interest guarantee on retirement savings accounts, a pre-determined factor for converting the accumulated savings account balance into a pension and embedded death and disability benefits. All benefits granted under a Swiss-based principal pension plan are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate's pay to an external pension foundation. Additional employer contributions may be required whenever the foundation's statutory funding ratio falls below a certain level. The associate also contributes to the plan. Alcon's Swiss pension obligation is set-up under an Alcon-sponsored arrangement affiliated with Copré La Collective de Prévoyance ("Copré") – a Swiss collective foundation. As a collective foundation, Copré is governed by its own board of trustees which is responsible for the foundation regulations and asset investment strategy for multiple entities participating in the collective foundation. Alcon maintains its own pension committee, consisting of representatives nominated by Alcon and the active insured associates. During the fourth quarter of 2021, Copré announced the rates to be used to convert participant balances to pension annuities for 2024 to 2026. This announcement resulted in a plan amendment with a benefit of $15 million recognized in Other income and a corresponding decrease in the DBO. During the third quarter of 2020, the selection of Copré resulted in a plan amendment with past service costs of $12 million recognized in Other expense and a corresponding increase in the DBO. The United States pension plans represent the second largest component of Alcon's total pension DBO and the third largest component of Alcon's total plan assets. The principal plan (Qualified Plan) is funded, whereas the plans providing additional benefits for executives (Defined Benefit Restoration Plan and Grandfathered Supplemental Executive Plan) are unfunded. Benefits in the Qualified Plan and Restoration Plan are frozen for all participants. Employer contributions are required for the Qualified Plan whenever the statutory funding ratio falls below a certain level. Furthermore, the United States other post-employment benefit plans (US OPEB plans) represent 99% of the total DBO for other post-employment benefit plans. These benefits in the US primarily consist of post-employment healthcare which has been closed to new members since 2015. Effective January 1, 2021, the Alcon sponsored group health plan for current and future eligible retired participants age 65 and over was changed to a private Medicare marketplace while providing an annual notional contribution to a Health Reimbursement Account for each covered member and spouse. The impact of the plan amendment in the fourth quarter of 2020 was a benefit of $164 million recognized in Other income and a corresponding decrease in the DBO in Provisions and other non-current liabilities. There is no statutory funding requirement for the US OPEB plans. The major pension arrangements in Germany are governed by the Occupational Pensions Act ("BetrAVG") and represent the third largest component of Alcon's total pension DBO and the fifth largest component of Alcon's total plan assets. The plans are partly funded by a Contractual Trust arrangement or direct insurances. The employer is responsible for contributing the premiums to the insurances and paying certain benefits when they fall due. All plans are closed for new entrants and the benefits are fully vested for all participants. For some participants the benefits are based on final salary and length of employment, and for others the benefit is earned each year based on the current salary in the year of service. Associates do not contribute towards the cost of the benefits. The pension plan in the United Kingdom represents the fourth largest component of Alcon's total pension DBO and the second largest component of Alcon's total plan assets. The plan is closed with only former Alcon associates entitled to current or future benefits. The Alcon United Kingdom Pension Scheme is governed and administered by a board of trustees in accordance with its Trust Deed. United Kingdom legislation requires that pension schemes are funded prudently (i.e., to a level in excess of the "best estimate" expected cost of providing benefits). Funding is assessed on a triennial basis using (prudent) assumptions agreed by the board of trustees and Alcon. The board of trustees is responsible for jointly agreeing with Alcon the level of contributions needed to eliminate any shortfall over a reasonable period of time, typically not exceeding 10 years. Under the governing documentation, if a surplus remains once liabilities have been settled it would be refunded to Alcon. Alcon has two pension plans with a surplus that is not recognized on the basis that future economic benefits are not available to the entity in the form of a reduction in future contributions or a cash refund. The following tables summarize the funded and unfunded DBO for pension and other post-employment benefit plans of Alcon associates at December 31, 2022 and 2021: Pension plans Other post-employment ($ millions) 2022 2021 2022 2021 Benefit obligation at January 1 791 817 300 332 Current service cost 20 24 8 10 Interest cost 12 9 8 7 Past service costs and settlements (3) (38) — — Administrative expenses 2 1 — — Remeasurement (gains) arising from changes in financial assumptions (185) (22) (62) (12) Remeasurement (gains)/losses arising from changes in demographic assumptions (15) — — 1 Remeasurement losses/(gains) arising from experience-related changes 3 67 (19) (25) Currency translation effects (31) (35) — — Benefit payments (36) (37) (18) (17) Contributions of associates 5 5 4 4 Benefit obligation at December 31 563 791 221 300 Fair value of plan assets at January 1 541 519 — — Interest income 8 6 — — Return on plan assets excluding interest income (93) 49 — — Currency translation effects (27) (18) — — Employer contributions 19 23 14 13 Contributions of associates 5 5 4 4 Settlements — (20) — — Benefit payments (36) (37) (18) (17) Effect of acquisitions, divestments or transfers — 14 — — Fair value of plan assets at December 31 417 541 — — Funded status (146) (250) (221) (300) Limitation on recognition of fund surplus at January 1 (20) (17) Change in limitation on recognition of fund surplus (including exchange rate differences) (1) (3) Limitation on recognition of fund surplus at December 31 (21) (20) Net liability in the balance sheet at December 31 (167) (270) (221) (300) The reconciliation of the net liability from January 1 to December 31 is as follows: Pension plans Other post-employment benefit plans ($ millions) 2022 2021 2022 2021 Net liability at January 1 (270) (315) (300) (332) Current service cost (20) (24) (8) (10) Net interest expense (4) (3) (8) (7) Administrative expenses (2) (1) — — Past service costs and settlements 3 18 — — Remeasurements 104 4 81 36 Currency translation effects 4 17 — — Employer contributions 19 23 14 13 Effect of acquisitions, divestments or transfers — 14 — — Change in limitation on recognition of fund surplus (1) (3) — — Net liability at December 31 (167) (270) (221) (300) Amounts recognized in the balance sheet Prepaid benefit cost 8 25 — — Accrued benefit liability (175) (295) (221) (300) The following tables provide detail of the DBO for pension plans by geography and type of member and of plan assets based on the geographical locations in which they are held: 2022 ($ millions) Switzerland United Germany United Rest of Total By type of member Active (207) (32) (38) — (79) (356) Deferred pensioners (6) (28) (18) (33) (9) (94) Pensioners (23) (35) (21) (25) (9) (113) Benefit obligation at December 31 (236) (95) (77) (58) (97) (563) Thereof: unfunded plans 35 24 — — 19 78 Thereof: unfunded portion of funded plans 26 7 60 — 4 97 Prepaid benefit costs and assets subject to limitation on recognition of fund surplus — — — (6) (23) (29) Fair value of plan assets at December 31 175 64 17 64 97 417 Funded status (61) (31) (60) 6 — (146) 2021 ($ millions) Switzerland United Germany United Rest of Total By type of member Active (295) (43) (64) — (99) (501) Deferred pensioners (11) (41) (28) (57) (14) (151) Pensioners (23) (42) (23) (40) (11) (139) Benefit obligation at December 31 (329) (126) (115) (97) (124) (791) Thereof: unfunded plans 47 29 — — 23 99 Thereof: unfunded portion of funded plans 87 6 94 — 9 196 Prepaid benefit costs and assets subject to limitation on recognition of fund surplus — — — (24) (21) (45) Fair value of plan assets at December 31 195 91 21 121 113 541 Funded status (134) (35) (94) 24 (11) (250) The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of Alcon associates: Pension plans Other post-employment 2022 2021 2022 2021 Discount rate 3.6 % 1.4 % 5.3 % 2.7 % Expected rate of pension increase 1.1 % 1.1 % Expected rate of salary increase 2.5 % 2.2 % Interest on savings account 2.9 % 1.3 % Current average life expectancy for a 65-year-old male (in years) 20 20 21 21 Current average life expectancy for a 65-year-old female (in years) 22 22 23 23 The following table shows additional details related to the weighted average discount rates for the principal plan for each significant country: Pension plans Other post-employment 2022 2021 2022 2021 Switzerland 2.2 % 0.2 % United States 5.3 % 2.8 % 5.3 % 2.7 % Germany 3.7 % 1.2 % United Kingdom 4.8 % 1.9 % Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for pension plans and other post-employment benefit plans in the Consolidated Financial Statements. This can result in substantial changes in Alcon's other comprehensive income, non-current liabilities and prepaid pension assets. The DBO is significantly impacted by assumptions related to the rate used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Increasing corporate bond yields increase the discount rate. An increase in the discount rate results in a decrease in the DBO and an increase in the funded status. The impact of increasing interest rates on a plan's assets is more difficult to predict. A significant part of plan assets is invested in bonds. Bond values typically are inversely correlated to interest rates. Bond values usually decrease when interest rates rise and may therefore partially offset the increase in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to fall when interest rates increase and therefore often offset the positive impact of the decreasing DBO on the funded status (although the correlation of interest rates with returns on equities is not as strong as with bonds, especially in the short term). The assumption for the expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. While the average rate remained flat in the current year at 1.1%, such pension increases generally decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases. Assumptions regarding life expectancy significantly impact the DBO. While the life expectancy assumption remained flat in the current year, generally an increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available. The following table shows the sensitivity of the defined benefit pension and other post-employment benefit obligations to the principal actuarial assumptions as of December 31, 2022: ($ millions) (Decrease)/increase in 2022 year-end liability 25 basis point increase in discount rate (22) 25 basis point decrease in discount rate 23 1 year increase in life expectancy 14 25 basis point increase in rate of pension increase 6 25 basis point decrease in rate of pension increase (1) (3) 25 basis point increase of interest on savings account 2 25 basis point decrease of interest on savings account (3) 25 basis point increase in rate of salary increase 3 25 basis point decrease in rate of salary increase (3) (1) Decrease in rate of pension increase is limited to zero. The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes of the assumptions may be correlated. When calculating the sensitivity of the DBO to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the PUC method at the end of the reporting period) has been applied as when calculating the net liability recognized in the Consolidated Balance Sheet. The healthcare cost trend rate assumptions used for other post-employment benefits are as follows: 2022 2021 2020 Healthcare cost trend rate assumed for next year 6.3 % 6.2 % 6.2 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2030 2029 2028 The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022, and 2021: Pension plans (as a percentage) Long-term Long-term 2022 2021 Equity securities 15 40 37 35 Debt securities 20 60 34 40 Real estate 5 20 14 11 Alternative investments 0 20 12 11 Cash and other investments 0 15 3 3 Total 100 100 Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund and private equity investments, usually do not have a quoted market price. The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with employer contributions and contributions of associates (where applicable), is sufficient to manage the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The weighted average duration of the DBO is 11.6 years and 15.5 years as of December 31, 2022 and December 31, 2021, respectively. Alcon's ordinary contribution to the various pension plans is based on the rules of each plan and its respective country. Additional contributions are made whenever required by local statute or law (i.e., usually when statutory funding levels fall below predetermined thresholds). The following table summarizes expected future cash flows for pension and other post-employment benefit plans as of December 31, 2022: ($ millions) Pension plans Other Employer contributions 2023 (estimated) 11 — Expected future benefit payments 2023 36 16 2024 43 18 2025 40 19 2026 34 20 2027 32 20 2028-2032 193 97 Defined contribution plans In many countries, associates are covered by defined contribution plans. Contributions charged to the 2022 Consolidated Income Statement for the defined contribution plans were $144 million (2021: $133 million; 2020: $136 million).

Equity-based compensation

Equity-based compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]
Equity-based compensation	Equity-based compensation For the year ended December 31, 2022, Alcon recorded equity-based compensation expense of $152 million (2021: $151 million, 2020: $113 million). Liabilities from cash-settled equity-based compensation plans were $12 million as of December 31, 2022 ($14 million as of December 31, 2021). At December 31, 2022, Alcon has various equity-based incentive plans, under which Alcon may grant awards in the form of restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), restricted stock awards ("RSAs"), or any other form of award at the discretion of the Company's Board of Directors. Certain associates in select countries may also participate in share ownership savings plans. Summary of unvested share movements The below table summarizes unvested share movements for all Alcon equity-based incentive plans through December 31, 2022 and 2021: 2022 2021 Number of Weighted average Fair value at grant date in $ millions Number of Weighted average Fair value at grant date in $ millions Unvested shares at January 1 5,627 60.96 343 5,417 54.90 297 Granted Restricted awards 1,453 76.61 111 1,456 72.05 105 Performance awards 518 74.48 39 429 72.71 31 Vested (2,447) 55.48 (136) (1,258) 50.94 (64) Forfeited (358) 71.74 (26) (417) 62.50 (26) Unvested shares at December 31 4,793 69.16 331 5,627 60.96 343 The remaining weighted-average vesting period of unvested equity-based awards as of December 31, 2022 was 1.2 years. Equity-based incentive plans The below table summarizes the number of shares authorized under the plans as of December 31, 2022: (thousands) Authorized shares Long-term Incentive Plan 20,000 Deferred Bonus Stock Plan (1) 1,500 Swiss Employee Share Ownership Plan 475 Other share savings plans 275 Total 22,250 (1) Beginning in 2020, the annual incentives for the Alcon CEO and certain senior-level associates no longer include deferrals of compensation in the form of equity-based awards subject to the provisions of this plan. No grants were issued under this plan in 2022 and 2021. Long-term Incentive Plan ("LTIP") - Restricted Stock Units and Restricted Stock Awards Under Alcon's LTIP, certain associates may receive grants of RSUs and RSAs (together "Restricted awards"). The awards generally vest on the third anniversary of the award and are generally forfeited if the employment relationship with Alcon terminates prior to vesting. Recipients of RSU awards do not have any shareholder rights, such as voting or dividend rights, until the shares are delivered. Alcon associates receiving grants of RSAs are entitled to the dividends that may be declared and paid over the vesting period only if the associates vest in such award. LTIP - Performance Stock Units The Alcon CEO and certain senior-level associates participate in Alcon's long-term performance program. PSUs granted under the LTIP each convert to one unrestricted Alcon Inc. share at vesting, subject to the achievement of performance measures. PSUs awarded to plan participants are granted at target incentive ranges from 35% to 430% of base compensation and vest over a three-year period. The payout between 0% and 200% of target is dependent upon four equally weighted performance metrics which are determined at the onset of the performance period by the Company's Board of Directors. The metrics include compound annual growth rate of Net sales, compound annual growth rate of core EPS, market share of peers, and innovation. The Company's Board of Directors and the Compensation Committee assess the performance against the defined measures, including input from the Innovation Committee for the innovation metric, and approve the final payout. PSUs granted under the performance plan do not carry voting rights, but do carry dividend equivalents that are paid in cash or Alcon Inc. shares at vesting, provided participants remain associates of Alcon. Swiss Employee Share Ownership Plan and other share savings plans Alcon associates in certain countries are encouraged to invest in share savings plans. Under the share savings plans, participants may elect to receive some of their wages or annual incentives in Alcon Inc. shares in lieu of cash. Subject to plan rules and limitations, as a reward for their participation in the share savings plans, at no additional cost to the participant, Alcon may partially match their investments in shares after a holding period of 3 years.

Related parties transactions

Related parties transactions	12 Months Ended
	Dec. 31, 2022
Related Party [Abstract]
Related parties transactions	Related parties transactions Executive officers The following table summarizes compensation information for key management personnel: ($ millions) 2022 2021 2020 Cash and other compensation 18.7 19.3 12.8 Post-employment benefits 0.9 0.9 1.1 Equity-based compensation 22.4 20.9 9.2 Total 42.0 41.1 23.1

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2022
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Commitments and contingencies	Commitments and contingencies Commitments Research & development Alcon has entered into long-term research agreements with various institutions which provide for potential milestone payments and other payments by Alcon that may be capitalized. As of December 31, 2022, the commitments to make payments under those agreements, and their estimated timing, were as follows: ($ millions) 2022 2023 6 2024 18 2025 24 2026 3 2027 41 Thereafter 83 Total 175 Other Alcon entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. For disclosure of Property, plant and equipment purchase commitments, see Note 8. Contingencies The Alcon companies have to observe the laws, government orders and regulations of the country in which they operate. A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property including under the Hatch-Waxman Act, and anti-bribery matters such as those under the FCPA, as amended. As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management's time and attention. In addition, such investigations may affect Alcon's reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and may lead to (or arise from) litigation. These factors have contributed to decisions by Alcon and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. Those government settlements have involved and may continue to involve, in current government investigations and proceedings, large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation. While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates. Note 18 contains additional information on these matters. Alcon is involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Alcon companies to sell their products, or require the payment of substantial damages or royalties. Alcon's potential for environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by Alcon as at risk for environmental remediation exposure. Alcon's future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to Alcon at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. Alcon has no significant environmental liabilities as at December 31, 2022 and 2021 and has incurred no significant remediation costs for the years ended December 31, 2022, 2021 and 2020.

Subsequent events

Subsequent events	12 Months Ended
	Dec. 31, 2022
Events After Reporting Period [Abstract]
Subsequent events	Subsequent events On February 14, 2023, three local bilateral facilities in Japan with commitments totaling $170 million (JPY22.5 billion) maturing in February 2023 were refinanced by three facilities with two year maturities. Refer to Note 18 to these Consolidated Financial Statements for information on any updates to significant legal proceedings subsequent to December 31, 2022. On February 27, 2023, the Company's Board of Directors (the "Board") approved the proposal to submit the 2022 financial statements of Alcon Inc. and these Consolidated Financial Statements for approval at the Annual General Meeting on May 5, 2023. Additionally on February 27, 2023, the Board proposed a dividend of CHF 0.21 per share to be approved at the same Annual General Meeting. If approved by the shareholders, the total dividend payments would amount to a maximum of approximately $113 million using the CHF/USD exchange rate as of February 21, 2023. The Board has evaluated subsequent events as they relate to Alcon for potential recognition or disclosures from January 1, 2023 to the date of the approval of these Consolidated Financial Statements and has determined there are no additional subsequent events to be reported in these Consolidated Financial Statements.

Alcon subsidiaries

Alcon subsidiaries	12 Months Ended
	Dec. 31, 2022
Disclosure Of Separate Financial Statements [Abstract]
Alcon subsidiaries	Alcon subsidiaries The following table lists the subsidiaries of Alcon Inc. with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements at and for the year ended December 31, 2022, respectively. The equity interest percentage shown in the table represents Alcon's share in voting rights in those entities. Unless otherwise stated, each entity has share capital consisting of equity held directly by the Company or another of its consolidated subsidiaries. Country of organization/Entity name Place of business Equity Argentina Alcon Laboratorios Argentina S.A. Buenos Aires 100 % Australia Alcon Laboratories (Australia) Pty Ltd Macquarie Park 100 % Austria Alcon Ophthalmika GmbH Wien 100 % Belgium Alcon Laboratories Belgium BVBA Puurs 100 % Alcon N.V. Vilvoorde 100 % Brazil Alcon Brasil Cuidados com a Saúde Ltda. São Paulo 100 % Canada Alcon Canada Inc. Mississauga, Ontario 100 % Chile Alcon Laboratorios Chile Ltd. Santiago de Chile 100 % China Alcon (China) Ophthalmic Product Co., Ltd. Beijing 100 % Alcon Hong Kong Limited Hong Kong 100 % Colombia Laboratorios Alcon de Colombia S.A. Santafé de Bogotá 100 % Czech Republic Alcon Pharmaceuticals (Czech Republic) s.r.o. Prague 100 % Denmark Alcon Nordic A/S Copenhagen 100 % Ecuador AlconLab Ecuador S.A. Quito 100 % France Laboratoires Alcon S.A.S. Rueil-Malmaison 100 % Germany Alcon Deutschland GmbH Freiburg im Breisgau 100 % CIBA Vision GmbH Grosswallstadt 100 % WaveLight GmbH Erlangen 100 % Greece Alcon Laboratories Hellas- Single Member Commercial and Industrial S.A.C.I. Maroussi, Athens 100 % Hungary Alcon Hungary Pharmaceuticals Trading Limited Liability Company Budapest 100 % India Alcon Laboratories (India) Private Limited Bangalore 100 % Indonesia PT. CIBA Vision Batam Batam 100 % Ireland Alcon Laboratories Ireland Limited Cork City 100 % Aerie Pharmaceuticals Ireland Limited Athlone 100 % Israel Optonol Ltd. Neve-Ilan 100 % Italy Alcon Italia S.p.A. Milano 100 % Japan Alcon Japan Ltd. Tokyo 100 % Country of organization/Entity name Place of business Equity Malaysia Alcon Laboratories (Malaysia) Sdn. Bhd. Petaling Jaya 100 % CIBA Vision Johor Sdn. Bhd. Johor 100 % Mexico Alcon Laboratorios, S.A. de C.V. Ciudad de Mexico 100 % Netherlands Alcon Finance B.V. Amsterdam 100 % Alcon Nederland B.V. Gorinchem 100 % New Zealand Alcon Laboratories (New Zealand) Ltd. Remuera 100 % Panama Alcon Centroamerica S.A. Panama City 100 % Peru Alcon Pharmaceutical del Peru S.A. Lima 100 % Philippines Alcon Laboratories (Philippines), Inc. Pasig City 100 % Poland Alcon Polska Sp. z o.o. Warszawa 100 % Portugal Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda. Porto Salvo 100 % Puerto Rico Alcon (Puerto Rico), Inc. Cataño, PR 100 % Romania Alcon Romania S.R.L. Bucharest 100 % Russian Federation Alcon Farmacevtika LLC Moscow 100 % Singapore Alcon Pte Ltd Singapore 100 % Alcon Singapore Manufacturing Pte Ltd Singapore 100 % CIBA Vision Asian Manufacturing and Logistics Pte Ltd. Singapore 100 % South Africa Alcon Laboratories (South Africa) (Pty) Ltd. Midrand 100 % South Korea Alcon Korea Ltd. Seoul 100 % Spain Alcon Healthcare S.A. Barcelona 100 % Switzerland Alcon Grieshaber AG Schaffhausen 100 % Alcon Management SA Vernier 100 % Alcon Pharmaceuticals Ltd. Fribourg 100 % Alcon Services AG Fribourg 100 % Alcon Switzerland SA Zug 100 % Thailand Alcon Laboratories (Thailand) Limited Bangkok 100 % Turkey Alcon Laboratuvarlari Ticaret A.S. Istanbul 100 % Ukraine Alcon Ukraine LLC Kiev 100 % Country of organization/Entity name Place of business Equity United Kingdom Alcon Eye Care UK Limited Frimley/Camberley 100 % United States of America Aerie Distribution, Inc. Fort Worth, TX 100 % Aerie Pharmaceuticals, Inc. Fort Worth, TX 100 % Alcon Finance Corporation Fort Worth, TX 100 % Alcon Laboratories, Inc. Fort Worth, TX 100 % Alcon RefractiveHorizons, LLC Fort Worth, TX 100 % Alcon Research, LLC Fort Worth, TX 100 % Alcon Vision, LLC Fort Worth, TX 100 % CIBA Vision, LLC Fort Worth, TX 100 % WaveLight, Inc. Fort Worth, TX 100 % Ivantis, Inc. Fort Worth, TX 100 % MDBackline, Inc. Fort Worth, TX 100 % PowerVision, Inc. Fort Worth, TX 100 % Tear Film Innovations, Inc. Fort Worth, TX 100 % TrueVision Systems, Inc. Fort Worth, TX 100 % Uruguay Alcon Laboratorios Uruguay S.A. Montevideo 100 %

Selected accounting policies (P

Selected accounting policies (Policies)	12 Months Ended
	Dec. 31, 2022
Corporate Information And Statement Of IFRS Compliance [Abstract]
Basis of preparation	Basis of preparation The accompanying Consolidated Financial Statements present our historical financial position, results of operations, comprehensive income/(loss), and cash flows in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). Alcon's principal accounting policies are described in this Note.
Foreign currencies	Foreign currencies The Consolidated Financial Statements are presented in US dollars ("USD"). The functional currency of individual entities incorporated into the Consolidated Financial Statements is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. For entities not operating in hyperinflationary economies, the entities results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: • Income, expense and cash flows using for each month the average exchange rate with the USD values for each month being aggregated during the year. • Balance sheet using year-end exchange rates. • Resulting exchange rate differences are recognized in other comprehensive income/(loss). The hyperinflationary economies in which Alcon operates are Argentina, Turkey and Venezuela. Argentina and Venezuela were hyperinflationary for all years presented. Turkey became hyperinflationary effective April 1, 2022, requiring retroactive implementation from January 1, 2022 of hyperinflationary accounting. The impact of the restatement of the non-monetary assets and liabilities with the general price index at the beginning of the period an economy becomes hyperinflationary is recorded in "Other reserves" in equity. The subsequent gains or losses resulting from the restatement of non-monetary assets and liabilities are recorded in "Other financial income & expense" in the Consolidated Income Statement.
Acquisition of assets	Acquisition of assets Assets separately acquired are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. The capitalized cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives. Freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset or "Cost of net sales" in the Consolidated Income Statement. Property, plant and equipment are assessed for impairment at the cash generating unit ("CGU") level whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. The following table shows the respective useful lives for property, plant and equipment: Useful life Buildings and improvements 10 to 40 years Machinery and other equipment Machinery and equipment 5 to 20 years Furniture and vehicles 5 to 10 years Computer hardware 3 to 7 years
Business combinations	Business combinations Effective January 1, 2020, Alcon adopted Amendments to IFRS 3, Business Combinations . The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary may include: • Fair values of the assets transferred; • Liabilities incurred to the former owners of the acquired business; • Equity interests issued by the Company; • Fair value of an asset or liability resulting from a contingent consideration arrangement; and • Fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. The excess of the consideration transferred over the fair value of the net identifiable assets acquired is recorded as goodwill, or directly in the income statement if it is a bargain purchase. Alcon primarily uses net present value techniques, utilizing post-tax cash flows and discount rates in estimating the fair value of identifiable assets acquired when allocating the purchase consideration paid for the acquisition. The estimates of the fair values involve significant judgment by management and include assumptions with measurement uncertainty such as, the amount and timing of projected cash flows, long-term sales forecasts, the timing and probability of regulatory and commercial success, and the discount rate. Acquisition related costs are expensed as incurred. Alcon may elect on a transaction-by-transaction basis to apply the optional concentration test to assess whether a transaction qualifies as a business. Under the test, when substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, Alcon will account for the transaction as an asset purchase and not a business combination. If the concentration test is not met, or Alcon elects not to apply this optional test, Alcon will perform an assessment focusing on the existence of inputs and processes that have the ability to create outputs to determine whether the transaction is an asset purchase or a business combination.
Goodwill	Goodwill Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of CGUs which are usually represented by the reportable segments, which are the same as Alcon's operating segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under "Other expense" in the Consolidated Income Statement.
Intangible assets available for use and Acquired In-Process Research & Development	Intangible assets available for use Alcon has the following classes of available-for-use intangible assets: Currently marketed products, Marketing know-how, Technologies, Other intangible assets (including computer software) and the Alcon brand name. Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names. Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products. Technologies represent identified and separable acquired know-how used in the research, development and production processes. Significant investments in internally developed and acquired software are capitalized and included in the "Other" category and amortized once available for use. The Alcon brand name is shown separately as it is the only Alcon intangible asset that is available for use with an indefinite useful life. Alcon considers it appropriate that the brand name has an indefinite life since the branded products have a history of strong revenue and cash flow performance, and Alcon has the intent and ability to support the brand with spending to maintain its value for the foreseeable future. Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually. The following table shows the respective useful lives for available-for-use intangible assets and the location in the Consolidated Income Statement in which the respective amortization and any potential impairment charge is recognized: Useful life Income statement location for Currently marketed products 5 to 20 years "Cost of net sales" Marketing know-how 25 years "Cost of net sales" Technologies 10 to 20 years "Cost of net sales" or "Research and Development" Other (including software) 3 to 10 years In the respective functional expense Alcon brand name Not amortized, indefinite useful life "Other expense" Acquired In-Process Research & Development ("IPR&D") Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as IPR&D. IPR&D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. IPR&D is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal ("FVLCOD") and its value in use ("VIU"). Usually, Alcon applies the FVLCOD method for its impairment assessments. Under this approach when evaluating IPR&D for potential impairment, FVLCOD is estimated using net present value techniques utilizing post-tax cash flows and discount rates as there are no direct or indirect observable prices in active markets for identical or similar assets. The estimates used in calculating the net present values involve significant judgment by management and include assumptions with measurement uncertainty such as, the amount and timing of projected cash flows, long-term sales forecasts, discount rate, and the timing and probability of regulatory and commercial success. In the limited cases where the VIU method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. Any impairment charge is recorded in the Consolidated Income Statement under "Research & development". Once a project included in IPR&D has been successfully developed it is transferred to the "Currently marketed products" category.
Impairment of goodwill, Alcon brand name and definite lived intangible assets	Impairment of goodwill, Alcon brand name and definite lived intangible assets A CGU to which goodwill has been allocated (reportable segments) is considered impaired when its carrying amount, including the goodwill, exceeds its recoverable amount, which is defined as the higher of its FVLCOD and its VIU. If the recoverable amount of the reportable segment is less than its carrying amount, an impairment loss shall be recognized. The impairment loss shall be allocated to reduce the carrying amount of any goodwill allocated to the reportable segment first, with any remaining impairment loss allocated to other assets of the reportable segment on a pro-rata basis of their carrying amount. An intangible asset other than goodwill is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its FVLCOD and its VIU. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset shall be reduced to its recoverable amount. That reduction is an impairment loss. Usually, Alcon applies the FVLCOD method for its impairment assessment. In most cases, no direct or indirect observable market prices for identical or similar assets are available to measure the FVLCOD. Therefore, an estimate of FVLCOD is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the VIU method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. FVLCOD reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. The estimates used in calculating the net present values involve significant judgment by management and include assumptions with measurement uncertainty, such as the following: • Amount and timing of projected cash flows; • Long-term sales forecasts for periods of up to 25 years including sales growth rates; • Royalty rate for the Alcon brand name; • Terminal growth rate; and • Discount rate. Other assumptions used in the net present values calculation include: • Future tax rate; • Actions of competitors (launch of competing products, marketing initiatives, etc.); and • Outcome of R&D activities and forecast of related costs (future product developments). Generally, for intangible assets with a definite useful life Alcon uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Alcon generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections considering the long-term expected growth rates and impact of demographic trends of the population to which Alcon products are prescribed, for later periods. Probability-weighted scenarios are typically used. Discount rates used consider Alcon estimated weighted average cost of capital adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant. Actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using net present value techniques.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, and other short-term and highly liquid investments. Other short-term and highly liquid investments are classified as cash and cash equivalents when original or weighted-average maturities are three months or less and amounts are readily convertible to known amounts of cash which are subject to an insignificant risk of changes in value. Bank overdrafts are usually presented within current financial debts on the Consolidated Balance Sheet except in cases where a right of offset has been agreed with a bank which then allows for presentation on a net basis.
Financial assets	Financial assets Non-current financial assets such as loans and long-term receivables from customers, primarily related to surgical equipment sales arrangements, advances and other deposits, are carried at amortized cost, which reflects the time value of money, less any allowances for uncollectable amounts. Alcon assesses on a forward-looking basis the expected credit losses associated with its non-current financial assets valued at amortized cost. For loans, advances and other deposits valued at amortized cost, impairments, which are based on their expected credit losses, and exchange rate losses are included in "Other expense" in the Consolidated Income Statement and exchange rate gains and interest income, using the effective interest rate method, are included in "Other income" in the Consolidated Income Statement. For long-term receivables from customers, provisions for uncollectable amounts, which are based on their expected credit losses, are recorded as marketing and selling costs recognized in the Consolidated Income Statement within "Selling, general & administration" expenses. Fund investments are valued at fair value through profit and loss ("FVPL"). Unrealized gains and losses, including exchange gains and losses, are recognized in the Consolidated Income Statement in "Other income" for gains and "Other expense" for losses. Equity securities and convertible notes receivable held as strategic investments are generally designated at the date of acquisition as financial assets valued at fair value through other comprehensive income ("FVOCI") with no subsequent recycling through profit and loss. Unrealized gains and losses, including exchange gains and losses, are recorded as a fair value adjustment in the Consolidated Statement of Comprehensive Income/(Loss). They are reclassified to "Other reserves" when the equity security is sold. If these equity securities and convertible notes receivable are not designated at the date of acquisition as financial assets valued at FVOCI, they are valued at FVPL, as described above for fund investments. Changes in fair value of options to acquire development stage companies are charged to research and development expense. Derivative financial instruments are initially recognized in the Consolidated Balance Sheet at fair value and are remeasured to their current fair value at the end of each subsequent reporting period. The valuation of forward exchange rate contracts and foreign exchange swaps are based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. Unsettled forward contracts and swaps are measured at fair value at quarter-end with changes in fair value recorded to the Consolidated Income Statement as unrealized gains or losses in "Other financial income & expense". Settled forward contracts and swaps are measured at maturity date at fair value with corresponding realized gains or losses recognized in the Consolidated Income Statement in "Other financial income & expense". No hedge accounting is applied for these arrangements.
Inventories	Inventories Inventory is valued at the lower of acquisition or production cost determined on a first-in, first-out basis and net realizable value. This value is used for the "Cost of net sales" and "Cost of other revenues" in the Consolidated Income Statement. Unsalable inventory is fully written off in the Consolidated Income Statement under "Cost of net sales" and "Cost of other revenues".
Trade receivables	Trade receivables Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as chargebacks and cash discounts. Provisions for expected credit losses are established using an expected credit loss model ("ECL"). The provisions are based on a forward-looking ECL, which includes possible default events on the trade receivables over the entire holding period of the trade receivable. These provisions represent the difference between the trade receivable's carrying amount and the estimated net collectible amount. Charges for doubtful trade receivables are recorded as marketing and selling costs recognized in the Consolidated Income Statement within "Selling, general & administration" expenses.
Leases	Leases As lessee, Alcon assesses whether a contract contains a lease at inception of a contract based on whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Alcon recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases for which Alcon has elected the recognition exemptions allowed under IFRS 16. Right-of-use assets Right-of-use assets are initially recognized at cost, which is comprised of the amount of the initial measurement of the corresponding lease liabilities, adjusted for any lease payments made at or prior to the commencement date of the lease, lease incentives received and initial direct costs incurred, as well as any expected costs for obligations to dismantle and remove right-of-use assets when they are no longer used. Right-of-use assets are depreciated on a straight-line basis over the shorter of the useful life of the right-of-use asset or the end of the lease term. Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. Lease liabilities Lease liabilities are accounted for at amortized cost and are initially measured at the present value of future lease payments and are classified as current or non-current based on the due dates of the underlying principal payments. In determining the lease term, Alcon evaluates the renewal options and termination options reasonably certain to be exercised. Lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the incremental borrowing rate Alcon would be expected to pay within the respective markets, on a borrowing with a similar term and security. Interest in the period is recorded within "Interest expense" in the Consolidated Income Statement. Lease liabilities are remeasured for changes in estimated lease term, future lease payments arising from a change in an index or rate, amounts expected to be payable under a residual value guarantee, or in assessment of whether Alcon will exercise a purchase, extension or termination option. Changes to initial lease contract terms are assessed to determine their impact on the scope of lease, and any modifications increasing the scope of the lease are treated as new contracts under the initial measurement principles, while modifications that do not increase or that decrease the scope of the lease result in an adjustment to the right-of-use asset which is remeasured as of the date of the modification. Principal payments made on lease liabilities and any initial direct costs paid are classified as financing cash outflows, while interest payments are classified as operating cash outflows. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the Consolidated Income Statement and are classified as cash flows from operating activities.
Legal liabilities	Legal liabilities Alcon is subject to contingencies arising in the ordinary course of business such as patent litigation and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes.
Contingent consideration	Contingent consideration In a business combination, it is necessary to recognize contingent future payments to previous owners representing contractually defined potential amounts as a liability. Usually for Alcon, these are linked to development or commercial milestones related to certain assets and are recognized as a financial liability at their fair value, which is then re-measured at each subsequent reporting date. For the determination of the fair value of a contingent consideration, various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the timing and probability of regulatory and commercial success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, appropriately discounted to reflect the impact of time. Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the Consolidated Income Statement in "Cost of net sales" for currently marketed products and in "Research & development" for IPR&D. The effect of unwinding the discount over time is recognized in "Interest expense" in the Consolidated Income Statement. Alcon accounts for variable or contingent consideration associated with asset acquisitions using the cost accumulation model. At the date of the asset acquisition, the intangible asset is initially recognized at the amount paid. Variable payments are subsequently capitalized as part of the cost of the asset when paid, on the basis that such payments represent the direct cost of acquisition.
Defined benefit pension plans and other post-employment benefits and defined contribution plans	Defined benefit pension plans and other post-employment benefits The liability or asset recognized in the balance sheet in respect of defined benefit pension plans and other post-employment benefits is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms approximating the terms of the related obligation. In countries where there is no sufficient market for such bonds, the market rates on government bonds are used. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed. The net interest on the net defined benefit liability is recognized as "Other expense" or "Other income". The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. Past service cost is recognized as "Other expense" or "Other income" in the Consolidated Income Statement for the change in the present value of a defined benefit obligation for employee service in prior periods resulting from a plan amendment or a curtailment. Remeasurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income/(loss).
Financial debts	Financial debts Financial debts are initially recognized at fair value, net of transaction costs incurred. Financial debts are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs and discounts) and the redemption amount is recognized in the Consolidated Income Statement over the period of the financial debts using the effective interest method. Fees paid on the establishment of credit facilities are recognized as transaction costs of the financial debt to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw down occurs. To the extent that there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalized as a prepayment for liquidity services and amortized over the period of the facility to which it relates, and is recognized in "Other financial income & expense" in the Consolidated Income Statement. Financial debts are derecognized from the balance sheet when the obligation specified in the contract is discharged, cancelled or expired. The difference between the carrying amount of a financial debt that has been extinguished and the consideration paid, including any non-cash assets transferred or liabilities assumed, is recognized in "Other financial income & expense" in the Consolidated Income Statement. Interest paid on financial debts is classified as operating activities in the Consolidated Statement of Cash Flows. Financial debts are classified as current liabilities unless Alcon has an unconditional right and intent to defer the settlement of the liability for at least twelve months after the reporting period.
Revenue	Revenue Net sales to third parties Revenue on the sale of Alcon products and services, which is recorded as "Net sales to third parties" in the Consolidated Income Statement, is recognized when a contractual promise to a customer (i.e., a performance obligation) has been fulfilled by transferring control over the promised goods and services to the customer, substantially all of which is at the point in time of shipment to or receipt of the products by the customer or when the services are performed. If contracts contain customer acceptance provisions, revenue would be recognized upon the satisfaction of acceptance criteria. The amount of revenue to be recognized is based on the consideration Alcon expects to receive in exchange for its goods and services. If a contract contains more than one performance obligation, the consideration is allocated based on the relative standalone selling price of each performance obligation. Surgical equipment may be sold together with other products and services under a single contract and may be structured as an outright cash sale, an installment sale, or lease. Surgical equipment installment sales and leases have a fixed payment amount which the customer may pay either in fixed intervals or as the customer purchases consumables and/or implantables. Revenues are recognized upon satisfaction of each of the performance obligations in the contract and the consideration is allocated based on the relative standalone selling price of each performance obligation. • Surgical equipment revenue from outright cash sales and installment sales arrangements is recognized at the point in time when control is transferred to the customer. The current portion of long-term receivables from customers and long-term receivables from customers for installment sales arrangements are recorded in "Other current assets" (see "Current portion of long-term receivables from customers" in Note 14 of these Consolidated Financial Statements) and "Financial assets" (see "Long-term receivables from customers" in Note 11 of these Consolidated Financial Statements), respectively. Financing income for installment sales arrangements longer than twelve months is recognized over the term of the arrangement in "Other income". Alcon applies the practical expedient under IFRS 15 to installment sales arrangements that are twelve months or less in duration. • In addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Leases in which Alcon transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair value of the equipment, which approximates the present value of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements longer than twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in "Other income". Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term in "Net sales to third parties". The consideration Alcon receives in exchange for its goods or services may be fixed or variable. Variable consideration is only recognized when it is highly probable that a significant reversal of cumulative sales will not occur. The most common elements of variable consideration are listed below: • Rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed health-care organizations and other customers, estimated payments for Medicare Part D prescription drug program coverage gap (commonly called the "donut hole"), patient co-pay program coupon utilization, as well as chargebacks are provisioned and recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience, regulations, the specific terms in the individual agreements, product pricing, channels and payors. • Cash discounts are offered to customers to encourage prompt payment and are provisioned and recorded as revenue deductions at the time the related sales are recorded. • Sales returns provisions are recognized and recorded as revenue deductions when there is historical experience of Alcon agreeing to customer returns and Alcon can reasonably estimate expected future returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts, chargebacks, payment for Medicare Part D prescription drug program, patient co-pay program coupon utilization and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. Other revenues "Other revenues" include revenue from contract manufacturing services which are recognized over time as the service obligations are completed and third party royalty income. Associated costs for contract manufacturing services are recognized in "Cost of other revenues".
Research & development	Research & development Internal research & development ("R&D") costs are fully charged to "Research & development" in the Consolidated Income Statement in the period in which they are incurred. Alcon considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland, China or Japan. Payments made to third parties to in-license or acquire intellectual property rights and products, including initial upfront and subsequent milestone payments, are capitalized as intangible assets. If additional payments are made to the originator company to continue to perform R&D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&D services not resulting in an additional transfer of intellectual property rights to Alcon. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Alcon of additional intellectual property developed at the risk of the originator company. Subsequent internal R&D costs in relation to IPR&D and other assets are expensed until such time that technical feasibility can be proven, as demonstrated by the receipt of marketing approval for the related product from a regulatory authority in a major market.
Equity-based compensation	Equity-based compensation Each of the periods presented include expense related to incentive compensation provided to eligible Alcon associates in the form of equity-settled or equity-based awards including restricted stock units ("RSUs") and performance stock units ("PSUs"). Alcon expenses the fair values of RSUs and PSUs granted to associates as compensation over the related vesting periods within the various functions where the associates are employed. The fair values of the awards are determined on their grant dates and are adjusted to account for the specific provisions of each of the corresponding grant agreements. Alcon RSUs do not entitle the recipients to dividends. As such, the fair value upon grant is based on the Alcon share price at the grant date adjusted for potential future dividends to be paid within the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under Alcon's plans are subject to performance criteria based on internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period relative to targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the Consolidated Income Statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. If a plan participant leaves Alcon for reasons other than retirement, disability or death, then unvested restricted shares, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Company's Board of Directors, for example, in connection with a reorganization.
Restructuring charges	Restructuring charges Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. Charges to increase restructuring provisions are included in "Other expense" in the Consolidated Income Statement. Corresponding releases are recorded in "Other income" in the Consolidated Income Statement.
Taxes	Taxes Taxes on income are expensed in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax basis of an asset or liability and its carrying value in the balance sheet prepared for purposes of these Consolidated Financial Statements, except for those temporary differences related to investments in subsidiaries where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary's retained earnings are only taken into account when a dividend has been planned. The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.
Earnings/(loss) per share	Earnings/(loss) per share Basic earnings/(loss) per share is based on the weighted average number of common shares outstanding. Diluted earnings/(loss) per share is based on the weighted average number of common shares outstanding and all dilutive potential common shares outstanding.
New standards and interpretations not yet adopted	New standards and interpretations not yet adoptedThere are no IFRS standards, interpretations or amendments not yet effective that would be expected to have a material impact on Alcon upon adoption.

Selected accounting policies (T

Selected accounting policies (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure of notes and other explanatory information [Abstract]
Disclosure of useful lives for property, plant and equipment	Useful life Buildings and improvements 10 to 40 years Machinery and other equipment Machinery and equipment 5 to 20 years Furniture and vehicles 5 to 10 years Computer hardware 3 to 7 years The following table summarizes the movements of property, plant & equipment in 2022: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2022 36 1,987 790 3,547 6,360 Additions — 10 554 123 687 Impact of business combination — 10 2 15 27 Disposals and derecognitions (1) — (13) (3) (172) (188) Reclassifications for assets placed in service — 127 (389) 262 — Currency translation effects (1) (30) 1 (81) (111) December 31, 2022 35 2,091 955 3,694 6,775 Accumulated depreciation January 1, 2022 — (802) (1) (1,846) (2,649) Depreciation charge — (92) — (238) (330) Impairment charge — — (2) — (2) Disposals and derecognitions (1) — 13 1 165 179 Currency translation effects — 11 — 41 52 December 31, 2022 — (870) (2) (1,878) (2,750) Net book value at December 31, 2022 35 1,221 953 1,816 4,025 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. As of December 31, 2022, commitments for purchases of property, plant & equipment were $248 million. The following table summarizes the movements of property, plant & equipment in 2021: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2021 35 1,884 573 3,425 5,917 Additions 2 8 654 57 721 Disposals and derecognitions (1) — (7) (8) (93) (108) Reclassifications for assets placed in service — 146 (410) 264 — Currency translation effects (1) (44) (19) (106) (170) December 31, 2021 36 1,987 790 3,547 6,360 Accumulated depreciation January 1, 2021 — (716) (8) (1,768) (2,492) Depreciation charge — (107) — (216) (323) Disposals and derecognitions (1) — 5 7 83 95 Currency translation effects — 16 — 55 71 December 31, 2021 — (802) (1) (1,846) (2,649) Net book value at December 31, 2021 36 1,185 789 1,701 3,711 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
Disclosure of useful lives for intangible assets and location in combined income statement	The following table shows the respective useful lives for available-for-use intangible assets and the location in the Consolidated Income Statement in which the respective amortization and any potential impairment charge is recognized: Useful life Income statement location for Currently marketed products 5 to 20 years "Cost of net sales" Marketing know-how 25 years "Cost of net sales" Technologies 10 to 20 years "Cost of net sales" or "Research and Development" Other (including software) 3 to 10 years In the respective functional expense Alcon brand name Not amortized, indefinite useful life "Other expense"

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Operating Segments [Abstract]
Disclosure of operating segments	Net sales and other revenues by segment ($ millions) 2022 2021 2020 Surgical Implantables 1,725 1,522 1,126 Consumables 2,499 2,388 1,952 Equipment/other 821 793 632 Total Surgical net sales to third parties 5,045 4,703 3,710 Vision Care Contact lenses 2,192 2,139 1,838 Ocular health 1,417 1,380 1,215 Total Vision Care net sales to third parties 3,609 3,519 3,053 Total net sales to third parties 8,654 8,222 6,763 Vision Care other revenues 63 69 70 Total net sales and other revenues 8,717 8,291 6,833 Segment contribution and reconciliation to income/(loss) before taxes ($ millions) 2022 2021 2020 Segment contribution Surgical 1,336 1,184 672 Vision Care 600 604 419 Total segment contribution 1,936 1,788 1,091 Not allocated to segments: Amortization of intangible assets (653) (590) (1,078) Impairment charges on intangible assets (62) (225) (167) General & administration (corporate) (255) (251) (232) Separation costs — (36) (217) Transformation costs (119) (68) (49) Fair value adjustments to contingent consideration liabilities 23 42 63 Past service costs for post-employment benefit plan amendments — 18 154 Acquisition and integration related costs (64) — — Other (134) (98) (47) Operating income/(loss) 672 580 (482) Interest expense (134) (120) (124) Other financial income & expense (75) (42) (29) Income/(loss) before taxes 463 418 (635) Included in segment contribution are: ($ millions) 2022 2021 2020 Depreciation of property, plant & equipment: Surgical (131) (129) (122) Vision Care (198) (194) (171) Not allocated to segments (1) — — Total depreciation of property, plant & equipment (330) (323) (293) Depreciation of right-of-use assets: Surgical (46) (50) (47) Vision Care (30) (31) (32) Total depreciation of right-of-use assets (76) (81) (79) Impairment charges on property, plant & equipment, net: Surgical (2) — (6) Vision Care — — — Total impairment charges on property, plant & equipment, net (2) — (6) Equity-based compensation: Surgical (74) (74) (55) Vision Care (61) (60) (45) Not allocated to segments (17) (17) (13) Total equity-based compensation (152) (151) (113)
Disclosure of geographical areas	The following table shows the United States, International and countries that accounted for more than 5% of at least one of the respective Alcon totals, for net sales for the years ended December 31, 2022, 2021 and 2020, and for selected non-current assets at December 31, 2022 and 2021: Net sales (2) Total of selected non-current assets (3) ($ millions unless indicated otherwise) (1) 2022 2021 2020 2022 2021 Country United States 3,897 45 % 3,651 44 % 2,975 44 % 11,739 51 % 10,200 47 % International 4,757 55 % 4,571 56 % 3,788 56 % 11,336 49 % 11,553 53 % thereof: Switzerland (country of domicile) 59 1 % 60 1 % 55 1 % 9,462 41 % 9,762 45 % Japan 568 7 % 621 8 % 650 10 % 44 — % 46 — % China 474 5 % 486 6 % 383 6 % 9 — % 16 — % Other 3,656 42 % 3,404 41 % 2,700 40 % 1,821 8 % 1,729 8 % Company total 8,654 100 % 8,222 100 % 6,763 100 % 23,075 100 % 21,753 100 % (1) International percentages may not sum due to rounding. (2) Net sales from operations by location of third-party customer. (3) Includes property, plant & equipment, right-of-use assets, goodwill and other intangible assets.

Interest expense and other fi_2

Interest expense and other financial income & expense (Tables)	12 Months Ended
	Dec. 31, 2022
Analysis of income and expense [abstract]
Disclosure of components of interest expense	Interest expense ($ millions) 2022 2021 2020 Interest expense on financial debts (110) (95) (94) Interest expense from discounting long-term liabilities (9) (12) (17) Interest expense on lease liabilities (15) (13) (13) Total interest expense (134) (120) (124)
Disclosure of components of other financial income & expense	Other financial income & expense ($ millions) 2022 2021 2020 Interest income 16 3 6 Loss on extinguishment of financial debt (5) — — Other financial expense (12) (10) (9) Monetary loss from hyperinflation accounting (16) (6) (4) Currency result, net (58) (29) (22) Total other financial income & expense (75) (42) (29)

Taxes (Tables)

Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Disclosure of components of income (loss) before taxes	Income/(loss) before taxes ($ millions) 2022 2021 2020 Switzerland 234 680 (585) Foreign 229 (262) (50) Total income/(loss) before taxes 463 418 (635)
Disclosure of components of current and deferred income tax expense	Current and deferred income tax (expense)/income ($ millions) 2022 2021 2020 Switzerland (17) (118) (14) Foreign (146) (116) (105) Current income tax expense (163) (234) (119) Switzerland 53 45 96 Foreign (18) 147 127 Deferred tax income 35 192 223 Total income tax (expense)/income (128) (42) 104
Disclosure of reconciliation of tax rate	The main elements contributing to the difference between Alcon's overall applicable tax rate and the effective tax rate are summarized in the below table. 2022 2021 2020 ($ millions unless indicated otherwise) (1) % % % Applicable tax rate (104) 22.5 % (39) 9.3 % 98 15.4 % Effect of disallowed expenditures (13) 2.8 % (10) 2.4 % (20) (3.1) % Effect of equity-based compensation (13) 2.8 % (7) 1.7 % (5) (0.8) % Effect of income taxed at reduced rates 4 (0.9) % 1 (0.2) % 4 0.6 % Effect of tax credits and allowances 11 (2.4) % 9 (2.2) % 9 1.4 % Effect of deductibility of a statutory expense in Switzerland (2) 23 (5.0) % 38 (9.1) % — — % Effect of adjustments to contingent consideration and other liabilities 3 (0.6) % 7 (1.7) % 17 2.7 % Effect of option payments — — % (2) 0.5 % (6) (0.9) % Effect of tax rate changes — — % (3) 0.7 % 10 1.6 % Effect of changes in uncertain tax positions (3) 10 (2.2) % (39) 9.3 % (8) (1.3) % Effect of 2022 APA on prior years (37) 8.0 % — — % — — % Effect of non-deductible amortization (7) 1.5 % — — % — — % Effect of other items (2) 0.4 % (3) 0.7 % (10) (1.6) % Effect of prior year items (3) 0.6 % 6 (1.4) % 15 2.4 % Effective tax rate (128) 27.6 % (42) 10.0 % 104 16.4 % (1) Percentages may not sum due to rounding. (2) Effect of deductibility of statutory expense in Switzerland relates to agreements for fiscal years 2022 and 2021. It is uncertain whether Alcon will obtain a similar benefit in future years. (3) Effect of changes in uncertain tax positions in 2022 primarily relate to recognition of the benefit of the effect of deductibility of a statutory expense in Switzerland for 2021, partially offset by a reserve for the deductibility of a statutory expense in Switzerland for 2022. Effect of changes in uncertain tax positions in 2021 primarily relate to international transfer pricing and a partial reserve for the deductibility of a statutory expense in Switzerland.

Share capital, dividends and _2

Share capital, dividends and earnings/(loss) per share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings per share [abstract]
Movement in the shares	The following table shows the movement in the shares: (shares in millions) Common stock shares outstanding Treasury stock shares Total shares January 1, 2020 488.3 3.4 491.7 Issuance of additional registered shares — 8.0 8.0 Settlement of equity-based awards 0.9 (0.9) — December 31, 2020 489.2 10.5 499.7 Settlement of equity-based awards 0.9 (0.9) — December 31, 2021 490.1 9.6 499.7 Settlement of equity-based awards 1.7 (1.7) — December 31, 2022 491.8 7.9 499.7

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	Useful life Buildings and improvements 10 to 40 years Machinery and other equipment Machinery and equipment 5 to 20 years Furniture and vehicles 5 to 10 years Computer hardware 3 to 7 years The following table summarizes the movements of property, plant & equipment in 2022: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2022 36 1,987 790 3,547 6,360 Additions — 10 554 123 687 Impact of business combination — 10 2 15 27 Disposals and derecognitions (1) — (13) (3) (172) (188) Reclassifications for assets placed in service — 127 (389) 262 — Currency translation effects (1) (30) 1 (81) (111) December 31, 2022 35 2,091 955 3,694 6,775 Accumulated depreciation January 1, 2022 — (802) (1) (1,846) (2,649) Depreciation charge — (92) — (238) (330) Impairment charge — — (2) — (2) Disposals and derecognitions (1) — 13 1 165 179 Currency translation effects — 11 — 41 52 December 31, 2022 — (870) (2) (1,878) (2,750) Net book value at December 31, 2022 35 1,221 953 1,816 4,025 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. As of December 31, 2022, commitments for purchases of property, plant & equipment were $248 million. The following table summarizes the movements of property, plant & equipment in 2021: ($ millions) Land Buildings & improvements Construction Machinery & Total Cost January 1, 2021 35 1,884 573 3,425 5,917 Additions 2 8 654 57 721 Disposals and derecognitions (1) — (7) (8) (93) (108) Reclassifications for assets placed in service — 146 (410) 264 — Currency translation effects (1) (44) (19) (106) (170) December 31, 2021 36 1,987 790 3,547 6,360 Accumulated depreciation January 1, 2021 — (716) (8) (1,768) (2,492) Depreciation charge — (107) — (216) (323) Disposals and derecognitions (1) — 5 7 83 95 Currency translation effects — 16 — 55 71 December 31, 2021 — (802) (1) (1,846) (2,649) Net book value at December 31, 2021 36 1,185 789 1,701 3,711 (1) Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets [Abstract]
Summary of movements of goodwill and intangible assets	The following table summarizes the movements of goodwill and other intangible assets in 2022: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Cost January 1, 2022 8,905 2,980 737 5,369 4,803 5,960 658 20,507 Impact of business combination 65 — 175 — 850 — — 1,025 Impact of asset acquisitions — — 10 — 385 — 12 407 Additions — — — — 151 — 57 208 Disposals and derecognitions (1) — — (2) — — — (7) (9) December 31, 2022 8,970 2,980 920 5,369 6,189 5,960 720 22,138 Accumulated amortization January 1, 2022 — — (180) (5,238) (3,471) (2,622) (231) (11,742) Amortization charge — — — (40) (279) (239) (95) (653) Disposals and derecognitions (1) — — 2 — — — 6 8 Impairment charges — — (3) — (59) — — (62) December 31, 2022 — — (181) (5,278) (3,809) (2,861) (320) (12,449) Net book value at December 31, 2022 8,970 2,980 739 91 2,380 3,099 400 9,689 (1) Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. The following table summarizes the allocation of the net book values of goodwill and other intangible assets by reportable segment at December 31, 2022: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Surgical 4,544 — 564 91 583 3,099 240 4,577 Vision Care 4,426 — 175 — 1,797 — 160 2,132 Not allocated to segments — 2,980 — — — — — 2,980 Net book value at December 31, 2022 8,970 2,980 739 91 2,380 3,099 400 9,689 The following table summarizes the movements of goodwill and other intangible assets in 2021: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Cost January 1, 2021 8,905 2,980 727 5,369 4,440 5,960 556 20,032 Additions — — 20 — 359 — 104 483 Reclassifications — — (10) — 10 — — — Disposals and derecognitions (1) — — — — (6) — (2) (8) December 31, 2021 8,905 2,980 737 5,369 4,803 5,960 658 20,507 Accumulated amortization January 1, 2021 — — — (5,199) (3,197) (2,384) (155) (10,935) Amortization charge — — — (39) (235) (238) (78) (590) Disposals and derecognitions (1) — — — — 6 — 2 8 Impairment charges — — (180) — (45) — — (225) December 31, 2021 — — (180) (5,238) (3,471) (2,622) (231) (11,742) Net book value at December 31, 2021 8,905 2,980 557 131 1,332 3,338 427 8,765 (1) Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. The following table summarizes the allocation of the net book values of goodwill and other intangible assets by reportable segment at December 31, 2021: Intangible assets other than goodwill ($ millions) Goodwill Alcon Acquired Technologies Currently Marketing Other Total Surgical 4,544 — 555 131 229 3,338 251 4,504 Vision Care 4,361 — 2 — 1,103 — 176 1,281 Not allocated to segments — 2,980 — — — — — 2,980 Net book value at December 31, 2021 8,905 2,980 557 131 1,332 3,338 427 8,765
Assumptions used in calculations for the recoverable amounts of goodwill and intangible assets	The following assumptions were used in the calculations for the recoverable amounts of goodwill and the Alcon brand name at December 31, 2022 and 2021: 2022 2021 (As a percentage) Surgical Vision Care Surgical Vision Care Terminal growth rate 3.0 3.0 3.0 3.0 Discount rate (post-tax) 9.0 8.75 7.0 6.5
Intangible asset impairment charges	The following table shows the intangible asset impairment charges in 2022, 2021 and 2020: ($ millions) 2022 2021 2020 Surgical (60) (178) (66) Vision Care (2) (47) (101) Total (62) (225) (167)

Deferred tax assets and liabi_2

Deferred tax assets and liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes [Abstract]
Disclosure of temporary difference, unused tax losses and unused tax credits	($ millions) Property, plant & equipment Intangible assets Pensions and other benefit obligations of associates Inventories Tax loss carry-forwards Other assets, provisions and accruals Total Gross deferred tax assets at December 31, 2021 28 5 116 372 188 452 1,161 Gross deferred tax liabilities at December 31, 2021 (246) (1,382) — (23) — (127) (1,778) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617) At December 31, 2021 (218) (1,377) 116 349 188 325 (617) (Charged)/credited to income (57) 102 1 (23) (168) 180 35 (Charged)/credited to equity — — — — 12 (31) (19) (Charged) to other comprehensive income — — (38) — — (5) (43) Impact of business combination (1) (250) — — 142 43 (66) Impact of asset acquisitions — — — — 57 — 57 Net deferred tax balance at December 31, 2022 (276) (1,525) 79 326 231 512 (653) Gross deferred tax assets at December 31, 2022 31 4 79 352 231 642 1,339 Gross deferred tax liabilities at December 31, 2022 (307) (1,529) — (26) — (130) (1,992) Net deferred tax balance at December 31, 2022 (276) (1,525) 79 326 231 512 (653) ($ millions) Property, plant & equipment Intangible assets Pensions and other benefit obligations of associates Inventories Tax loss carry-forwards Other assets, provisions and accruals Total Gross deferred tax assets at December 31, 2020 24 5 128 381 174 314 1,026 Gross deferred tax liabilities at December 31, 2020 (215) (1,519) — (23) — (66) (1,823) Net deferred tax balance at December 31, 2020 (191) (1,514) 128 358 174 248 (797) At December 31, 2020 (191) (1,514) 128 358 174 248 (797) (Charged)/credited to income (27) 137 1 (9) 4 86 192 (Charged)/credited to equity — — (2) — 7 3 8 (Charged)/credited to other comprehensive income — — (11) — 3 (12) (20) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617) Gross deferred tax assets at December 31, 2021 28 5 116 372 188 452 1,161 Gross deferred tax liabilities at December 31, 2021 (246) (1,382) — (23) — (127) (1,778) Net deferred tax balance at December 31, 2021 (218) (1,377) 116 349 188 325 (617)
Disclosure of components in deferred taxes	The below table presents the Net deferred tax balance as of December 31, 2022 after offsetting $928 million of deferred tax assets and liabilities within the same tax jurisdiction. ($ millions) At December 31, 2022 Deferred tax assets 411 Deferred tax liabilities (1,064) Net deferred tax liabilities (653) The below table presents the Net deferred tax balance as of December 31, 2021 after offsetting $752 million of deferred tax assets and liabilities within the same tax jurisdiction. ($ millions) At December 31, 2021 Deferred tax assets 409 Deferred tax liabilities (1,026) Net deferred tax liabilities (617)
Disclosure of impact of deferred taxes on current taxes payable	The below table presents deferred tax assets and deferred tax liabilities expected to have an impact on current taxes payable after more than twelve months. ($ billions) At December 31, 2022 At December 31, 2021 Deferred tax assets 1.0 0.8 Deferred tax liabilities 1.9 1.7

Financial and other non-curre_2

Financial and other non-current assets (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of financial assets	Financial assets ($ millions) 2022 2021 Long-term financial investments measured at FVOCI 88 46 Long-term financial investments measured at FVPL 20 6 Long-term receivables from customers 119 110 Non-current minimum lease payments from finance lease agreements 38 35 Long-term loans, advances and security deposits 22 20 Total financial assets 287 217 The below table provides detail related to financial instruments as of December 31, 2022 and December 31, 2021. ($ millions) Note 2022 2021 Cash and cash equivalents Cash in current accounts 281 246 Cash held in time deposits and money market funds 699 1,329 Total cash and cash equivalents 980 1,575 Financial assets - measured at fair value through other comprehensive income ("FVOCI") Long-term financial investments 11 88 46 Total financial assets - measured at FVOCI 88 46 Financial assets - measured at amortized costs (1) Trade receivables 13 1,673 1,496 Income tax receivables 13 9 Other current assets (excluding prepaid expenses and other current assets measured at FVPL) 14 303 309 Long-term receivables from customers 11 119 110 Non-current minimum lease payments from finance lease agreements 11 38 35 Long-term loans, advances and security deposits 11 22 20 Total financial assets - measured at amortized costs 2,168 1,979 Financial assets - measured at fair value through profit and loss ("FVPL") Equity securities of public companies 14 — 3 Deferred compensation assets 11 139 155 Derivative financial instruments 14 8 3 Long-term financial investments 11 20 6 Total financial assets - measured at FVPL 167 167 Total financial assets 3,403 3,767 Financial liabilities - measured at amortized cost or cost (1) Current financial liabilities Financial debts 16 97 107 Lease liabilities 15 71 67 Trade payables 861 903 Total current financial liabilities - measured at amortized cost or cost 1,029 1,077 Non-current financial liabilities Financial debts 16 4,541 3,966 Lease liabilities 15 359 339 Total non-current financial liabilities - measured at amortized cost or cost 4,900 4,305 Total financial liabilities - measured at amortized cost or cost 5,929 5,382 Financial liabilities - measured at FVPL Contingent consideration liabilities 18 98 112 Derivative financial instruments 16 10 7 Total financial liabilities - measured at FVPL 108 119 Total financial liabilities 6,037 5,501 Net financial assets and financial liabilities (2,634) (1,734) (1) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debts with a fair value of $4,145 million and carrying value of $4,541 million as of December 31, 2022. As of December 31, 2021, the Series 2026, 2029, 2030 and 2049 Notes recorded in Non-current financial debts had a fair value of $2,891 million and carrying value of $2,728 million. The fair value of notes was determined using Level 2 inputs. The notes were valued using a quoted market price for such notes, which have low trading volumes.
Disclosure of maturity analysis of finance lease payments receivable	The following table shows the receivables of the gross investments in finance leases and the net present value of the minimum lease payments, as well as unearned finance income, related to surgical equipment lease arrangements. The finance income is recorded in "Other income". 2022 2021 ($ millions) Total future payments Unearned interest income Present Provision Net Total future payments Unearned interest income Present Provision Net Not later than one year (1) 28 (2) 26 (1) 25 32 (2) 30 (2) 28 Between one and five years 49 (2) 47 (10) 37 47 (2) 45 (12) 33 Later than five years 1 — 1 — 1 2 — 2 — 2 Total 78 (4) 74 (11) 63 81 (4) 77 (14) 63 (1) The current portion of the minimum lease payments is recorded in Trade receivables or Other current assets (to the extent not yet invoiced).
Disclosure of details of non-current assets	Other non-current assets ($ millions) 2022 2021 Deferred compensation plans 139 155 Prepaid post-employment benefit plans 8 25 Other non-current assets 96 54 Total other non-current assets 243 234

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Inventories [Abstract]
Disclosure of details of inventories	($ millions) 2022 2021 Raw material, consumables 433 336 Work in progress 201 169 Finished products 1,475 1,394 Total inventories 2,109 1,899

Trade receivables (Tables)

Trade receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Summary of trade receivables	The following tables provide details related to Trade receivables as of December 31, 2022 and 2021, including trade receivables that are not overdue as specified in the payment terms and conditions established with Alcon's customers, as well as an analysis of overdue amounts, expected credit loss rates and related provisions for doubtful trade receivables: 2022 ($ millions) Gross trade receivables Provision Trade receivables, net Expected credit loss rates Not overdue 1,390 (2) 1,388 0.1 % Past due for not more than one month 125 (1) 124 0.8 % Past due for more than one month but less than three months 93 (2) 91 2.2 % Past due for more than three months but less than six months 56 (4) 52 7.1 % Past due for more than six months but less than one year 28 (16) 12 57.1 % Past due for more than one year 38 (32) 6 84.2 % Total 1,730 (57) 1,673 2021 ($ millions) Gross trade receivables Provision Trade receivables, net Expected credit loss rates Not overdue 1,273 (2) 1,271 0.2 % Past due for not more than one month 96 (1) 95 1.0 % Past due for more than one month but less than three months 74 (1) 73 1.4 % Past due for more than three months but less than six months 43 (2) 41 4.7 % Past due for more than six months but less than one year 23 (13) 10 56.5 % Past due for more than one year 42 (36) 6 85.7 % Total 1,551 (55) 1,496
Movement in the provision for doubtful trade receivables	The following table summarizes the movement in the provision for doubtful trade receivables: ($ millions) 2022 2021 2020 January 1 (55) (68) (48) Provisions for doubtful trade receivables charged to the Consolidated Income Statement (40) (20) (48) Utilization of provisions for doubtful trade receivables 7 8 15 Reversal of provisions for doubtful trade receivables 28 23 14 Currency translation effects 3 2 (1) December 31 (57) (55) (68)
Summary of trade receivables from closely monitored countries	The following table shows the gross trade receivables balance from these closely monitored countries as of December 31, 2022 and 2021, the amounts that are past due for more than one year and the related amount of the provisions for doubtful trade receivables that have been recorded: ($ millions) 2022 2021 Total balance of gross trade receivables from closely monitored countries 280 252 Past due for more than one year 8 10 Provisions for doubtful trade receivables (10) (11)
Summary of trade receivables by major currencies	Trade receivables include amounts denominated in the following major currencies: ($ millions) 2022 2021 US dollar (USD) 701 526 Euro (EUR) 256 243 Japanese yen (JPY) 154 160 Chinese yuan (CNY) 102 122 Brazilian real (BRL) 55 44 Indian rupee (INR) 33 36 Canadian dollar (CAD) 35 39 Australian dollar (AUD) 29 24 British pound (GBP) 31 29 Russian ruble (RUB) 28 35 South Korean won (KRW) 37 38 Mexican peso (MXN) 26 25 Other currencies 186 175 Total trade receivables, net 1,673 1,496

Other current assets (Tables)

Other current assets (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Schedule of other current assets	The following table provides details related to Other current assets as of December 31, 2022 and 2021: ($ millions) 2022 2021 Current portion of long-term receivables from customers 102 97 Current portion of minimum lease payments from finance lease agreements 25 28 Prepaid expenses 107 92 VAT receivables 99 105 Other receivables, security deposits and current assets 77 79 Derivative financial instruments 8 3 Equity securities in public companies — 3 Total other current assets 418 407

Right-of-use assets and Lease_2

Right-of-use assets and Lease liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Schedule of right-of-use assets	Right-of-use assets as of December 31, 2022 and 2021 were comprised of the following: ($ millions) 2022 2021 Land 15 17 Buildings 347 326 Machinery & equipment and other assets 29 29 Total right-of-use assets 391 372 Depreciation charges of $76 million and $81 million for the years ended December 31, 2022 and 2021, respectively, are shown in the table below by underlying class of asset: ($ millions) 2022 2021 Land 1 1 Buildings 58 60 Machinery & equipment and other assets 17 20 Total depreciation of right-of-use assets 76 81
Contractual maturities of undiscounted lease liabilities	The contractual maturities of the undiscounted lease liabilities as of December 31, 2022 and 2021, are as follows: Lease liabilities undiscounted ($ millions) 2022 2021 Not later than one year 85 80 Between one and five years 226 197 Later than five years 233 237 Total lease liabilities undiscounted 544 514 Lease liabilities ($ millions) 2022 2021 Not later than one year 71 67 Between one and five years 180 157 Later than five years 179 182 Total lease liabilities 430 406 The following table provides details on the maturity of the contractual undiscounted cash flows for Alcon's borrowings as of December 31, 2022 and 2021: 2022 2021 ($ millions) Nominal amount - Current and non-current financial debt Derivatives Total Nominal amount - Current and non-current financial debt Derivatives Total Not later than one year 97 10 107 107 7 114 Between one and five years 500 — 500 1,743 — 1,743 Later than five years 4,083 — 4,083 2,250 — 2,250 Total contractual undiscounted cash flows 4,680 10 4,690 4,100 7 4,107 Unamortized debt discount and issuance costs (42) — (42) (27) — (27) Total carrying value 4,638 10 4,648 4,073 7 4,080 The following table provides details on the maturity of the future contractual interest payments commitments as of December 31, 2022 and 2021: ($ millions) 2022 2021 Not later than one year 169 94 Between one and five years 651 340 Later than five years 1,563 583 Total cash flows 2,383 1,017
Schedule of additional disclosures related to leases	The following table provides additional disclosures related to Right-of-use assets and Lease liabilities: ($ millions) 2022 2021 Interest expense on lease liabilities 15 13 Expense on short-term, low value and variable leases 3 7 Total cash outflows for leases 87 92 Thereof: Lease liability payments (1) 69 72 Interest payments (2) 15 13 Short-term, low value and variable lease payments (2) 3 7 (1) Reported as cash outflows from financing activities net of lease incentives received (2) Included within total net cash flows from operating activities

Non-current and current finan_2

Non-current and current financial debts (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Schedule of financial debts	The below table summarizes non-current and current Financial debts outstanding as of December 31, 2022 and 2021. ($ millions) 2022 2021 Non-current financial debts Facility B, floating rate debt due 2024 — 796 Facility C, floating rate debt due 2024 — 395 Local facilities (Japan), floating rate debt due 2023 — 47 2.750% Series 2026 Notes 497 496 2.375% Series 2028 Notes 527 — 3.000% Series 2029 Notes 994 993 2.600% Series 2030 Notes 746 745 5.375% Series 2032 Notes 692 — 3.800% Series 2049 Notes 494 494 5.750% Series 2052 Notes 591 — Revolving facility, floating rate due 2026 — — Total non-current financial debts 4,541 3,966 Current financial debts Local facilities, floating rate: Japan 69 84 All others 2 17 Other short-term financial debts, floating rate 26 6 Derivatives 10 7 Total current financial debts 107 114 Total financial debts 4,648 4,080
Maturity of contractual undiscounted cash flows for borrowings	The contractual maturities of the undiscounted lease liabilities as of December 31, 2022 and 2021, are as follows: Lease liabilities undiscounted ($ millions) 2022 2021 Not later than one year 85 80 Between one and five years 226 197 Later than five years 233 237 Total lease liabilities undiscounted 544 514 Lease liabilities ($ millions) 2022 2021 Not later than one year 71 67 Between one and five years 180 157 Later than five years 179 182 Total lease liabilities 430 406 The following table provides details on the maturity of the contractual undiscounted cash flows for Alcon's borrowings as of December 31, 2022 and 2021: 2022 2021 ($ millions) Nominal amount - Current and non-current financial debt Derivatives Total Nominal amount - Current and non-current financial debt Derivatives Total Not later than one year 97 10 107 107 7 114 Between one and five years 500 — 500 1,743 — 1,743 Later than five years 4,083 — 4,083 2,250 — 2,250 Total contractual undiscounted cash flows 4,680 10 4,690 4,100 7 4,107 Unamortized debt discount and issuance costs (42) — (42) (27) — (27) Total carrying value 4,638 10 4,648 4,073 7 4,080 The following table provides details on the maturity of the future contractual interest payments commitments as of December 31, 2022 and 2021: ($ millions) 2022 2021 Not later than one year 169 94 Between one and five years 651 340 Later than five years 1,563 583 Total cash flows 2,383 1,017

Financial instruments - addit_2

Financial instruments - additional disclosures (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Instruments [Abstract]
Disclosure of financial assets	Financial assets ($ millions) 2022 2021 Long-term financial investments measured at FVOCI 88 46 Long-term financial investments measured at FVPL 20 6 Long-term receivables from customers 119 110 Non-current minimum lease payments from finance lease agreements 38 35 Long-term loans, advances and security deposits 22 20 Total financial assets 287 217 The below table provides detail related to financial instruments as of December 31, 2022 and December 31, 2021. ($ millions) Note 2022 2021 Cash and cash equivalents Cash in current accounts 281 246 Cash held in time deposits and money market funds 699 1,329 Total cash and cash equivalents 980 1,575 Financial assets - measured at fair value through other comprehensive income ("FVOCI") Long-term financial investments 11 88 46 Total financial assets - measured at FVOCI 88 46 Financial assets - measured at amortized costs (1) Trade receivables 13 1,673 1,496 Income tax receivables 13 9 Other current assets (excluding prepaid expenses and other current assets measured at FVPL) 14 303 309 Long-term receivables from customers 11 119 110 Non-current minimum lease payments from finance lease agreements 11 38 35 Long-term loans, advances and security deposits 11 22 20 Total financial assets - measured at amortized costs 2,168 1,979 Financial assets - measured at fair value through profit and loss ("FVPL") Equity securities of public companies 14 — 3 Deferred compensation assets 11 139 155 Derivative financial instruments 14 8 3 Long-term financial investments 11 20 6 Total financial assets - measured at FVPL 167 167 Total financial assets 3,403 3,767 Financial liabilities - measured at amortized cost or cost (1) Current financial liabilities Financial debts 16 97 107 Lease liabilities 15 71 67 Trade payables 861 903 Total current financial liabilities - measured at amortized cost or cost 1,029 1,077 Non-current financial liabilities Financial debts 16 4,541 3,966 Lease liabilities 15 359 339 Total non-current financial liabilities - measured at amortized cost or cost 4,900 4,305 Total financial liabilities - measured at amortized cost or cost 5,929 5,382 Financial liabilities - measured at FVPL Contingent consideration liabilities 18 98 112 Derivative financial instruments 16 10 7 Total financial liabilities - measured at FVPL 108 119 Total financial liabilities 6,037 5,501 Net financial assets and financial liabilities (2,634) (1,734) (1) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debts with a fair value of $4,145 million and carrying value of $4,541 million as of December 31, 2022. As of December 31, 2021, the Series 2026, 2029, 2030 and 2049 Notes recorded in Non-current financial debts had a fair value of $2,891 million and carrying value of $2,728 million. The fair value of notes was determined using Level 2 inputs. The notes were valued using a quoted market price for such notes, which have low trading volumes.
Disclosure of financial liabilities	The below table provides detail related to financial instruments as of December 31, 2022 and December 31, 2021. ($ millions) Note 2022 2021 Cash and cash equivalents Cash in current accounts 281 246 Cash held in time deposits and money market funds 699 1,329 Total cash and cash equivalents 980 1,575 Financial assets - measured at fair value through other comprehensive income ("FVOCI") Long-term financial investments 11 88 46 Total financial assets - measured at FVOCI 88 46 Financial assets - measured at amortized costs (1) Trade receivables 13 1,673 1,496 Income tax receivables 13 9 Other current assets (excluding prepaid expenses and other current assets measured at FVPL) 14 303 309 Long-term receivables from customers 11 119 110 Non-current minimum lease payments from finance lease agreements 11 38 35 Long-term loans, advances and security deposits 11 22 20 Total financial assets - measured at amortized costs 2,168 1,979 Financial assets - measured at fair value through profit and loss ("FVPL") Equity securities of public companies 14 — 3 Deferred compensation assets 11 139 155 Derivative financial instruments 14 8 3 Long-term financial investments 11 20 6 Total financial assets - measured at FVPL 167 167 Total financial assets 3,403 3,767 Financial liabilities - measured at amortized cost or cost (1) Current financial liabilities Financial debts 16 97 107 Lease liabilities 15 71 67 Trade payables 861 903 Total current financial liabilities - measured at amortized cost or cost 1,029 1,077 Non-current financial liabilities Financial debts 16 4,541 3,966 Lease liabilities 15 359 339 Total non-current financial liabilities - measured at amortized cost or cost 4,900 4,305 Total financial liabilities - measured at amortized cost or cost 5,929 5,382 Financial liabilities - measured at FVPL Contingent consideration liabilities 18 98 112 Derivative financial instruments 16 10 7 Total financial liabilities - measured at FVPL 108 119 Total financial liabilities 6,037 5,501 Net financial assets and financial liabilities (2,634) (1,734) (1) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debts with a fair value of $4,145 million and carrying value of $4,541 million as of December 31, 2022. As of December 31, 2021, the Series 2026, 2029, 2030 and 2049 Notes recorded in Non-current financial debts had a fair value of $2,891 million and carrying value of $2,728 million. The fair value of notes was determined using Level 2 inputs. The notes were valued using a quoted market price for such notes, which have low trading volumes.
Disclosure of fair value measurement of assets	The following tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of December 31, 2022 and December 31, 2021. December 31, 2022 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 88 — 88 Long-term financial investments measured at FVPL — — 20 — 20 Long-term receivables from customers — — — 119 119 Deferred compensation assets (1) 139 — — — 139 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, advances and security deposits — — — 22 22 Non-current financial assets 139 — 108 179 426 Current financial assets Money market funds 229 — — — 229 Current portion of long-term receivables from customers (2) — — — 102 102 Current portion of minimum lease payments from finance lease agreements (2) — — — 25 25 VAT receivables (2) — — — 99 99 Other receivables, security deposits and current assets (2) — — — 77 77 Derivative financial instruments (2) — 8 — — 8 Current financial assets 229 8 — 303 540 Financial assets at fair value and amortized cost or cost 368 8 108 482 966 Financial liabilities Contingent consideration liabilities — — (98) — (98) Non-current financial debt — — — (4,541) (4,541) Current financial debt — — — (97) (97) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (98) (4,638) (4,746) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets. December 31, 2021 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 46 — 46 Long-term financial investments measured at FVPL — — 6 — 6 Long-term receivables from customers — — — 110 110 Deferred compensation assets (1) 155 — — — 155 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, advances and security deposits — — — 20 20 Non-current financial assets 155 — 52 165 372 Current financial assets Money market funds 624 — — — 624 Equity securities of public companies (2) 3 — — — 3 Current portion of long-term receivables from customers (2) — — — 97 97 Current portion of minimum lease payments from finance lease agreements (2) — — — 28 28 VAT receivables (2) — — — 105 105 Other receivables, security deposits and current assets (2) — — — 79 79 Derivative financial instruments (2) — 3 — — 3 Current financial assets 627 3 — 309 939 Financial assets at fair value and amortized cost or cost 782 3 52 474 1,311 Financial liabilities Contingent consideration liabilities — — (112) — (112) Non-current financial debt — — — (3,966) (3,966) Current financial debt — — — (107) (107) Derivative financial instruments — (7) — — (7) Financial liabilities at fair value and amortized cost — (7) (112) (4,073) (4,192) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets Long-term financial investments measured Financial investments ($ millions) 2022 2021 2022 2021 Balance as of January 1 46 28 6 24 Additions 45 18 — — (Loss) recognized in Consolidated Statement of Comprehensive Income/(Loss) (2) — — — Unrealized gain/(loss) in Consolidated Income Statement — — 14 (3) Amortization — — — (12) Settlement (1) — — (3) Balance as of December 31 88 46 20 6
Disclosure of fair value measurement of liabilities	The following tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of December 31, 2022 and December 31, 2021. December 31, 2022 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 88 — 88 Long-term financial investments measured at FVPL — — 20 — 20 Long-term receivables from customers — — — 119 119 Deferred compensation assets (1) 139 — — — 139 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, advances and security deposits — — — 22 22 Non-current financial assets 139 — 108 179 426 Current financial assets Money market funds 229 — — — 229 Current portion of long-term receivables from customers (2) — — — 102 102 Current portion of minimum lease payments from finance lease agreements (2) — — — 25 25 VAT receivables (2) — — — 99 99 Other receivables, security deposits and current assets (2) — — — 77 77 Derivative financial instruments (2) — 8 — — 8 Current financial assets 229 8 — 303 540 Financial assets at fair value and amortized cost or cost 368 8 108 482 966 Financial liabilities Contingent consideration liabilities — — (98) — (98) Non-current financial debt — — — (4,541) (4,541) Current financial debt — — — (97) (97) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (98) (4,638) (4,746) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets. December 31, 2021 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost Total Non-current financial assets Long-term financial investments measured at FVOCI — — 46 — 46 Long-term financial investments measured at FVPL — — 6 — 6 Long-term receivables from customers — — — 110 110 Deferred compensation assets (1) 155 — — — 155 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, advances and security deposits — — — 20 20 Non-current financial assets 155 — 52 165 372 Current financial assets Money market funds 624 — — — 624 Equity securities of public companies (2) 3 — — — 3 Current portion of long-term receivables from customers (2) — — — 97 97 Current portion of minimum lease payments from finance lease agreements (2) — — — 28 28 VAT receivables (2) — — — 105 105 Other receivables, security deposits and current assets (2) — — — 79 79 Derivative financial instruments (2) — 3 — — 3 Current financial assets 627 3 — 309 939 Financial assets at fair value and amortized cost or cost 782 3 52 474 1,311 Financial liabilities Contingent consideration liabilities — — (112) — (112) Non-current financial debt — — — (3,966) (3,966) Current financial debt — — — (107) (107) Derivative financial instruments — (7) — — (7) Financial liabilities at fair value and amortized cost — (7) (112) (4,073) (4,192) (1) Recorded in Other non-current assets. (2) Recorded in Other current assets Contingent consideration liabilities ($ millions) 2022 2021 Balance as of January 1 (112) (157) Accretion for passage of time (9) (12) Adjustments for changes in assumptions 23 42 Payments — 15 Balance as of December 31 (98) (112)

Provisions and other non-curr_2

Provisions and other non-current liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of provisions and other non-current liabilities	The below table provides details related to Provisions and other non-current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accrued liability for employee benefits: Defined benefit pension plans 22 175 295 Other long-term employee benefits and deferred compensation 160 177 Other post-employment benefits 22 221 300 Provisions for litigation and other legal matters — — Contingent consideration 17 98 112 Other non-current liabilities 132 56 Total provisions and other non-current liabilities 786 940
Disclosure of details of non-current product liabilities and other legal matter provisions	Litigation and other legal matters provision movements ($ millions) 2022 2021 2020 January 1 53 — — Additions to provisions 175 54 9 Cash payments (21) (1) (9) Releases of provisions (1) — — December 31 206 53 — Less current portion (206) (53) — Non-current provisions for litigation and other legal matters at December 31 — — —

Provisions and other current _2

Provisions and other current liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of provisions and other current liabilities	The following table provides details related to Provisions and other current liabilities as of December 31, 2022 and 2021: ($ millions) Note 2022 2021 Accruals for compensation and benefits including social security 465 489 Accruals for deductions from revenue 386 264 Deferred income 89 108 Taxes other than income taxes 98 93 Restructuring provisions 64 17 Accrued expenses for goods and services received but not invoiced 95 76 Accruals for royalties 12 10 Provisions for litigation and other legal matters 18 206 53 Accrued equity-based payments 12 14 Accrued interest on financial debts 31 19 Other payables 66 58 Total provisions and other current liabilities 1,524 1,201
Disclosure of movement of accruals for deductions from revenue	The following table shows the movement of accruals for deductions from revenue: ($ millions) 2022 2021 2020 January 1 264 217 212 Additions 878 677 540 Impact of business combination 86 — — Payments/utilizations (829) (619) (537) Changes in offset against gross trade receivables (3) (5) (2) Currency translation effects (10) (6) 4 December 31 386 264 217
Disclosure of movement of restructuring provisions	The following table shows the movement of restructuring provisions: ($ millions) 2022 2021 2020 January 1 17 10 28 Additions 72 21 22 Cash payments (24) (14) (40) Releases (1) — — December 31 64 17 10

Consolidated statement of cas_3

Consolidated statement of cash flows - additional details (Tables)	12 Months Ended
	Dec. 31, 2022
Cash Flow Statement [Abstract]
Disclosure of detailed information about cash flow statement line items	($ millions) 2022 2021 2020 Property, plant & equipment 332 323 299 Right-of-use assets 76 81 79 Intangible assets 715 815 1,245 Financial assets (14) 3 5 Other non-current assets 2 (2) (2) Total 1,111 1,220 1,626
Disclosure of detailed information of change in net current assets and other operating cash flow items	($ millions) 2022 2021 2020 (Increase) in inventories (217) (326) (159) (Increase)/decrease in trade receivables (164) (198) 43 (Decrease)/increase in trade payables (48) 60 (21) Net change in other operating assets (63) (24) 127 Net change in other operating liabilities (30) 174 (35) Total (522) (314) (45)
Disclosure of reconciliation of liabilities arising from financing activities	Financial Liabilities ($ millions) Non-current financial debts Current financial debts Non-current lease liabilities Current lease liabilities January 1, 2022 3,966 114 339 67 Proceeds from non-current financial debts, net of issuance costs 1,815 — Repayment of non-current financial debts (1,176) — Proceeds from 2022 Bridge Loan Facility, net of issuance costs — 771 Repayment of 2022 Bridge Loan Facility — (775) Impact from business combination — 316 22 5 Repayment of financial debts assumed in acquisition of business — (316) Additions to leases 68 13 Impact of asset acquisitions 2 1 Change in current financial debts — (42) Amortization of discounts on financial debts 1 — Payments of lease liabilities, net — (69) Interest payments for amounts included in lease liabilities classified as cash flows from operating activities — (15) Changes in fair values and other non-cash changes, net 5 8 (2) 13 Currency translation effects (23) (16) (10) (4) Reclassification from non-current to current (47) 47 (60) 60 December 31, 2022 4,541 107 359 71 Financial Liabilities ($ millions) Non-current financial debts Current financial debts Non-current lease liabilities Current lease liabilities January 1, 2021 3,949 169 315 70 Proceeds from non-current financial debts, net of issuance costs 52 — Additions to leases 106 9 Change in current financial debts — (43) Amortization of discounts on financial debts 1 — Payments of lease liabilities, net — (72) Interest payments for amounts included in lease liabilities classified as cash flows from operating activities — (13) Changes in fair values and other non-cash changes, net 4 — (2) 8 Currency translation effects (40) (12) (10) (5) Reclassification from non-current to current — — (70) 70 December 31, 2021 3,966 114 339 67
Disclosure of non-cash investing and financing activity	($ millions) 2022 2021 2020 Treasury stock issued for settlement of equity-based compensation plan, net of withholding taxes 128 63 54 Non-cash additions of right-of-use assets in exchange for a lease liability 81 115 107 Non-cash additions of property, plant & equipment 62 52 83 Non-cash additions of intangible assets 105 6 33

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations And Asset Acquisitions [Abstract]
Purchase price allocation for business combinations	The below table summarizes the preliminary purchase price allocation for business combinations for the years ended December 31, 2022, 2021 and 2020. ($ millions) 2022 2021 2020 Property, plant and equipment 27 — — Right-of-use assets 29 — — Currently marketed products 850 — — Acquired in-process research & development 175 — — Deferred tax assets 189 — — Inventories 49 — — Trade receivables 70 — — Short-term investments 79 — — Cash and cash equivalents 78 — — Other assets 15 — — Lease liabilities (27) — — Deferred tax liabilities (255) — — Provisions and other non-current and current liabilities (235) — — Current income tax liabilities (46) — — Trade payables (3) — — Financial debts (316) — — Net identifiable assets acquired 679 — — Goodwill 65 — — Total purchase consideration 744 — — Acquired liquidity (78) — — Net assets recognized as a result of business combinations 666 — —
Purchase price allocation for asset acquisitions	The below table summarizes the purchase price allocation for asset acquisitions for the years ended December 31, 2022, 2021 and 2020. ($ millions) 2022 2021 2020 Currently marketed products 385 — — Acquired in-process research & development 10 — — Other intangible assets (including software) 12 — — Deferred tax assets 57 — — Trade receivables 10 — — Inventory 16 — — Cash and cash equivalents 4 — — Other assets 6 — — Trade payables and other liabilities (11) — — Net identifiable assets acquired 489 — — Acquired liquidity (4) — — Net assets recognized as a result of asset acquisitions 485 — —

Post-employment benefits for _2

Post-employment benefits for associates (Tables)	12 Months Ended
	Dec. 31, 2022
Employee Benefits [Abstract]
Summary of funded and unfunded Defined Benefit Obligations and Reconciliation of net liability	The following tables summarize the funded and unfunded DBO for pension and other post-employment benefit plans of Alcon associates at December 31, 2022 and 2021: Pension plans Other post-employment ($ millions) 2022 2021 2022 2021 Benefit obligation at January 1 791 817 300 332 Current service cost 20 24 8 10 Interest cost 12 9 8 7 Past service costs and settlements (3) (38) — — Administrative expenses 2 1 — — Remeasurement (gains) arising from changes in financial assumptions (185) (22) (62) (12) Remeasurement (gains)/losses arising from changes in demographic assumptions (15) — — 1 Remeasurement losses/(gains) arising from experience-related changes 3 67 (19) (25) Currency translation effects (31) (35) — — Benefit payments (36) (37) (18) (17) Contributions of associates 5 5 4 4 Benefit obligation at December 31 563 791 221 300 Fair value of plan assets at January 1 541 519 — — Interest income 8 6 — — Return on plan assets excluding interest income (93) 49 — — Currency translation effects (27) (18) — — Employer contributions 19 23 14 13 Contributions of associates 5 5 4 4 Settlements — (20) — — Benefit payments (36) (37) (18) (17) Effect of acquisitions, divestments or transfers — 14 — — Fair value of plan assets at December 31 417 541 — — Funded status (146) (250) (221) (300) Limitation on recognition of fund surplus at January 1 (20) (17) Change in limitation on recognition of fund surplus (including exchange rate differences) (1) (3) Limitation on recognition of fund surplus at December 31 (21) (20) Net liability in the balance sheet at December 31 (167) (270) (221) (300) The reconciliation of the net liability from January 1 to December 31 is as follows: Pension plans Other post-employment benefit plans ($ millions) 2022 2021 2022 2021 Net liability at January 1 (270) (315) (300) (332) Current service cost (20) (24) (8) (10) Net interest expense (4) (3) (8) (7) Administrative expenses (2) (1) — — Past service costs and settlements 3 18 — — Remeasurements 104 4 81 36 Currency translation effects 4 17 — — Employer contributions 19 23 14 13 Effect of acquisitions, divestments or transfers — 14 — — Change in limitation on recognition of fund surplus (1) (3) — — Net liability at December 31 (167) (270) (221) (300) Amounts recognized in the balance sheet Prepaid benefit cost 8 25 — — Accrued benefit liability (175) (295) (221) (300)
Breakdown of DBO for pension plans by geography and type of member	The following tables provide detail of the DBO for pension plans by geography and type of member and of plan assets based on the geographical locations in which they are held: 2022 ($ millions) Switzerland United Germany United Rest of Total By type of member Active (207) (32) (38) — (79) (356) Deferred pensioners (6) (28) (18) (33) (9) (94) Pensioners (23) (35) (21) (25) (9) (113) Benefit obligation at December 31 (236) (95) (77) (58) (97) (563) Thereof: unfunded plans 35 24 — — 19 78 Thereof: unfunded portion of funded plans 26 7 60 — 4 97 Prepaid benefit costs and assets subject to limitation on recognition of fund surplus — — — (6) (23) (29) Fair value of plan assets at December 31 175 64 17 64 97 417 Funded status (61) (31) (60) 6 — (146) 2021 ($ millions) Switzerland United Germany United Rest of Total By type of member Active (295) (43) (64) — (99) (501) Deferred pensioners (11) (41) (28) (57) (14) (151) Pensioners (23) (42) (23) (40) (11) (139) Benefit obligation at December 31 (329) (126) (115) (97) (124) (791) Thereof: unfunded plans 47 29 — — 23 99 Thereof: unfunded portion of funded plans 87 6 94 — 9 196 Prepaid benefit costs and assets subject to limitation on recognition of fund surplus — — — (24) (21) (45) Fair value of plan assets at December 31 195 91 21 121 113 541 Funded status (134) (35) (94) 24 (11) (250)
Defined benefit plans assumptions	The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of Alcon associates: Pension plans Other post-employment 2022 2021 2022 2021 Discount rate 3.6 % 1.4 % 5.3 % 2.7 % Expected rate of pension increase 1.1 % 1.1 % Expected rate of salary increase 2.5 % 2.2 % Interest on savings account 2.9 % 1.3 % Current average life expectancy for a 65-year-old male (in years) 20 20 21 21 Current average life expectancy for a 65-year-old female (in years) 22 22 23 23 The following table shows additional details related to the weighted average discount rates for the principal plan for each significant country: Pension plans Other post-employment 2022 2021 2022 2021 Switzerland 2.2 % 0.2 % United States 5.3 % 2.8 % 5.3 % 2.7 % Germany 3.7 % 1.2 % United Kingdom 4.8 % 1.9 % The healthcare cost trend rate assumptions used for other post-employment benefits are as follows: 2022 2021 2020 Healthcare cost trend rate assumed for next year 6.3 % 6.2 % 6.2 % Rate to which the cost trend rate is assumed to decline 4.5 % 4.5 % 4.5 % Year that the rate reaches the ultimate trend rate 2030 2029 2028
Disclosure of sensitivity analysis for actuarial assumptions	The following table shows the sensitivity of the defined benefit pension and other post-employment benefit obligations to the principal actuarial assumptions as of December 31, 2022: ($ millions) (Decrease)/increase in 2022 year-end liability 25 basis point increase in discount rate (22) 25 basis point decrease in discount rate 23 1 year increase in life expectancy 14 25 basis point increase in rate of pension increase 6 25 basis point decrease in rate of pension increase (1) (3) 25 basis point increase of interest on savings account 2 25 basis point decrease of interest on savings account (3) 25 basis point increase in rate of salary increase 3 25 basis point decrease in rate of salary increase (3) (1) Decrease in rate of pension increase is limited to zero.
Fair value of plan assets and asset allocation	The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2022, and 2021: Pension plans (as a percentage) Long-term Long-term 2022 2021 Equity securities 15 40 37 35 Debt securities 20 60 34 40 Real estate 5 20 14 11 Alternative investments 0 20 12 11 Cash and other investments 0 15 3 3 Total 100 100
Schedule of expected future cash flows for benefit plans	The following table summarizes expected future cash flows for pension and other post-employment benefit plans as of December 31, 2022: ($ millions) Pension plans Other Employer contributions 2023 (estimated) 11 — Expected future benefit payments 2023 36 16 2024 43 18 2025 40 19 2026 34 20 2027 32 20 2028-2032 193 97

Equity-based compensation (Tabl

Equity-based compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangements [Abstract]
Disclosure of number and weighted average exercise prices of other equity instruments	The below table summarizes unvested share movements for all Alcon equity-based incentive plans through December 31, 2022 and 2021: 2022 2021 Number of Weighted average Fair value at grant date in $ millions Number of Weighted average Fair value at grant date in $ millions Unvested shares at January 1 5,627 60.96 343 5,417 54.90 297 Granted Restricted awards 1,453 76.61 111 1,456 72.05 105 Performance awards 518 74.48 39 429 72.71 31 Vested (2,447) 55.48 (136) (1,258) 50.94 (64) Forfeited (358) 71.74 (26) (417) 62.50 (26) Unvested shares at December 31 4,793 69.16 331 5,627 60.96 343
Summary of shares authorized	The below table summarizes the number of shares authorized under the plans as of December 31, 2022: (thousands) Authorized shares Long-term Incentive Plan 20,000 Deferred Bonus Stock Plan (1) 1,500 Swiss Employee Share Ownership Plan 475 Other share savings plans 275 Total 22,250 (1) Beginning in 2020, the annual incentives for the Alcon CEO and certain senior-level associates no longer include deferrals of compensation in the form of equity-based awards subject to the provisions of this plan. No grants were issued under this plan in 2022 and 2021.

Related parties transactions (T

Related parties transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party [Abstract]
Disclosure of transactions between related parties	The following table summarizes compensation information for key management personnel: ($ millions) 2022 2021 2020 Cash and other compensation 18.7 19.3 12.8 Post-employment benefits 0.9 0.9 1.1 Equity-based compensation 22.4 20.9 9.2 Total 42.0 41.1 23.1

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Summary of commitments to make payments under long-term research agreements	As of December 31, 2022, the commitments to make payments under those agreements, and their estimated timing, were as follows: ($ millions) 2022 2023 6 2024 18 2025 24 2026 3 2027 41 Thereafter 83 Total 175

Alcon subsidiaries (Tables)

Alcon subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Of Separate Financial Statements [Abstract]
Disclosure of details of subsidiaries	The following table lists the subsidiaries of Alcon Inc. with Total assets or Net sales to third parties in excess of $5 million included in the Consolidated Financial Statements at and for the year ended December 31, 2022, respectively. The equity interest percentage shown in the table represents Alcon's share in voting rights in those entities. Unless otherwise stated, each entity has share capital consisting of equity held directly by the Company or another of its consolidated subsidiaries. Country of organization/Entity name Place of business Equity Argentina Alcon Laboratorios Argentina S.A. Buenos Aires 100 % Australia Alcon Laboratories (Australia) Pty Ltd Macquarie Park 100 % Austria Alcon Ophthalmika GmbH Wien 100 % Belgium Alcon Laboratories Belgium BVBA Puurs 100 % Alcon N.V. Vilvoorde 100 % Brazil Alcon Brasil Cuidados com a Saúde Ltda. São Paulo 100 % Canada Alcon Canada Inc. Mississauga, Ontario 100 % Chile Alcon Laboratorios Chile Ltd. Santiago de Chile 100 % China Alcon (China) Ophthalmic Product Co., Ltd. Beijing 100 % Alcon Hong Kong Limited Hong Kong 100 % Colombia Laboratorios Alcon de Colombia S.A. Santafé de Bogotá 100 % Czech Republic Alcon Pharmaceuticals (Czech Republic) s.r.o. Prague 100 % Denmark Alcon Nordic A/S Copenhagen 100 % Ecuador AlconLab Ecuador S.A. Quito 100 % France Laboratoires Alcon S.A.S. Rueil-Malmaison 100 % Germany Alcon Deutschland GmbH Freiburg im Breisgau 100 % CIBA Vision GmbH Grosswallstadt 100 % WaveLight GmbH Erlangen 100 % Greece Alcon Laboratories Hellas- Single Member Commercial and Industrial S.A.C.I. Maroussi, Athens 100 % Hungary Alcon Hungary Pharmaceuticals Trading Limited Liability Company Budapest 100 % India Alcon Laboratories (India) Private Limited Bangalore 100 % Indonesia PT. CIBA Vision Batam Batam 100 % Ireland Alcon Laboratories Ireland Limited Cork City 100 % Aerie Pharmaceuticals Ireland Limited Athlone 100 % Israel Optonol Ltd. Neve-Ilan 100 % Italy Alcon Italia S.p.A. Milano 100 % Japan Alcon Japan Ltd. Tokyo 100 % Country of organization/Entity name Place of business Equity Malaysia Alcon Laboratories (Malaysia) Sdn. Bhd. Petaling Jaya 100 % CIBA Vision Johor Sdn. Bhd. Johor 100 % Mexico Alcon Laboratorios, S.A. de C.V. Ciudad de Mexico 100 % Netherlands Alcon Finance B.V. Amsterdam 100 % Alcon Nederland B.V. Gorinchem 100 % New Zealand Alcon Laboratories (New Zealand) Ltd. Remuera 100 % Panama Alcon Centroamerica S.A. Panama City 100 % Peru Alcon Pharmaceutical del Peru S.A. Lima 100 % Philippines Alcon Laboratories (Philippines), Inc. Pasig City 100 % Poland Alcon Polska Sp. z o.o. Warszawa 100 % Portugal Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda. Porto Salvo 100 % Puerto Rico Alcon (Puerto Rico), Inc. Cataño, PR 100 % Romania Alcon Romania S.R.L. Bucharest 100 % Russian Federation Alcon Farmacevtika LLC Moscow 100 % Singapore Alcon Pte Ltd Singapore 100 % Alcon Singapore Manufacturing Pte Ltd Singapore 100 % CIBA Vision Asian Manufacturing and Logistics Pte Ltd. Singapore 100 % South Africa Alcon Laboratories (South Africa) (Pty) Ltd. Midrand 100 % South Korea Alcon Korea Ltd. Seoul 100 % Spain Alcon Healthcare S.A. Barcelona 100 % Switzerland Alcon Grieshaber AG Schaffhausen 100 % Alcon Management SA Vernier 100 % Alcon Pharmaceuticals Ltd. Fribourg 100 % Alcon Services AG Fribourg 100 % Alcon Switzerland SA Zug 100 % Thailand Alcon Laboratories (Thailand) Limited Bangkok 100 % Turkey Alcon Laboratuvarlari Ticaret A.S. Istanbul 100 % Ukraine Alcon Ukraine LLC Kiev 100 % Country of organization/Entity name Place of business Equity United Kingdom Alcon Eye Care UK Limited Frimley/Camberley 100 % United States of America Aerie Distribution, Inc. Fort Worth, TX 100 % Aerie Pharmaceuticals, Inc. Fort Worth, TX 100 % Alcon Finance Corporation Fort Worth, TX 100 % Alcon Laboratories, Inc. Fort Worth, TX 100 % Alcon RefractiveHorizons, LLC Fort Worth, TX 100 % Alcon Research, LLC Fort Worth, TX 100 % Alcon Vision, LLC Fort Worth, TX 100 % CIBA Vision, LLC Fort Worth, TX 100 % WaveLight, Inc. Fort Worth, TX 100 % Ivantis, Inc. Fort Worth, TX 100 % MDBackline, Inc. Fort Worth, TX 100 % PowerVision, Inc. Fort Worth, TX 100 % Tear Film Innovations, Inc. Fort Worth, TX 100 % TrueVision Systems, Inc. Fort Worth, TX 100 % Uruguay Alcon Laboratorios Uruguay S.A. Montevideo 100 %

Description of business (Detail

Description of business (Details) $ in Millions	Dec. 31, 2022 USD ($) segment
Corporate Information And Statement Of IFRS Compliance [Abstract]
Number of reporting segments | segment	2
Total asset and net sales threshold | $	$ 5

Selected accounting policies -

Selected accounting policies - Schedule of useful lives for property, plant, and equipment (Details)	12 Months Ended
	Dec. 31, 2022
Bottom of range | Buildings and improvements
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	10 years
Bottom of range | Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	5 years
Bottom of range | Furniture and vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	5 years
Bottom of range | Computer hardware
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	3 years
Top of range | Buildings and improvements
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	40 years
Top of range | Machinery and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	20 years
Top of range | Furniture and vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	10 years
Top of range | Computer hardware
Disclosure of detailed information about property, plant and equipment [line items]
Useful life	7 years

Selected accounting policies _2

Selected accounting policies - Schedule of useful lives of intangible assets (Details)	12 Months Ended
	Dec. 31, 2022
Currently marketed products | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	5 years
Currently marketed products | Top of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	20 years
Marketing know-how
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	25 years
Technologies | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	10 years
Technologies | Top of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	20 years
Other (including software) | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	3 years
Other (including software) | Top of range
Disclosure of detailed information about intangible assets [line items]
Finite-lived intangible asset, useful life	10 years

Selected accounting policies _3

Selected accounting policies - Additional information (Details)	12 Months Ended
	Dec. 31, 2022
Corporate Information And Statement Of IFRS Compliance [Abstract]
Cash flow projection period	5 years

Significant transactions (Detai

Significant transactions (Details) $ / shares in Units, € in Millions								12 Months Ended
	Dec. 06, 2022 USD ($)	Nov. 21, 2022 USD ($) $ / shares	Jul. 08, 2022 USD ($)	May 31, 2022 USD ($)	May 31, 2022 EUR (€)	Jan. 07, 2022 USD ($)	Jun. 08, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 EUR (€)	May 31, 2022 EUR (€)	May 30, 2022 USD ($)	May 27, 2020 USD ($)
Disclosure of detailed information about business combination [line items]
Consideration paid								$ 666,000,000	$ 0	$ 0
Goodwill								8,970,000,000	8,905,000,000
Borrowings								4,648,000,000	4,080,000,000
Repayments of non-current borrowings								1,176,000,000	0	0
Purchase of intangible assets								$ 109,000,000	$ 480,000,000	$ 88,000,000
Aerie
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired		100%
Price paid (in dollars per share) | $ / shares		$ 15.25
Consideration transferred		$ 744,000,000
Consideration paid		666,000,000
Borrowings recognised as of acquisition date		316,200,000
Goodwill		65,000,000
Eysuvis and Inveltys
Disclosure of detailed information about business combination [line items]
Upfront payment			$ 60,000,000
Inventory, net of liabilities			14,000,000
Purchase consideration			79,000,000
Intangible assets			$ 71,000,000
Ivantis, Inc.
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired						100%
Upfront payment						$ 479,000,000
Simbrinza
Disclosure of detailed information about business combination [line items]
Purchase of intangible assets							$ 355,000,000
Series 2032 Notes
Disclosure of detailed information about business combination [line items]
Borrowings	$ 700,000,000
Borrowings, interest rate	5.375%							5.375%			5.375%
Series 2052 Notes
Disclosure of detailed information about business combination [line items]
Borrowings	$ 600,000,000
Borrowings, interest rate	5.75%							5.75%			5.75%
Facility B Term Loan
Disclosure of detailed information about business combination [line items]
Borrowings													$ 800,000,000
Repayments of non-current borrowings	$ 640,000,000				€ 160
Bridge Loan Facility
Disclosure of detailed information about business combination [line items]
Borrowings		$ 775,000,000
Repayments of non-current borrowings	$ 775,000,000
Series 2028 Notes
Disclosure of detailed information about business combination [line items]
Borrowings				$ 537,000,000				$ 533,000,000			€ 500	€ 500
Borrowings, interest rate				2.375%				2.375%			2.375%	2.375%
Facility C Term Loan
Disclosure of detailed information about business combination [line items]
Repayments of non-current borrowings				$ 376,000,000	€ 350
Series 2030 Notes
Disclosure of detailed information about business combination [line items]
Borrowings														$ 750,000,000
Borrowings, interest rate								2.60%			2.60%			2.60%

Segment Information - Narrative

Segment Information - Narrative (Details)	Dec. 31, 2022 segment
Operating Segments [Abstract]
Number of reporting segments	2

Segment Information - Net sales

Segment Information - Net sales and other revenues by segment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of operating segments [line items]
Net sales to third parties	$ 8,654	$ 8,222	$ 6,763
Other revenues	63	69	70
Net sales and other revenues	8,717	8,291	6,833
Surgical
Disclosure of operating segments [line items]
Net sales to third parties	5,045	4,703	3,710
Surgical | Implantables
Disclosure of operating segments [line items]
Net sales to third parties	1,725	1,522	1,126
Surgical | Consumables
Disclosure of operating segments [line items]
Net sales to third parties	2,499	2,388	1,952
Surgical | Equipment/other
Disclosure of operating segments [line items]
Net sales to third parties	821	793	632
Vision Care
Disclosure of operating segments [line items]
Net sales to third parties	3,609	3,519	3,053
Vision Care | Contact lenses
Disclosure of operating segments [line items]
Net sales to third parties	2,192	2,139	1,838
Vision Care | Ocular health
Disclosure of operating segments [line items]
Net sales to third parties	$ 1,417	$ 1,380	$ 1,215

Segment Information - Segment c

Segment Information - Segment contribution and reconciliation to income/(loss) before taxes (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of operating segments [line items]
Segment contribution		$ 1,936	$ 1,788	$ 1,091
Amortization of intangible assets		(653)	(590)	(1,078)
Impairment charges	$ 61	(62)	(225)	(167)
General & administration (corporate)		(255)	(251)	(232)
Separation costs		0	(36)	(217)
Transformation costs		(119)	(68)	(49)
Fair value adjustments to contingent consideration liabilities		23	42	63
Past service costs and settlements		0	18	154
Acquisition and integration related costs		(64)	0	0
Other		(134)	(98)	(47)
Operating income/(loss)		672	580	(482)
Interest expense		(134)	(120)	(124)
Other financial income & expense		(75)	(42)	(29)
Income/(loss) before taxes		463	418	(635)
Total depreciation of property, plant & equipment		(330)	(323)	(293)
Total depreciation of right-of-use assets		(76)	(81)	(79)
Total impairment charges on property, plant & equipment, net		(2)	0	(6)
Total equity-based compensation		(152)	(151)	(113)
Not allocated to segments
Disclosure of operating segments [line items]
Total depreciation of property, plant & equipment		(1)	0	0
Total equity-based compensation		(17)	(17)	(13)
Surgical
Disclosure of operating segments [line items]
Segment contribution		1,336	1,184	672
Impairment charges		(60)	(178)	(66)
Surgical | Operating segments
Disclosure of operating segments [line items]
Total depreciation of property, plant & equipment		(131)	(129)	(122)
Total depreciation of right-of-use assets		(46)	(50)	(47)
Total impairment charges on property, plant & equipment, net		(2)	0	(6)
Total equity-based compensation		(74)	(74)	(55)
Vision Care
Disclosure of operating segments [line items]
Segment contribution		600	604	419
Impairment charges		(2)	(47)	(101)
Vision Care | Operating segments
Disclosure of operating segments [line items]
Total depreciation of property, plant & equipment		(198)	(194)	(171)
Total depreciation of right-of-use assets		(30)	(31)	(32)
Total impairment charges on property, plant & equipment, net		0	0	0
Total equity-based compensation		$ (61)	$ (60)	$ (45)

Segment Information - Net sal_2

Segment Information - Net sales by region (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of geographical areas [line items]
Net sales to third parties	$ 8,654	$ 8,222	$ 6,763
Percentage of entity's revenue	100%	100%	100%
Total of selected non-current asset	$ 23,075	$ 21,753
Percentage of entity's non-current asset	100%	100%
Foreign countries | United States
Disclosure of geographical areas [line items]
Net sales to third parties	$ 3,897	$ 3,651	$ 2,975
Percentage of entity's revenue	45%	44%	44%
Total of selected non-current asset	$ 11,739	$ 10,200
Percentage of entity's non-current asset	51%	47%
Foreign countries | Japan
Disclosure of geographical areas [line items]
Net sales to third parties	$ 568	$ 621	$ 650
Percentage of entity's revenue	7%	8%	10%
Total of selected non-current asset	$ 44	$ 46
Percentage of entity's non-current asset	0%	0%
Foreign countries | China
Disclosure of geographical areas [line items]
Net sales to third parties	$ 474	$ 486	$ 383
Percentage of entity's revenue	5%	6%	6%
Total of selected non-current asset	$ 9	$ 16
Percentage of entity's non-current asset	0%	0%
Foreign countries | Other
Disclosure of geographical areas [line items]
Net sales to third parties	$ 3,656	$ 3,404	$ 2,700
Percentage of entity's revenue	42%	41%	40%
Total of selected non-current asset	$ 1,821	$ 1,729
Percentage of entity's non-current asset	8%	8%
International
Disclosure of geographical areas [line items]
Net sales to third parties	$ 4,757	$ 4,571	$ 3,788
Percentage of entity's revenue	55%	56%	56%
Total of selected non-current asset	$ 11,336	$ 11,553
Percentage of entity's non-current asset	49%	53%
Country of domicile | Switzerland
Disclosure of geographical areas [line items]
Net sales to third parties	$ 59	$ 60	$ 55
Percentage of entity's revenue	1%	1%	1%
Total of selected non-current asset	$ 9,462	$ 9,762
Percentage of entity's non-current asset	41%	45%

Interest expense and other fi_3

Interest expense and other financial income & expense - Interest expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Analysis of income and expense [abstract]
Interest expense on financial debts	$ (110)	$ (95)	$ (94)
Interest expense from discounting long-term liabilities	(9)	(12)	(17)
Interest expense on lease liabilities	(15)	(13)	(13)
Total interest expense	$ (134)	$ (120)	$ (124)

Interest expense and other fi_4

Interest expense and other financial income & expense - Other financial income & expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Analysis of income and expense [abstract]
Interest income	$ 16	$ 3	$ 6
Loss on extinguishment of financial debt	(5)	0	0
Other financial expense	(12)	(10)	(9)
Monetary loss from hyperinflation accounting	(16)	(6)	(4)
Currency result, net	(58)	(29)	(22)
Total other financial income & expense	$ (75)	$ (42)	$ (29)

Taxes - (Loss) before taxes (De

Taxes - (Loss) before taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total income/(loss) before taxes	$ 463	$ 418	$ (635)
Country of domicile
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total income/(loss) before taxes	234	680	(585)
Foreign countries
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Total income/(loss) before taxes	$ 229	$ (262)	$ (50)

Taxes - Current and deferred in

Taxes - Current and deferred income tax expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current income tax expense	$ (163)	$ (234)	$ (119)
Deferred tax income	35	192	223
Total income tax (expense)/income	(128)	(42)	104
Country of domicile
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current income tax expense	(17)	(118)	(14)
Deferred tax income	53	45	96
Foreign countries
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Current income tax expense	(146)	(116)	(105)
Deferred tax income	$ (18)	$ 147	$ 127

Taxes - Analysis of tax rate (D

Taxes - Analysis of tax rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Applicable tax rate	$ (104)	$ (39)	$ 98
Effect of disallowed expenditures	(13)	(10)	(20)
Effect of equity-based compensation	(13)	(7)	(5)
Effect of income taxed at reduced rates	4	1	4
Effect of tax credits and allowances	11	9	9
Effect of deductibility of a statutory expense in Switzerland	23	38	0
Effect of adjustments to contingent consideration and other liabilities	3	7	17
Effect of option payments	0	(2)	(6)
Tax effect from change in tax rate	0	(3)	10
Effect of changes in uncertain tax positions	10	(39)	(8)
Effect of 2022 APA on prior years	(37)	0	0
Tax Effect Of Nondeductible Amortization Expense, Amount	(7)	0	0
Effect of other items	(2)	(3)	(10)
Effect of prior year items	(3)	6	15
Total income tax (expense)/income	$ (128)	$ (42)	$ 104
Reconciliation of average effective tax rate and applicable tax rate [abstract]
Applicable tax rate	22.50%	9.30%	15.40%
Effect of disallowed expenditures	2.80%	2.40%	(3.10%)
Effect of equity-based compensation	2.80%	1.70%	(0.80%)
Effect of income taxed at reduced rates	(0.90%)	(0.20%)	0.60%
Effect of tax credits and allowances	(2.40%)	(2.20%)	1.40%
Effect of deductibility of a statutory expense in Switzerland	(5.00%)	(9.10%)	0%
Effect of adjustments to contingent consideration and other liabilities	(0.60%)	(1.70%)	2.70%
Effect of option payments	0%	0.50%	(0.90%)
Effect of tax rate changes	0%	0.70%	1.60%
Effect of changes in uncertain tax positions	(2.20%)	9.30%	(1.30%)
Effect of 2022 APA on prior years	8%	0%	0%
Effect of non-deductible amortization	1.50%	0%	0%
Effect of other items	0.40%	0.70%	(1.60%)
Effect of prior year items	0.60%	(1.40%)	2.40%
Effective tax rate	27.60%	10%	16.40%
Effect of current year taxes	$ 64

Share capital, dividends and _3

Share capital, dividends and earnings/(loss) per share - Narrative (Details) SFr / shares in Units, SFr in Thousands, shares in Millions, $ in Millions		1 Months Ended				12 Months Ended
	Nov. 10, 2020 CHF (SFr) SFr / shares shares	May 31, 2022 USD ($)	May 31, 2022 SFr / shares	May 31, 2021 USD ($)	May 31, 2021 SFr / shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 shares	Dec. 31, 2022 CHF (SFr) shares
Earnings per share [abstract]
Share capital						$ 20	$ 20		SFr 20,000
Number of shares issued (in shares)						499.7			499.7
Nominal value (in CHF per share) | SFr / shares	SFr 0.04
Share capital, increase (decrease) in authorized amount | SFr	SFr 320
Number of additional shares authorized (in shares)	8
Treasury stock (in shares)						7.9			7.9
Dividends (per share) | SFr / shares			SFr 0.20		SFr 0.10
Dividends | $		$ 100		$ 54
Basic (in shares)						491.4	490	489
Diluted (in shares)						494.4	493.4	489
Diluted weighted average shares adjustment (in shares)						3	3.4
Antidilutive securities excluded from computation (in shares)								2.8

Share capital, dividends and _4

Share capital, dividends and earnings/(loss) per share - Share activity (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Treasury Stock [Roll Forward]
Issuance of additional registered shares (in shares)			8
Treasury stock, balance (in shares)	7.9
Balance (in shares)	499.7	499.7	491.7
Balance (in shares)	499.7	499.7	499.7
Common stock shares outstanding
Reconciliation of number of shares outstanding [abstract]
Number of shares outstanding (in shares)	490.1	489.2	488.3
Settlement of equity-based awards (in shares)	1.7	0.9	0.9
Number of shares outstanding (in shares)	491.8	490.1	489.2
Treasury stock shares
Reconciliation of Treasury Stock [Roll Forward]
Treasury stock, balance (in shares)	9.6	10.5	3.4
Issuance of additional registered shares (in shares)			8
Settlement of equity-based awards (in shares)	(1.7)	(0.9)	(0.9)
Treasury stock, balance (in shares)		9.6	10.5

Property, plant and equipment_2

Property, plant and equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	$ 3,711
Depreciation charge	(330)	$ (323)	$ (293)
Impairment charge	(2)	0	(6)
Property, plant and equipment, ending balance	4,025	3,711
Commitments for purchases of property, plant and equipment	248	186
Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	6,360	5,917
Additions	687	721
Impact of business combination	27
Disposals and derecognitions	(188)	(108)
Reclassifications for assets placed in service	0	0
Currency translation effects	(111)	(170)
Property, plant and equipment, ending balance	6,775	6,360	5,917
Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	(2,649)	(2,492)
Depreciation charge	(330)	(323)
Impairment charge	(2)
Disposals and derecognitions	179	95
Currency translation effects	52	71
Property, plant and equipment, ending balance	(2,750)	(2,649)	(2,492)
Land
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	36
Property, plant and equipment, ending balance	35	36
Land | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	36	35
Additions	0	2
Impact of business combination	0
Disposals and derecognitions	0	0
Reclassifications for assets placed in service	0	0
Currency translation effects	(1)	(1)
Property, plant and equipment, ending balance	35	36	35
Land | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	0	0
Depreciation charge	0	0
Impairment charge	0
Disposals and derecognitions	0	0
Currency translation effects	0	0
Property, plant and equipment, ending balance	0	0	0
Buildings and improvements
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	1,185
Property, plant and equipment, ending balance	1,221	1,185
Buildings and improvements | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	1,987	1,884
Additions	10	8
Impact of business combination	10
Disposals and derecognitions	(13)	(7)
Reclassifications for assets placed in service	127	146
Currency translation effects	(30)	(44)
Property, plant and equipment, ending balance	2,091	1,987	1,884
Buildings and improvements | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	(802)	(716)
Depreciation charge	(92)	(107)
Impairment charge	0
Disposals and derecognitions	13	5
Currency translation effects	11	16
Property, plant and equipment, ending balance	(870)	(802)	(716)
Construction in progress
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	789
Property, plant and equipment, ending balance	953	789
Construction in progress | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	790	573
Additions	554	654
Impact of business combination	2
Disposals and derecognitions	(3)	(8)
Reclassifications for assets placed in service	(389)	(410)
Currency translation effects	1	(19)
Property, plant and equipment, ending balance	955	790	573
Construction in progress | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	(1)	(8)
Depreciation charge	0	0
Impairment charge	(2)
Disposals and derecognitions	1	7
Currency translation effects	0	0
Property, plant and equipment, ending balance	(2)	(1)	(8)
Machinery & other equipment
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	1,701
Property, plant and equipment, ending balance	1,816	1,701
Machinery & other equipment | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	3,547	3,425
Additions	123	57
Impact of business combination	15
Disposals and derecognitions	(172)	(93)
Reclassifications for assets placed in service	262	264
Currency translation effects	(81)	(106)
Property, plant and equipment, ending balance	3,694	3,547	3,425
Machinery & other equipment | Accumulated depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Property, plant and equipment, beginning balance	(1,846)	(1,768)
Depreciation charge	(238)	(216)
Impairment charge	0
Disposals and derecognitions	165	83
Currency translation effects	41	55
Property, plant and equipment, ending balance	$ (1,878)	$ (1,846)	$ (1,768)

Goodwill and intangible asset_2

Goodwill and intangible assets - Summary of movements of goodwill and intangible assets (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		$ 8,765
Amortization charge		653	$ 590	$ 1,078
Impairment charges	$ 61	(62)	(225)	(167)
Intangible assets and goodwill at end of period		9,689	8,765
Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		20,507	20,032
Impact of business combination		1,025
Impact of asset acquisitions		407
Additions		208	483
Reclassifications			0
Disposals and derecognitions		(9)	(8)
Intangible assets and goodwill at end of period		22,138	20,507	20,032
Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(11,742)	(10,935)
Amortization charge		(653)	(590)
Disposals and derecognitions		8	8
Impairment charges		(62)	(225)
Intangible assets and goodwill at end of period		(12,449)	(11,742)	(10,935)
Goodwill
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		8,905
Intangible assets and goodwill at end of period		8,970	8,905
Goodwill | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		8,905	8,905
Impact of business combination		65
Intangible assets and goodwill at end of period		8,970	8,905	8,905
Goodwill | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		0	0
Intangible assets and goodwill at end of period		0	0	0
Alcon brand name
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		2,980
Intangible assets and goodwill at end of period		2,980	2,980
Alcon brand name | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		2,980	2,980
Intangible assets and goodwill at end of period		2,980	2,980	2,980
Alcon brand name | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		0	0
Intangible assets and goodwill at end of period		0	0	0
Acquired in-process research & development
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		557
Intangible assets and goodwill at end of period		739	557
Acquired in-process research & development | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		737	727
Impact of business combination		175
Impact of asset acquisitions		10
Additions		0	20
Reclassifications			(10)
Disposals and derecognitions		(2)
Intangible assets and goodwill at end of period		920	737	727
Acquired in-process research & development | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(180)	0
Disposals and derecognitions		2
Impairment charges		(3)	(180)
Intangible assets and goodwill at end of period		(181)	(180)	0
Technologies
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		131
Intangible assets and goodwill at end of period		91	131
Technologies | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		5,369	5,369
Intangible assets and goodwill at end of period		5,369	5,369	5,369
Technologies | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(5,238)	(5,199)
Amortization charge		(40)	(39)
Intangible assets and goodwill at end of period		(5,278)	(5,238)	(5,199)
Currently marketed products
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		1,332
Intangible assets and goodwill at end of period		2,380	1,332
Currently marketed products | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		4,803	4,440
Impact of business combination		850
Impact of asset acquisitions		385
Additions		151	359
Reclassifications			10
Disposals and derecognitions		0	(6)
Intangible assets and goodwill at end of period		6,189	4,803	4,440
Currently marketed products | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(3,471)	(3,197)
Amortization charge		(279)	(235)
Disposals and derecognitions		0	6
Impairment charges		(59)	(45)
Intangible assets and goodwill at end of period		(3,809)	(3,471)	(3,197)
Marketing know-how
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		3,338
Intangible assets and goodwill at end of period		3,099	3,338
Marketing know-how | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		5,960	5,960
Intangible assets and goodwill at end of period		5,960	5,960	5,960
Marketing know-how | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(2,622)	(2,384)
Amortization charge		(239)	(238)
Intangible assets and goodwill at end of period		(2,861)	(2,622)	(2,384)
Other (including software)
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		427
Intangible assets and goodwill at end of period		400	427
Other (including software) | Cost
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		658	556
Impact of asset acquisitions		12
Additions		57	104
Reclassifications			0
Disposals and derecognitions		(7)	(2)
Intangible assets and goodwill at end of period		720	658	556
Other (including software) | Accumulated depreciation
Reconciliation of changes in intangible assets and goodwill [abstract]
Intangible assets and goodwill at beginning of period		(231)	(155)
Amortization charge		(95)	(78)
Disposals and derecognitions		6	2
Impairment charges			0
Intangible assets and goodwill at end of period		$ (320)	$ (231)	$ (155)

Goodwill and intangible asset_3

Goodwill and intangible assets - Goodwill and intangible asset by segment (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	$ 9,689	$ 8,765
Goodwill
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	8,970	8,905
Alcon brand name
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	2,980	2,980
Acquired in-process research & development
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	739	557
Technologies
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	91	131
Currently marketed products
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	2,380	1,332
Marketing know-how
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	3,099	3,338
Other (including software)
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	400	427
Operating segments | Technologies
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	91
Operating segments | Surgical
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	4,577	4,504
Operating segments | Surgical | Goodwill
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	4,544	4,544
Operating segments | Surgical | Acquired in-process research & development
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	564	555
Operating segments | Surgical | Technologies
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	91	131
Operating segments | Surgical | Currently marketed products
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	583	229
Operating segments | Surgical | Marketing know-how
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	3,099	3,338
Operating segments | Surgical | Other (including software)
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	240	251
Operating segments | Vision Care
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	2,132	1,281
Operating segments | Vision Care | Goodwill
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	4,426	4,361
Operating segments | Vision Care | Acquired in-process research & development
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	175	2
Operating segments | Vision Care | Currently marketed products
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	1,797	1,103
Operating segments | Vision Care | Other (including software)
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	160	176
Not allocated to segments
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	2,980	2,980
Not allocated to segments | Alcon brand name
Disclosure of detailed information about intangible assets [line items]
Intangible assets and goodwill	$ 2,980	$ 2,980

Goodwill and intangible asset_4

Goodwill and intangible assets - Intangible asset assumptions (Details)	Dec. 31, 2022	Dec. 31, 2021
Surgical
Disclosure of detailed information about intangible assets [line items]
Terminal growth rate	3%	3%
Discount rate (post-tax)	9%	7%
Vision Care
Disclosure of detailed information about intangible assets [line items]
Terminal growth rate	3%	3%
Discount rate (post-tax)	8.75%	6.50%

Goodwill and intangible asset_5

Goodwill and intangible assets - Intangible asset impairment charges (Details) $ in Millions	3 Months Ended					12 Months Ended
	Jun. 30, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)
Disclosure of detailed information about intangible assets [line items]
Impairment charges	$ (61)					$ 62	$ 225	$ 167
Cash flow projection forecast duration						5 years
Discount rate, measurement input
Disclosure of detailed information about intangible assets [line items]
Significant unobservable input, assets | shares	0.078
Research and development
Disclosure of detailed information about intangible assets [line items]
Impairment charges							(180)
Cost of net sales
Disclosure of detailed information about intangible assets [line items]
Impairment charges								106
Surgical
Disclosure of detailed information about intangible assets [line items]
Impairment charges						$ 60	178	66
Recoverable amount	$ 15							65
Surgical | Discount rate, measurement input
Disclosure of detailed information about intangible assets [line items]
Significant unobservable input, assets | shares						0.075
Surgical | Research and development
Disclosure of detailed information about intangible assets [line items]
Impairment charges			$ 178
Surgical | Cost of net sales
Disclosure of detailed information about intangible assets [line items]
Impairment charges	(59)							65
Vision Care
Disclosure of detailed information about intangible assets [line items]
Impairment charges						$ 2	$ 47	101
Recoverable amount				$ 48					$ 88
Vision Care | Discount rate, measurement input
Disclosure of detailed information about intangible assets [line items]
Significant unobservable input, assets | shares						0.070
Vision Care | Research and development
Disclosure of detailed information about intangible assets [line items]
Impairment charges	$ 2	$ 2			$ (61)
Vision Care | Cost of net sales
Disclosure of detailed information about intangible assets [line items]
Impairment charges				$ 45				$ 41

Deferred tax assets and liabi_3

Deferred tax assets and liabilities - Activity in deferred tax asset (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	$ 1,161	$ 1,026
Gross, deferred tax liabilities, beginning balance	(1,778)	(1,823)
Net, deferred tax liability (asset), beginning balance	(617)	(797)
(Charged)/credited to income	35	192
(Charged)/credited to equity	(19)	8
(Charged) to other comprehensive income	(43)	(20)
Impact of business combination	(66)
Impact of asset acquisitions	57
Gross deferred tax assets, ending balance	1,339	1,161
Gross, deferred tax liabilities, ending balance	(1,992)	(1,778)
Net, deferred tax liability (asset), ending balance	(653)	(617)
Property, plant & equipment
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	28	24
Gross, deferred tax liabilities, beginning balance	(246)	(215)
Net, deferred tax liability (asset), beginning balance	(218)	(191)
(Charged)/credited to income	(57)	(27)
(Charged)/credited to equity	0	0
(Charged) to other comprehensive income	0	0
Impact of business combination	(1)
Impact of asset acquisitions	0
Gross deferred tax assets, ending balance	31	28
Gross, deferred tax liabilities, ending balance	(307)	(246)
Net, deferred tax liability (asset), ending balance	(276)	(218)
Intangible assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	5	5
Gross, deferred tax liabilities, beginning balance	(1,382)	(1,519)
Net, deferred tax liability (asset), beginning balance	(1,377)	(1,514)
(Charged)/credited to income	102	137
(Charged)/credited to equity	0	0
(Charged) to other comprehensive income	0	0
Impact of business combination	(250)
Impact of asset acquisitions	0
Gross deferred tax assets, ending balance	4	5
Gross, deferred tax liabilities, ending balance	(1,529)	(1,382)
Net, deferred tax liability (asset), ending balance	(1,525)	(1,377)
Pensions and other benefit obligations of associates
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	116	128
Gross, deferred tax liabilities, beginning balance	0	0
Net, deferred tax liability (asset), beginning balance	116	128
(Charged)/credited to income	1	1
(Charged)/credited to equity	0	(2)
(Charged) to other comprehensive income	(38)	(11)
Impact of business combination	0
Impact of asset acquisitions	0
Gross deferred tax assets, ending balance	79	116
Gross, deferred tax liabilities, ending balance	0	0
Net, deferred tax liability (asset), ending balance	79	116
Inventories
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	372	381
Gross, deferred tax liabilities, beginning balance	(23)	(23)
Net, deferred tax liability (asset), beginning balance	349	358
(Charged)/credited to income	(23)	(9)
(Charged)/credited to equity	0	0
(Charged) to other comprehensive income	0	0
Impact of business combination	0
Impact of asset acquisitions	0
Gross deferred tax assets, ending balance	352	372
Gross, deferred tax liabilities, ending balance	(26)	(23)
Net, deferred tax liability (asset), ending balance	326	349
Tax loss carry-forwards
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	188	174
Gross, deferred tax liabilities, beginning balance	0	0
Net, deferred tax liability (asset), beginning balance	188	174
(Charged)/credited to income	(168)	4
(Charged)/credited to equity	12	7
(Charged) to other comprehensive income	0	3
Impact of business combination	142
Impact of asset acquisitions	57
Gross deferred tax assets, ending balance	231	188
Gross, deferred tax liabilities, ending balance	0	0
Net, deferred tax liability (asset), ending balance	231	188
Other assets, provisions and accruals
Reconciliation of changes in deferred tax liability (asset) [abstract]
Gross deferred tax assets, beginning balance	452	314
Gross, deferred tax liabilities, beginning balance	(127)	(66)
Net, deferred tax liability (asset), beginning balance	325	248
(Charged)/credited to income	180	86
(Charged)/credited to equity	(31)	3
(Charged) to other comprehensive income	(5)	(12)
Impact of business combination	43
Impact of asset acquisitions	0
Gross deferred tax assets, ending balance	642	452
Gross, deferred tax liabilities, ending balance	(130)	(127)
Net, deferred tax liability (asset), ending balance	$ 512	$ 325

Deferred tax assets and liabi_4

Deferred tax assets and liabilities - Net deferred tax balance (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Offsetting amounts	$ 928	$ 752
Deferred tax assets	411	409
Deferred tax liabilities	(1,064)	(1,026)
Net deferred tax liabilities	$ (653)	$ (617)	$ (797)

Deferred tax assets and liabi_5

Deferred tax assets and liabilities - Impact on current taxes payable (Details) - USD ($) $ in Billions	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Abstract]
Deferred tax assets	$ 1	$ 0.8
Deferred tax liabilities	$ 1.9	$ 1.7

Deferred tax assets and liabi_6

Deferred tax assets and liabilities - Additional information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Taxes [Abstract]
Unremitted earnings retained for reinvestment	$ 9,000,000,000	$ 9,000,000,000
Temporary differences and unused tax losses for which no deferred tax assets were recognized	9,000,000,000	9,000,000,000
Capital loss carryforwards for which no deferred tax assets were recognized, expiring in four years	120,000,000	103,000,000
Tax loss carryforwards capitalized	1,429,000,000	1,047,000,000
Tax loss carryforwards expiring in five years	45,000,000
Tax loss carryforwards not expiring in five years	1,384,000,000
Amount with indefinite carryforward period	776,000,000
Tax loss carryforwards expiring in 6 to 20 years	608,000,000
Gross value of tax loss carryforwards for which no deferred tax assets were recognized	438,000,000
Tax loss carryforwards expired in period	$ 0	$ 0	$ 0

Financial and other non-curre_3

Financial and other non-current assets - Financial Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Long-term financial investments measured at FVOCI	$ 88	$ 46
Long-term financial investments measured at FVPL	20	6
Long-term receivables from customers	119	110
Non-current minimum lease payments from finance lease agreements	38	35
Long-term loans, advances and security deposits	22	20
Total financial assets	$ 287	$ 217

Financial and other non-curre_4

Financial and other non-current assets - Minimum finance lease payments (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of finance lease payments receivable [line items]
Total future payments	$ 78	$ 81
Unearned interest income	(4)	(4)
Present value	74	77
Provision	(11)	(14)
Net book value	63	63
Not later than one year
Disclosure of maturity analysis of finance lease payments receivable [line items]
Total future payments	28	32
Unearned interest income	(2)	(2)
Present value	26	30
Provision	(1)	(2)
Net book value	25	28
Between one and five years
Disclosure of maturity analysis of finance lease payments receivable [line items]
Total future payments	49	47
Unearned interest income	(2)	(2)
Present value	47	45
Provision	(10)	(12)
Net book value	37	33
Later than five years
Disclosure of maturity analysis of finance lease payments receivable [line items]
Total future payments	1	2
Unearned interest income	0	0
Present value	1	2
Provision	0	0
Net book value	$ 1	$ 2

Financial and other non-curre_5

Financial and other non-current assets - Other Non-current Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Deferred compensation plans	$ 139	$ 155
Prepaid post-employment benefit plans	8	25
Other non-current assets	96	54
Total other non-current assets	$ 243	$ 234

Inventories - Additional inform

Inventories - Additional information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Inventories [Line Items]
Inventory write-down	$ 200	$ 220	$ 304
Reversal of inventory write-down	72	83	91
Cost of net sales
Disclosure Of Inventories [Line Items]
Inventory recognized as expense	2,700	2,500	2,100
Cost of other revenues
Disclosure Of Inventories [Line Items]
Inventory recognized as expense	$ 59	$ 62	$ 63

Inventories - Schedule of inven

Inventories - Schedule of inventories (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Inventories [Abstract]
Raw material, consumables	$ 433	$ 336
Work in progress	201	169
Finished products	1,475	1,394
Total inventories	$ 2,109	$ 1,899

Trade receivables - Components

Trade receivables - Components of trade receivables (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of provision matrix [line items]
Gross trade receivables	$ 1,730	$ 1,551
Provision	(57)	(55)	$ (68)	$ (48)
Trade receivables, net	1,673	1,496
Not overdue
Disclosure of provision matrix [line items]
Gross trade receivables	1,390	1,273
Provision	(2)	(2)
Trade receivables, net	$ 1,388	$ 1,271
Expected credit loss rates	0.10%	0.20%
Past due for not more than one month
Disclosure of provision matrix [line items]
Gross trade receivables	$ 125	$ 96
Provision	(1)	(1)
Trade receivables, net	$ 124	$ 95
Expected credit loss rates	0.80%	1%
Past due for more than one month but less than three months
Disclosure of provision matrix [line items]
Gross trade receivables	$ 93	$ 74
Provision	(2)	(1)
Trade receivables, net	$ 91	$ 73
Expected credit loss rates	2.20%	1.40%
Past due for more than three months but less than six months
Disclosure of provision matrix [line items]
Gross trade receivables	$ 56	$ 43
Provision	(4)	(2)
Trade receivables, net	$ 52	$ 41
Expected credit loss rates	7.10%	4.70%
Past due for more than six months but less than one year
Disclosure of provision matrix [line items]
Gross trade receivables	$ 28	$ 23
Provision	(16)	(13)
Trade receivables, net	$ 12	$ 10
Expected credit loss rates	57.10%	56.50%
Past due for more than one year
Disclosure of provision matrix [line items]
Gross trade receivables	$ 38	$ 42
Provision	(32)	(36)
Trade receivables, net	$ 6	$ 6
Expected credit loss rates	84.20%	85.70%

Trade receivables - Movement in

Trade receivables - Movement in provision for trade receivables (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in allowance account for credit losses of financial assets [abstract]
Beginning balance	$ (55)	$ (68)	$ (48)
Provisions for doubtful trade receivables charged to the Consolidated Income Statement	(40)	(20)	(48)
Utilization of provisions for doubtful trade receivables	7	8	15
Reversal of provisions for doubtful trade receivables	28	23	14
Currency translation effects	3	2	(1)
Ending balance	$ (57)	$ (55)	$ (68)

Trade receivables - Trade recei

Trade receivables - Trade receivables from closely monitored countries (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Trade Receivables [Line Items]
Gross trade receivables	$ 1,730	$ 1,551
Provisions for doubtful trade receivables	(57)	(55)	$ (68)	$ (48)
Greece, Italy, Portugal, Spain, Brazil, Russia, Turkey, Saudi Arabia, and Argentina
Trade Receivables [Line Items]
Gross trade receivables	280	252
Provisions for doubtful trade receivables	(10)	(11)
Past due for more than one year
Trade Receivables [Line Items]
Gross trade receivables	38	42
Provisions for doubtful trade receivables	(32)	(36)
Past due for more than one year | Greece, Italy, Portugal, Spain, Brazil, Russia, Turkey, Saudi Arabia, and Argentina
Trade Receivables [Line Items]
Gross trade receivables	$ 8	$ 10

Trade receivables - Trade rec_2

Trade receivables - Trade receivables by currency (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of geographical areas [line items]
Total trade receivables, net	$ 1,673	$ 1,496
US dollar (USD)
Disclosure of geographical areas [line items]
Total trade receivables, net	701	526
Euro (EUR)
Disclosure of geographical areas [line items]
Total trade receivables, net	256	243
Japanese yen (JPY)
Disclosure of geographical areas [line items]
Total trade receivables, net	154	160
Chinese yuan (CNY)
Disclosure of geographical areas [line items]
Total trade receivables, net	102	122
Brazilian real (BRL)
Disclosure of geographical areas [line items]
Total trade receivables, net	55	44
Indian rupee (INR)
Disclosure of geographical areas [line items]
Total trade receivables, net	33	36
Canadian dollar (CAD)
Disclosure of geographical areas [line items]
Total trade receivables, net	35	39
Australian dollar (AUD)
Disclosure of geographical areas [line items]
Total trade receivables, net	29	24
British pound (GBP)
Disclosure of geographical areas [line items]
Total trade receivables, net	31	29
Russian ruble (RUB)
Disclosure of geographical areas [line items]
Total trade receivables, net	28	35
South Korean won (KRW)
Disclosure of geographical areas [line items]
Total trade receivables, net	37	38
Mexican peso (MXN)
Disclosure of geographical areas [line items]
Total trade receivables, net	26	25
Other currencies
Disclosure of geographical areas [line items]
Total trade receivables, net	$ 186	$ 175

Other current assets (Details)

Other current assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Current portion of long-term receivables from customers	$ 102	$ 97
Current portion of minimum lease payments from finance lease agreements	25	28
Prepaid expenses	107	92
VAT receivables	99	105
Other receivables, security deposits and current assets	77	79
Derivative financial instruments	8	3
Equity securities in public companies	0	3
Total other current assets	$ 418	$ 407

Right-of-use assets and Lease_3

Right-of-use assets and Lease liabilities - Components of Right-of-Use Assets (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	$ 391	$ 372
Land
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	15	17
Buildings and improvements
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	347	326
Machinery & equipment and other assets
Disclosure of quantitative information about right-of-use assets [line items]
Right-of-use assets	$ 29	$ 29

Right-of-use assets and Lease_4

Right-of-use assets and Lease liabilities - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Depreciation of right-of-use assets	$ 76	$ 81	$ 79
Total lease liabilities	430	406
Current lease liabilities	71	67
Non-current lease liabilities	$ 359	$ 339

Right-of-use assets and Lease_5

Right-of-use assets and Lease liabilities - Components of Right-of-Use Assets Depreciation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation of right-of-use assets	$ 76	$ 81	$ 79
Land
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation of right-of-use assets	1	1
Buildings and improvements
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation of right-of-use assets	58	60
Machinery & equipment and other assets
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation of right-of-use assets	$ 17	$ 20

Right-of-use assets and Lease_6

Right-of-use assets and Lease liabilities - Maturity of Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of maturity analysis of lease payments [Line Items]
Total lease liabilities undiscounted	$ 544	$ 514
Total lease liabilities	430	406
Not later than one year
Disclosure of maturity analysis of lease payments [Line Items]
Total lease liabilities undiscounted	85	80
Total lease liabilities	71	67
Between one and five years
Disclosure of maturity analysis of lease payments [Line Items]
Total lease liabilities undiscounted	226	197
Total lease liabilities	180	157
Later than five years
Disclosure of maturity analysis of lease payments [Line Items]
Total lease liabilities undiscounted	233	237
Total lease liabilities	$ 179	$ 182

Right-of-use assets and Lease_7

Right-of-use assets and Lease liabilities - Additional Disclosures Related to Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Interest expense on lease liabilities	$ 15	$ 13	$ 13
Expense on short-term, low value and variable leases	3	7
Total cash outflows for leases	87	92
Lease liability payments	69	72	$ 69
Interest payments	15	13
Short-term and low value lease payments	$ 3	$ 7

Non-current and current finan_3

Non-current and current financial debts - Schedule of financial debts (Details) € in Millions	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 06, 2022 USD ($)	May 31, 2022 USD ($)	May 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	May 27, 2020 USD ($)
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	$ 4,541,000,000					$ 3,966,000,000
Total current financial debts	107,000,000					114,000,000
Total financial debts	4,648,000,000					4,080,000,000
Facility B, floating rate debt due 2024
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0					796,000,000
Facility C, floating rate debt due 2024
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0					395,000,000
Local facilities (Japan), floating rate debt due 2023
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0					47,000,000
Total current financial debts	$ 69,000,000					84,000,000
Series 2026 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.75%	2.75%
Total non-current financial debts	$ 497,000,000					496,000,000
Series 2028 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.375%	2.375%		2.375%	2.375%
Total non-current financial debts	$ 527,000,000					0
Total financial debts	$ 533,000,000	€ 500		$ 537,000,000	€ 500
Series 2029 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	3%	3%
Total non-current financial debts	$ 994,000,000					993,000,000
Series 2030 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.60%	2.60%					2.60%
Total non-current financial debts	$ 746,000,000					745,000,000
Total financial debts							$ 750,000,000
Series 2032 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	5.375%	5.375%	5.375%
Total non-current financial debts	$ 692,000,000					0
Total financial debts			$ 700,000,000
Series 2049 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	3.80%	3.80%
Total non-current financial debts	$ 494,000,000					494,000,000
Series 2052 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	5.75%	5.75%	5.75%
Total non-current financial debts	$ 591,000,000					0
Total financial debts			$ 600,000,000
Revolving facility, floating rate due 2026
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0					0
Local facilities, all other
Disclosure of detailed information about borrowings [line items]
Total current financial debts	2,000,000					17,000,000
Other short-term financial debts, floating rate
Disclosure of detailed information about borrowings [line items]
Total current financial debts	26,000,000					6,000,000
Derivatives
Disclosure of detailed information about borrowings [line items]
Total current financial debts	10,000,000					7,000,000
Total financial debts	$ 10,000,000					$ 7,000,000

Non-current and current finan_4

Non-current and current financial debts - Additional information (Details) € in Millions							1 Months Ended		3 Months Ended	12 Months Ended
	Dec. 20, 2022 USD ($)	Dec. 06, 2022 USD ($)	Nov. 21, 2022 USD ($)	May 31, 2022 USD ($)	May 31, 2022 EUR (€)	May 27, 2020 USD ($)	Feb. 28, 2022	Feb. 28, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Feb. 14, 2023 USD ($)	Dec. 31, 2022 EUR (€)	Sep. 14, 2022 USD ($)	May 31, 2022 EUR (€)	May 30, 2022 USD ($)
Disclosure of detailed information about borrowings [line items]
Interest expense										$ 110,000,000	$ 95,000,000	$ 94,000,000
Borrowings									$ 4,648,000,000	4,648,000,000	4,080,000,000
Repayment of borrowings										$ 775,000,000	$ 0	$ 0
Write off of unamortized deferred financing costs				$ 1,000,000					$ 4,000,000
Aerie
Disclosure of detailed information about borrowings [line items]
Net proceeds used for acquisition			$ 771,000,000
Borrowings recognised as of acquisition date			316,200,000
Series 2028 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate				2.375%					2.375%	2.375%				2.375%		2.375%
Borrowings				$ 537,000,000					$ 533,000,000	$ 533,000,000				€ 500		€ 500
Borrowings, issuance percentage				99.476%												99.476%
Borrowing costs incurred				$ 3,000,000
Series 2028 Notes | Borrowings discount
Disclosure of detailed information about borrowings [line items]
Borrowings				(3,000,000)
Facility C Term Loan
Disclosure of detailed information about borrowings [line items]
Repayment of borrowings				376,000,000	€ 350
Facility B Term Loan
Disclosure of detailed information about borrowings [line items]
Borrowings																	$ 800,000,000
Repayment of borrowings		$ 640,000,000		$ 160,000,000
Bridge Loan Facility
Disclosure of detailed information about borrowings [line items]
Borrowings			775,000,000
Borrowing costs incurred			$ 4,000,000
Repayment of borrowings		$ 775,000,000
Maximum borrowing capacity															$ 900,000,000
Series 2032 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate		5.375%							5.375%	5.375%				5.375%
Borrowings		$ 700,000,000
Borrowings, issuance percentage		99.458%
Borrowing costs incurred		$ 4,000,000
Series 2032 Notes | Borrowings discount
Disclosure of detailed information about borrowings [line items]
Borrowings		$ (4,000,000)
Series 2052 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate		5.75%							5.75%	5.75%				5.75%
Borrowings		$ 600,000,000
Borrowings, issuance percentage		99.674%
Borrowing costs incurred		$ 7,000,000
Series 2052 Notes | Borrowings discount
Disclosure of detailed information about borrowings [line items]
Borrowings		$ (2,000,000)
Senior Notes due 2024
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate			1.50%
Borrowings									$ 200,000	$ 200,000
Repayment of borrowings	$ 316,000,000
Series 2030 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate						2.60%			2.60%	2.60%				2.60%
Borrowings						$ 750,000,000
Borrowings, issuance percentage						99.843%
Borrowing costs incurred						$ 5,000,000
Series 2030 Notes | Borrowings discount
Disclosure of detailed information about borrowings [line items]
Borrowings						$ (1,000,000)
Revolving facility, floating rate due 2026
Disclosure of detailed information about borrowings [line items]
Undrawn borrowing facilities								$ 1,000,000,000
Local bilateral facilities, Japan
Disclosure of detailed information about borrowings [line items]
Borrowings									$ 69,000,000	$ 69,000,000			$ 170,000,000
Borrowings, term							1 year
Undrawn borrowing facilities									$ 101,000,000	$ 101,000,000
Weighted average
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate									2.70%	2.70%	2.30%			2.70%
Bottom of range | Local bilateral facilities, Japan
Disclosure of detailed information about borrowings [line items]
Borrowings, term								1 year
Top of range | Local bilateral facilities, Japan
Disclosure of detailed information about borrowings [line items]
Borrowings, term								2 years

Non-current and current finan_5

Non-current and current financial debts - Maturity of borrowings (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 4,648	$ 4,080
Cost
Disclosure of detailed information about borrowings [line items]
Borrowings	4,690	4,107
Cost | Not later than one year
Disclosure of detailed information about borrowings [line items]
Borrowings	107	114
Cost | Between one and five years
Disclosure of detailed information about borrowings [line items]
Borrowings	500	1,743
Cost | Later than five years
Disclosure of detailed information about borrowings [line items]
Borrowings	4,083	2,250
Unamortized debt discount and issuance costs
Disclosure of detailed information about borrowings [line items]
Borrowings	(42)	(27)
Nominal amount - Current and non-current financial debt
Disclosure of detailed information about borrowings [line items]
Borrowings	4,638	4,073
Nominal amount - Current and non-current financial debt | Cost
Disclosure of detailed information about borrowings [line items]
Borrowings	4,680	4,100
Nominal amount - Current and non-current financial debt | Cost | Not later than one year
Disclosure of detailed information about borrowings [line items]
Borrowings	97	107
Nominal amount - Current and non-current financial debt | Cost | Between one and five years
Disclosure of detailed information about borrowings [line items]
Borrowings	500	1,743
Nominal amount - Current and non-current financial debt | Cost | Later than five years
Disclosure of detailed information about borrowings [line items]
Borrowings	4,083	2,250
Nominal amount - Current and non-current financial debt | Unamortized debt discount and issuance costs
Disclosure of detailed information about borrowings [line items]
Borrowings	(42)	(27)
Derivatives
Disclosure of detailed information about borrowings [line items]
Borrowings	10	7
Derivatives | Cost
Disclosure of detailed information about borrowings [line items]
Borrowings	10	7
Derivatives | Cost | Not later than one year
Disclosure of detailed information about borrowings [line items]
Borrowings	10	7
Derivatives | Cost | Between one and five years
Disclosure of detailed information about borrowings [line items]
Borrowings	0	0
Derivatives | Cost | Later than five years
Disclosure of detailed information about borrowings [line items]
Borrowings	0	0
Derivatives | Unamortized debt discount and issuance costs
Disclosure of detailed information about borrowings [line items]
Borrowings	$ 0	$ 0

Non-current and current finan_6

Non-current and current financial debts - Maturity of interest expense (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about borrowings [line items]
Interest payable	$ 2,383	$ 1,017
Not later than one year
Disclosure of detailed information about borrowings [line items]
Interest payable	169	94
Between one and five years
Disclosure of detailed information about borrowings [line items]
Interest payable	651	340
Later than five years
Disclosure of detailed information about borrowings [line items]
Interest payable	$ 1,563	$ 583

Financial instruments - addit_3

Financial instruments - additional disclosures - Details of net financial assets and financial liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	$ 3,403	$ 3,767
Total financial liabilities	6,037	5,501
Net financial assets and financial liabilities	(2,634)	(1,734)
Financial debts | Senior notes due 2026, 2028, 2029, 2030, 2032, 2049 and 2052
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	4,541
Financial liabilities, at fair value	4,145
Financial debts | Senior notes due 2026, 2029, 2030, and 2049
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities		2,728
Financial liabilities, at fair value		2,891
Financial liabilities - measured at amortized cost or cost
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	5,929	5,382
Financial liabilities - measured at amortized cost or cost | Financial debts
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	97	107
Financial liabilities - measured at amortized cost or cost | Lease liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	71	67
Financial liabilities - measured at amortized cost or cost | Trade payables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	861	903
Financial liabilities - measured at amortized cost or cost | Current financial liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	1,029	1,077
Financial liabilities - measured at amortized cost or cost | Financial debts
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	4,541	3,966
Financial liabilities - measured at amortized cost or cost | Lease liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	359	339
Financial liabilities - measured at amortized cost or cost | Non-current financial liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	4,900	4,305
Financial liabilities - measured at FVPL
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	108	119
Financial liabilities - measured at FVPL | Contingent consideration liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	98	112
Financial liabilities - measured at FVPL | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial liabilities	10	7
Cash in current accounts
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	281	246
Cash held in time deposits and money market funds
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	699	1,329
Cash and cash equivalents
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	980	1,575
Financial assets - measured at fair value through other comprehensive income ("FVOCI")
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	88	46
Financial assets - measured at fair value through other comprehensive income ("FVOCI") | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	88	46
Financial assets - measured at amortized costs
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	2,168	1,979
Financial assets - measured at amortized costs | Trade receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	1,673	1,496
Financial assets - measured at amortized costs | Income tax receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	13	9
Financial assets - measured at amortized costs | Other current assets (excluding prepaid expenses and other current assets measured at FVPL)
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	303	309
Financial assets - measured at amortized costs | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	119	110
Financial assets - measured at amortized costs | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	38	35
Financial assets - measured at amortized costs | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	22	20
Financial assets - measured at fair value through profit and loss ("FVPL")
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	167	167
Financial assets - measured at fair value through profit and loss ("FVPL") | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	20	6
Financial assets - measured at fair value through profit and loss ("FVPL") | Equity securities of public companies
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	0	3
Financial assets - measured at fair value through profit and loss ("FVPL") | Deferred compensation assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	139	155
Financial assets - measured at fair value through profit and loss ("FVPL") | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Total financial assets	$ 8	$ 3

Financial instruments - addit_4

Financial instruments - additional disclosures - Schedule of fair value of assets and liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Valued at amortized cost or cost
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	$ (4,638)	$ (4,073)
Valued at amortized cost or cost | Non-current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(4,541)	(3,966)
Valued at amortized cost or cost | Current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(97)	(107)
Valued at amortized cost or cost
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	179	165
Current financial assets	303	309
Financial assets at fair value and amortized cost or cost	482	474
Valued at amortized cost or cost | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	119	110
Current financial assets	102	97
Valued at amortized cost or cost | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	38	35
Current financial assets	25	28
Valued at amortized cost or cost | VAT receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	99	105
Valued at amortized cost or cost | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	22	20
Valued at amortized cost or cost | Other receivables, security deposits and current assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	77	79
Recurring fair value measurement
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	426	372
Current financial assets	540	939
Financial assets at fair value and amortized cost or cost	966	1,311
Financial liabilities at fair value and amortized cost	(4,746)	(4,192)
Recurring fair value measurement | Contingent consideration liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(98)	(112)
Recurring fair value measurement | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(10)	(7)
Recurring fair value measurement | Valued at amortized cost or cost | Non-current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(4,541)	(3,966)
Recurring fair value measurement | Valued at amortized cost or cost | Current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(97)	(107)
Recurring fair value measurement | Equity securities of public companies
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets		3
Recurring fair value measurement | Deferred compensation assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	139	155
Recurring fair value measurement | Money market funds
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	229	624
Recurring fair value measurement | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	8	3
Recurring fair value measurement | Measured at FVOCI | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	88	46
Recurring fair value measurement | Measured at FVPL | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	20	6
Recurring fair value measurement | Valued at amortized cost or cost | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	119	110
Current financial assets	102	97
Recurring fair value measurement | Valued at amortized cost or cost | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	38	35
Current financial assets	25	28
Recurring fair value measurement | Valued at amortized cost or cost | VAT receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	99	105
Recurring fair value measurement | Valued at amortized cost or cost | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	22	20
Recurring fair value measurement | Valued at amortized cost or cost | Other receivables, security deposits and current assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	77	79
Recurring fair value measurement | Level 1
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	139	155
Current financial assets	229	627
Financial assets at fair value and amortized cost or cost	368	782
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 1 | Contingent consideration liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 1 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Non-current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 1 | Equity securities of public companies
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets		3
Recurring fair value measurement | Level 1 | Deferred compensation assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	139	155
Recurring fair value measurement | Level 1 | Money market funds
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	229	624
Recurring fair value measurement | Level 1 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 1 | Measured at FVOCI | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 1 | Measured at FVPL | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | VAT receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 1 | Valued at amortized cost or cost | Other receivables, security deposits and current assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 2
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	8	3
Financial assets at fair value and amortized cost or cost	8	3
Financial liabilities at fair value and amortized cost	(10)	(7)
Recurring fair value measurement | Level 2 | Contingent consideration liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 2 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	(10)	(7)
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Non-current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 2 | Equity securities of public companies
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets		0
Recurring fair value measurement | Level 2 | Deferred compensation assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 2 | Money market funds
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 2 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	8	3
Recurring fair value measurement | Level 2 | Measured at FVOCI | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 2 | Measured at FVPL | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | VAT receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 2 | Valued at amortized cost or cost | Other receivables, security deposits and current assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 3
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	108	52
Current financial assets	0	0
Financial assets at fair value and amortized cost or cost	108	52
Financial liabilities at fair value and amortized cost	(98)	112
Recurring fair value measurement | Level 3 | Contingent consideration liabilities
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	98	112
Recurring fair value measurement | Level 3 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Non-current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Current financial debt
Disclosure of fair value measurement of assets and liabilities [Line Items]
Financial liabilities at fair value and amortized cost	0	0
Recurring fair value measurement | Level 3 | Equity securities of public companies
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets		0
Recurring fair value measurement | Level 3 | Deferred compensation assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 3 | Money market funds
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 3 | Derivative financial instruments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 3 | Measured at FVOCI | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	88	46
Recurring fair value measurement | Level 3 | Measured at FVPL | Long-term financial investments
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	20	6
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Long-term receivables from customers
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Non-current minimum lease payments from finance lease agreements
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | VAT receivables
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Long-term loans, advances and security deposits
Disclosure of fair value measurement of assets and liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement | Level 3 | Valued at amortized cost or cost | Other receivables, security deposits and current assets
Disclosure of fair value measurement of assets and liabilities [Line Items]
Current financial assets	$ 0	$ 0

Financial instruments - addit_5

Financial instruments - additional disclosures - Activity in level 3 financial assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	$ 3,767
Balance as of December 31	3,403	$ 3,767
Measured at FVOCI
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	46
Balance as of December 31	88	46
Measured at FVPL
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	167
Balance as of December 31	167	167
Long-term financial investments | Measured at FVOCI
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	46
Balance as of December 31	88	46
Long-term financial investments | Measured at FVPL
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	6
Balance as of December 31	20	6
Long-term financial investments | Level 3 | Measured at FVOCI
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	46	28
Additions	45	18
(Loss) recognized in Consolidated Statement of Comprehensive Income/(Loss)	(2)	0
Unrealized gain/(loss) in Consolidated Income Statement	0	0
Amortization	0	0
Settlement	(1)	0
Balance as of December 31	88	46
Long-term financial investments | Level 3 | Measured at FVPL
Reconciliation of changes in fair value measurement, assets [abstract]
Balance as of January 1	6	24
Additions	0	0
(Loss) recognized in Consolidated Statement of Comprehensive Income/(Loss)	0	0
Unrealized gain/(loss) in Consolidated Income Statement	14	(3)
Amortization	0	(12)
Settlement	0	(3)
Balance as of December 31	$ 20	$ 6

Financial instruments - addit_6

Financial instruments - additional disclosures - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure of nature and extent of risks arising from financial instruments [line items]
Contingent amounts	$ 395	$ 395
Derivative assets (liabilities)	(2)	(4)
Derivative financial instruments	8	3
Current derivative financial liabilities	$ (10)	(7)
Debt at fixed interest rates	98%
Commodity price risk
Disclosure of nature and extent of risks arising from financial instruments [line items]
Reasonably possible change in risk variable, percent	10%
Interest rate risk [member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Reasonably possible change in risk variable, percent	1%
Reasonably possible change in risk variable, impact on loss before taxes	$ 9
Contingent consideration liabilities | Level 3
Disclosure of nature and extent of risks arising from financial instruments [line items]
Adjustments for changes in assumptions	23	42
Payments	$ 0	$ 15
Long-term target minimum
Disclosure of nature and extent of risks arising from financial instruments [line items]
Success probability	55,000,000%	55,000,000%
Long-term target maximum
Disclosure of nature and extent of risks arising from financial instruments [line items]
Success probability	57,000,000%	80,000,000%
Significant parameters, measurement input | Contingent consideration liabilities
Disclosure of nature and extent of risks arising from financial instruments [line items]
Percentage of possible increase in unobservable input, liabilities	10%
Percentage of reasonably possible decrease in unobservable input, liabilities	10%
Increase (decrease) in fair value due to possible increase in unobservable input, recognised in profit or loss, before tax, liabilities	$ 18
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, recognised in profit or loss, before tax, liabilities	$ 18
Long-term financial investments | Pricing, measurement input
Disclosure of nature and extent of risks arising from financial instruments [line items]
Percentage of possible increase in unobservable input, assets	10%
Percentage of reasonably possible decrease in unobservable input, assets	10%
Increase (decrease) in fair value due to increase in unobservable input, profit or loss, assets	$ 11
Increase (decrease) in fair value due to increase in unobservable input, comprehensive income, assets	11
Increase (decrease) in fair value due to decrease in unobservable input, comprehensive income, assets	11
Increase (decrease) in fair value due to decrease in unobservable input, profit or loss, assets	$ 11

Financial instruments - addit_7

Financial instruments - additional disclosures - Activity in level 3 financial liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of changes in fair value measurement, liabilities [abstract]
Balance as of January 1	$ (5,501)
Balance as of December 31	(6,037)	$ (5,501)
Level 3 | Contingent consideration liabilities
Reconciliation of changes in fair value measurement, liabilities [abstract]
Balance as of January 1	(112)	(157)
Accretion for passage of time	(9)	(12)
Adjustments for changes in assumptions	23	42
Payments	0	15
Balance as of December 31	$ (98)	$ (112)

Provisions and other non-curr_3

Provisions and other non-current liabilities - Provisions and other non-current liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accrued liability for employee benefits:
Defined benefit pension plans	$ 175	$ 295
Other long-term employee benefits and deferred compensation	160	177
Other post-employment benefits	221	300
Provisions for litigation and other legal matters	0	0
Contingent consideration	98	112
Other non-current liabilities	132	56
Total provisions and other non-current liabilities	$ 786	$ 940

Provisions and other non-curr_4

Provisions and other non-current liabilities - Additional information (Details) $ in Thousands	Mar. 23, 2022 USD ($)	Jun. 25, 2020 USD ($)	Jun. 23, 2020 case	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of other provisions [line items]
Provisions for litigation and other legal matters				$ 206,000	$ 53,000
Deferred Prosecution Agreement, term		3 years
Loss contingency amount	$ 20,000	$ 8,925
JJSVI patent and copyright infringement action
Disclosure of other provisions [line items]
Number of patents allegedly infringed | case			12
Provisions for litigation and other legal matters				$ 199,000

Provisions and other non-curr_5

Provisions and other non-current liabilities - Product liability, governmental investigations and other legal matters provision movements (Details) - Litigation and other legal matters - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in other provisions [abstract]
January 1	$ 53	$ 0	$ 0
Additions to provisions	175	54	9
Cash payments	(21)	(1)	(9)
Releases	(1)	0	0
December 31	206	53	0
Less current portion	(206)	(53)	0
Non-current provisions for litigation and other legal matters at December 31	$ 0	$ 0	$ 0

Provisions and other current _3

Provisions and other current liabilities - Provisions and other current liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Subclassifications of assets, liabilities and equities [abstract]
Accruals for compensation and benefits including social security	$ 465	$ 489
Accruals for deductions from revenue	386	264	$ 217	$ 212
Deferred income	89	108
Taxes other than income taxes	98	93
Restructuring provisions	64	17
Accrued expenses for goods and services received but not invoiced	95	76
Accruals for royalties	12	10
Provisions for litigation and other legal matters	206	53
Accrued equity-based payments	12	14
Accrued interest on financial debts	31	19
Other payables	66	58
Total provisions and other current liabilities	$ 1,524	$ 1,201

Provisions and other current _4

Provisions and other current liabilities - Accruals for deductions from revenue (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
January 1	$ 264	$ 217	$ 212
Additions	878	677	540
Impact of business combination	86	0	0
Payments/utilizations	(829)	(619)	(537)
Changes in offset against gross trade receivables	(3)	(5)	(2)
Currency translation effects	(10)	(6)	4
December 31	$ 386	$ 264	$ 217

Provisions and other current _5

Provisions and other current liabilities - Restructuring provisions (Details) - Restructuring provisions - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in other provisions [abstract]
January 1	$ 17	$ 10	$ 28
Additions	72	21	22
Cash payments	(24)	(14)	(40)
Releases	(1)	0	0
December 31	$ 64	$ 17	$ 10

Consolidated statement of cas_4

Consolidated statement of cash flows - additional details - Depreciation, amortization, impairments and fair value adjustments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	$ 1,111	$ 1,220	$ 1,626
Property, plant & equipment
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	332	323	299
Right-of-use assets
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	76	81	79
Intangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	715	815	1,245
Financial assets
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	(14)	3	5
Other non-current assets
Disclosure of detailed information about property, plant and equipment [line items]
Depreciation, amortization, impairments and fair value adjustments	$ 2	$ (2)	$ (2)

Consolidated statement of cas_5

Consolidated statement of cash flows - additional details - Change in net current assets and other operating cash flow items (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Statement [Abstract]
(Increase) in inventories	$ (217)	$ (326)	$ (159)
(Increase)/decrease in trade receivables	(164)	(198)	43
(Decrease)/increase in trade payables	(48)	60	(21)
Net change in other operating assets	(63)	(24)	127
Net payments out of provisions and other cash movements in non-current liabilities	(30)	174	(35)
Total	$ (522)	$ (314)	$ (45)

Consolidated statement of cas_6

Consolidated statement of cash flows - additional details - Reconciliation of assets and liabilities arising from financing activities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Liabilities
Proceeds from non-current financial debts, net of issuance costs	$ 1,815	$ 52	$ 744
Repayment of non-current financial debts	(1,176)	0	0
Lease liabilities
January 1, 2022	406
Payments of lease liabilities, net	(69)	(72)	(69)
December 31, 2022	430	406
Non-current financial debt
Financial Liabilities
January 1, 2022	3,966	3,949
Proceeds from non-current financial debts, net of issuance costs	1,815	52
Repayment of non-current financial debts	(1,176)
Amortization of discounts on financial debts	1	1
Changes in fair values and other non-cash changes, net	5	4
Currency translation effects	(23)	(40)
Reclassification from non-current to current	(47)
December 31, 2022	4,541	3,966	3,949
Current financial debt
Financial Liabilities
January 1, 2022	114	169
Proceeds from 2022 Bridge Loan Facility, net of issuance costs	771
Repayment of 2022 Bridge Loan Facility	(775)
Impact from business combination	316
Repayment of financial debts assumed in acquisition of business	(316)
Change in current financial debts	(42)	(43)
Changes in fair values and other non-cash changes, net	8
Currency translation effects	(16)	(12)
Reclassification from non-current to current	47
December 31, 2022	107	114	169
Non-current lease liabilities
Financial Liabilities
Impact from business combination	22
Lease liabilities
January 1, 2022	339	315
Additions to leases	68	106
Impact of asset acquisitions	2
Changes in fair values and other non-cash changes, net	(2)	(2)
Currency translation effects	(10)	(10)
Reclassification from non-current to current	(60)	(70)
December 31, 2022	359	339	315
Current lease liabilities
Financial Liabilities
Impact from business combination	5
Lease liabilities
January 1, 2022	67	70
Additions to leases	13	9
Impact of asset acquisitions	1
Payments of lease liabilities, net	(69)	(72)
Interest payments for amounts included in lease liabilities classified as cash flows from operating activities	(15)	(13)
Changes in fair values and other non-cash changes, net	13	8
Currency translation effects	(4)	(5)
Reclassification from non-current to current	60	70
December 31, 2022	$ 71	$ 67	$ 70

Consolidated statement of cas_7

Consolidated statement of cash flows - additional details - Non-cash investing and financing activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash Flow Statement [Abstract]
Treasury stock issued for settlement of equity-based compensation plan, net of withholding taxes	$ 128	$ 63	$ 54
Non-cash additions of right-of-use assets in exchange for a lease liability	81	115	107
Non-cash additions of property, plant & equipment	62	52	83
Non-cash additions of intangible assets	$ 105	$ 6	$ 33

Acquisitions - Purchase price a

Acquisitions - Purchase price allocation for business combinations (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about business combination [line items]
Goodwill	$ 8,970	$ 8,905
Business combinations
Disclosure of detailed information about business combination [line items]
Property, plant and equipment	27	0	$ 0
Right-of-use assets	29	0	0
Currently marketed products	850	0	0
Acquired in-process research & development	175	0	0
Deferred tax assets	189	0	0
Inventories	49	0	0
Trade receivables	70	0	0
Short-term investments	79	0	0
Cash and cash equivalents	78	0	0
Other assets	15	0	0
Lease liabilities	(27)	0	0
Deferred tax liabilities	(255)	0	0
Provisions and other non-current and current liabilities	(235)	0	0
Current income tax liabilities	(46)	0	0
Trade payables	(3)	0	0
Financial debts	(316)	0	0
Net identifiable assets acquired	679	0	0
Goodwill	65	0	0
Total purchase consideration	744	0	0
Acquired liquidity	(78)	0	0
Net assets recognized as a result of business combinations	$ 666	$ 0	$ 0

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions			1 Months Ended	12 Months Ended
	Nov. 21, 2022	Jan. 07, 2022	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Significant Transactions [Line Items]
Consideration paid				$ 666	$ 0	$ 0
Estimated potential undiscounted amount of future payments for contingent liability			$ 71	71
Contingent liability, discount			0.3
Pro forma net sales				8,776
Pro forma net income				192
Acquisitions of assets, net of cash acquired				485	$ 0	$ 0
Ivantis, Inc.
Significant Transactions [Line Items]
Percentage of voting equity interests acquired		100%
Acquisitions of assets, net of cash acquired				477
Outstanding shares and equity acquired		100%
Upfront payment		$ 479
Direct acquisition costs				2
Aerie
Significant Transactions [Line Items]
Percentage of voting equity interests acquired	100%
Price paid (in dollars per share)	$ 15.25
Consideration transferred	$ 744
Consideration paid	666
Contingent liability, acquisition	$ 57
Acquisition and integration costs				$ 20
Acquired business, increase in net sales			16
Acquired business, reduction in net income			$ 32

Acquisitions - Purchase price_2

Acquisitions - Purchase price allocation for asset acquisitions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Combinations And Asset Acquisitions [Abstract]
Currently marketed products	$ 385	$ 0	$ 0
Acquired in-process research & development	10	0	0
Other intangible assets (including software)	12	0	0
Deferred tax assets	57	0	0
Trade receivables	10	0	0
Inventory	16	0	0
Cash and cash equivalents	4	0	0
Other assets	6	0	0
Trade payables and other liabilities	(11)	0	0
Net identifiable assets acquired	489	0	0
Acquired liquidity	(4)	0	0
Net assets recognized as a result of asset acquisitions	$ 485	$ 0	$ 0

Post-employment benefits for _3

Post-employment benefits for associates - Additional information (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [line items]
Weighted average duration of defined benefit obligation				11 years 7 months 6 days	15 years 6 months
Defined contribution plans charges				$ 144	$ 133	$ 136
Provisions and Other Non-current Liabilities
Disclosure of defined benefit plans [line items]
Gain (loss) on plan amendment	$ (15)	$ (164)	$ 12
Other Income
Disclosure of defined benefit plans [line items]
Increase (decrease) in DBO	$ (15)	$ (164)
Other Expense
Disclosure of defined benefit plans [line items]
Increase (decrease) in DBO			$ 12
Benefit obligation
Disclosure of defined benefit plans [line items]
Top four countries, percentage				88%
Pension plans | United Kingdom | Foreign countries
Disclosure of defined benefit plans [line items]
Maximum number of years to eliminate shortfall				10 years
Other post-employment benefit plans | Benefit obligation | United States
Disclosure of defined benefit plans [line items]
Associates covered, percentage				99%

Post-employment benefits for _4

Post-employment benefits for associates - Summary of funded and unfunded DBO and net liability (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of net defined benefit liability (asset) [line items]
Past service costs and settlements	$ 0	$ 18	$ 154
Pension plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	270	315
Current service cost	20	24
Interest cost (income)	4	3
Past service costs and settlements	(3)	(18)
Administrative expenses	2	1
Currency translation effects	(4)	(17)
Employer contributions	19	23
Effect of acquisitions, divestments or transfers	0	14
Net defined benefit obligation (asset) at end of period	167	270	315
Funded status	(146)	(250)
Limitation on recognition of fund surplus at January 1	(20)	(17)
Change in limitation on recognition of fund surplus (including exchange rate differences)	(1)	(3)
Limitation on recognition of fund surplus at December 31	(21)	(20)	(17)
Pension plans | Benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	791	817
Current service cost	20	24
Interest cost (income)	12	9
Past service costs and settlements	(3)	(38)
Administrative expenses	2	1
Remeasurement (gains) arising from changes in financial assumptions	(185)	(22)
Remeasurement (gains)/losses arising from changes in demographic assumptions	(15)	0
Remeasurement losses/(gains) arising from experience-related changes	3	67
Currency translation effects	(31)	(35)
Benefit payments	36	37
Contributions of associates	(5)	(5)
Net defined benefit obligation (asset) at end of period	563	791	817
Pension plans | Plan assets
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	(541)	(519)
Interest cost (income)	(8)	(6)
Return on plan assets excluding interest income	(93)	49
Currency translation effects	27	18
Benefit payments	(36)	(37)
Employer contributions	19	23
Contributions of associates	5	5
Settlements	0	(20)
Effect of acquisitions, divestments or transfers	0	14
Net defined benefit obligation (asset) at end of period	(417)	(541)	(519)
Other post-employment benefit plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	300	332
Current service cost	8	10
Interest cost (income)	8	7
Past service costs and settlements	0	0
Administrative expenses	0	0
Currency translation effects	0	0
Employer contributions	14	13
Effect of acquisitions, divestments or transfers	0	0
Net defined benefit obligation (asset) at end of period	221	300	332
Funded status	(221)	(300)
Change in limitation on recognition of fund surplus (including exchange rate differences)	0	0
Other post-employment benefit plans | Benefit obligation
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	300	332
Current service cost	8	10
Interest cost (income)	8	7
Past service costs and settlements	0	0
Administrative expenses	0	0
Remeasurement (gains) arising from changes in financial assumptions	(62)	(12)
Remeasurement (gains)/losses arising from changes in demographic assumptions	0	1
Remeasurement losses/(gains) arising from experience-related changes	(19)	(25)
Currency translation effects	0	0
Benefit payments	18	17
Contributions of associates	(4)	(4)
Net defined benefit obligation (asset) at end of period	221	300	332
Other post-employment benefit plans | Plan assets
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit obligation (asset) at beginning of period	0	0
Interest cost (income)	0	0
Return on plan assets excluding interest income	0	0
Currency translation effects	0	0
Benefit payments	(18)	(17)
Employer contributions	14	13
Contributions of associates	4	4
Settlements	0	0
Effect of acquisitions, divestments or transfers	0	0
Net defined benefit obligation (asset) at end of period	$ 0	$ 0	$ 0

Post-employment benefits for _5

Post-employment benefits for associates - Reconciliation of net liability (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of net defined benefit liability (asset) [line items]
Past service costs and settlements	$ 0	$ (18)	$ (154)
Pension plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	(270)	(315)
Current service cost	(20)	(24)
Net interest expense	(4)	(3)
Administrative expenses	(2)	(1)
Past service costs and settlements	3	18
Remeasurements	104	4
Currency translation effects	4	17
Employer contributions	19	23
Change in limitation on recognition of fund surplus	(1)	(3)
Net defined benefit liability at end of period	(167)	(270)	(315)
Other post-employment benefit plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	(300)	(332)
Current service cost	(8)	(10)
Net interest expense	(8)	(7)
Administrative expenses	0	0
Past service costs and settlements	0	0
Remeasurements	81	36
Currency translation effects	0	0
Employer contributions	14	13
Change in limitation on recognition of fund surplus	0	0
Net defined benefit liability at end of period	(221)	(300)	$ (332)
Prepaid benefit cost | Pension plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	25
Net defined benefit liability at end of period	8	25
Prepaid benefit cost | Other post-employment benefit plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	0
Net defined benefit liability at end of period	0	0
Accrued benefit liability | Pension plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	(295)
Net defined benefit liability at end of period	(175)	(295)
Accrued benefit liability | Other post-employment benefit plans
Disclosure of net defined benefit liability (asset) [line items]
Net defined benefit liability at beginning of period	(300)
Net defined benefit liability at end of period	$ (221)	$ (300)

Post-employment benefits for _6

Post-employment benefits for associates - Breakdown of DBO for pension plans by geography and type of member (Details) - Pension plans - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	$ (563)	$ (791)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	(29)	(45)
Fair value of plan assets	417	541
Funded status	(146)	(250)
Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(356)	(501)
Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(94)	(151)
Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(113)	(139)
Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(78)	(99)
Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(97)	(196)
Country of domicile | Switzerland
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(236)	(329)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	0	0
Fair value of plan assets	175	195
Funded status	(61)	(134)
Country of domicile | Switzerland | Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(207)	(295)
Country of domicile | Switzerland | Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(6)	(11)
Country of domicile | Switzerland | Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(23)	(23)
Country of domicile | Switzerland | Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(35)	(47)
Country of domicile | Switzerland | Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(26)	(87)
Foreign countries | United States
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(95)	(126)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	0	0
Fair value of plan assets	64	91
Funded status	(31)	(35)
Foreign countries | United States | Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(32)	(43)
Foreign countries | United States | Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(28)	(41)
Foreign countries | United States | Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(35)	(42)
Foreign countries | United States | Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(24)	(29)
Foreign countries | United States | Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(7)	(6)
Foreign countries | Germany
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(77)	(115)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	0	0
Fair value of plan assets	17	21
Funded status	(60)	(94)
Foreign countries | Germany | Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(38)	(64)
Foreign countries | Germany | Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(18)	(28)
Foreign countries | Germany | Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(21)	(23)
Foreign countries | Germany | Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	0	0
Foreign countries | Germany | Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(60)	(94)
Foreign countries | United Kingdom
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(58)	(97)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	(6)	(24)
Fair value of plan assets	64	121
Funded status	6	24
Foreign countries | United Kingdom | Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	0	0
Foreign countries | United Kingdom | Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(33)	(57)
Foreign countries | United Kingdom | Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(25)	(40)
Foreign countries | United Kingdom | Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	0	0
Foreign countries | United Kingdom | Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	0	0
Foreign countries | Rest of the world
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(97)	(124)
Prepaid benefit costs and assets subject to limitation on recognition of fund surplus	(23)	(21)
Fair value of plan assets	97	113
Funded status	0	(11)
Foreign countries | Rest of the world | Active
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(79)	(99)
Foreign countries | Rest of the world | Deferred pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(9)	(14)
Foreign countries | Rest of the world | Pensioners
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(9)	(11)
Foreign countries | Rest of the world | Unfunded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	(19)	(23)
Foreign countries | Rest of the world | Unfunded portion of funded plans
Disclosure of net defined benefit liability (asset) [line items]
Defined benefit obligation, at present value	$ (4)	$ (9)

Post-employment benefits for _7

Post-employment benefits for associates - Weighted average actuarial assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Pension plans
Disclosure of defined benefit plans [line items]
Discount rate	3.60%	1.40%
Expected rate of pension increase	1.10%	1.10%
Expected rate of salary increase	2.50%	2.20%
Interest on savings account	2.90%	1.30%
Current average life expectancy for a 65-year-old male (in years)	20 years	20 years
Current average life expectancy for a 65-year-old female (in years)	22 years	22 years
Pension plans | Switzerland | Country of domicile
Disclosure of defined benefit plans [line items]
Discount rate	2.20%	0.20%
Pension plans | United States | Foreign countries
Disclosure of defined benefit plans [line items]
Discount rate	5.30%	2.80%
Pension plans | Germany | Foreign countries
Disclosure of defined benefit plans [line items]
Discount rate	3.70%	1.20%
Pension plans | United Kingdom | Foreign countries
Disclosure of defined benefit plans [line items]
Discount rate	4.80%	1.90%
Other post-employment benefit plans
Disclosure of defined benefit plans [line items]
Discount rate	5.30%	2.70%
Expected rate of pension increase
Expected rate of salary increase
Interest on savings account
Current average life expectancy for a 65-year-old male (in years)	21 years	21 years
Current average life expectancy for a 65-year-old female (in years)	23 years	23 years
Other post-employment benefit plans | United States | Foreign countries
Disclosure of defined benefit plans [line items]
Discount rate	5.30%	2.70%

Post-employment benefits for _8

Post-employment benefits for associates - Sensitivity analysis (Details) $ in Millions	Dec. 31, 2022 USD ($)
Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Increase (decrease) in defined benefit obligation due to increase in actuarial assumption	$ (22)
Increase (decrease) in defined benefit obligation due to decrease in actuarial assumption	23
Life expectancy
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Increase (decrease) in defined benefit obligation due to increase in actuarial assumption	14
Rate of pension increase
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Increase (decrease) in defined benefit obligation due to increase in actuarial assumption	6
Increase (decrease) in defined benefit obligation due to decrease in actuarial assumption	(3)
Interest on savings account
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Increase (decrease) in defined benefit obligation due to increase in actuarial assumption	2
Increase (decrease) in defined benefit obligation due to decrease in actuarial assumption	(3)
Rate of salary increase
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Increase (decrease) in defined benefit obligation due to increase in actuarial assumption	3
Increase (decrease) in defined benefit obligation due to decrease in actuarial assumption	$ (3)

Post-employment benefits for _9

Post-employment benefits for associates - Healthcare cost trend rate assumptions used for other post-employment benefits (Details) - Other post-employment benefit plans	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of defined benefit plans [line items]
Healthcare cost trend rate assumed for next year	6.30%	6.20%	6.20%
Rate to which the cost trend rate is assumed to decline	4.50%	4.50%	4.50%

Post-employment benefits for_10

Post-employment benefits for associates - Weighted average plan asset allocation (Details) - Pension plans	Dec. 31, 2022	Dec. 31, 2021
Disclosure of fair value of plan assets [line items]
Equity securities, allocation percentage	37%	35%
Debt securities, allocation percentage	34%	40%
Real estate, allocation percentage	14%	11%
Alternative investments, allocation percentage	12%	11%
Cash and other investments, allocation percentage	3%	3%
Total, allocation percentage	100%	100%
Long-term target minimum
Disclosure of fair value of plan assets [line items]
Equity securities, target	15%
Debt securities, target	20%
Real estate, target	5%
Alternative investments, target	0%
Cash and other investments, target	0%
Long-term target maximum
Disclosure of fair value of plan assets [line items]
Equity securities, target	40%
Debt securities, target	60%
Real estate, target	20%
Alternative investments, target	20%
Cash and other investments, target	15%

Post-employment benefits for_11

Post-employment benefits for associates - Schedule of expected future cash flows (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Pension plans
Employer contributions
2023 (estimated)	$ 11
Other post-employment benefit plans
Employer contributions
2023 (estimated)	0
2023 | Pension plans
Expected future benefit payments
Settlements	36
2023 | Other post-employment benefit plans
Expected future benefit payments
Settlements	16
2024 | Pension plans
Expected future benefit payments
Settlements	43
2024 | Other post-employment benefit plans
Expected future benefit payments
Settlements	18
2025 | Pension plans
Expected future benefit payments
Settlements	40
2025 | Other post-employment benefit plans
Expected future benefit payments
Settlements	19
2026 | Pension plans
Expected future benefit payments
Settlements	34
2026 | Other post-employment benefit plans
Expected future benefit payments
Settlements	20
2027 | Pension plans
Expected future benefit payments
Settlements	32
2027 | Other post-employment benefit plans
Expected future benefit payments
Settlements	20
2028-2032 | Pension plans
Expected future benefit payments
Settlements	193
2028-2032 | Other post-employment benefit plans
Expected future benefit payments
Settlements	$ 97

Equity-based compensation - Add

Equity-based compensation - Additional information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) metric	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Equity-based compensation expense	$ 152	$ 151	$ 113
Accrued equity-based payments	$ 12	$ 14
Remaining weighted-average vesting period	1 year 2 months 12 days
Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period	3 years
Number of metrics | metric	4
Swiss Employee Share Ownership Plan and Other Share Savings Plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Holding period	3 years
Minimum | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Target incentive percentage	35%
Payout percent	0%
Maximum | Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Target incentive percentage	430%
Payout percent	200%

Equity-based compensation - Sum

Equity-based compensation - Summary of non-vested share movements (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) shares $ / shares	Dec. 31, 2021 USD ($) shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Unvested shares at January 1 (in shares) | shares	5,627	5,417
Vested (in shares) | shares	(2,447)	(1,258)
Forfeited (in shares) | shares	(358)	(417)
Unvested shares at December 31 (in shares) | shares	4,793	5,627
Outstanding, beginning balance, weighted average fair value at grant date (in dollars per share) | $ / shares	$ 60.96	$ 54.90
Vested, weighted average fair value at grant date (in dollars per share) | $ / shares	55.48	50.94
Forfeited, weighted average fair value at grant date (in dollars per share) | $ / shares	71.74	62.50
Outstanding, ending balance, weighted average fair value at grant date (in dollars per share) | $ / shares	$ 69.16	$ 60.96
Fair value, beginning balance, unvested | $	$ 343	$ 297
Fair value, vested | $	(136)	(64)
Fair value, forfeited | $	(26)	(26)
Fair value, ending balance, unvested | $	$ 331	$ 343
Restricted awards
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted (in shares) | shares	1,453	1,456
Granted, weighted average fair value at grant date (in dollars per share) | $ / shares	$ 76.61	$ 72.05
Fair value, granted | $	$ 111	$ 105
Performance awards
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted (in shares) | shares	518	429
Granted, weighted average fair value at grant date (in dollars per share) | $ / shares	$ 74.48	$ 72.71
Fair value, granted | $	$ 39	$ 31

Equity-based compensation - S_2

Equity-based compensation - Summary of shares authorized (Details) shares in Thousands	Dec. 31, 2022 shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized shares (in shares)	22,250
Long-term Incentive Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized shares (in shares)	20,000
Deferred Bonus Stock Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized shares (in shares)	1,500
Swiss Employee Share Ownership Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized shares (in shares)	475
Other share savings plans
Disclosure of terms and conditions of share-based payment arrangement [line items]
Authorized shares (in shares)	275

Related parties transactions -

Related parties transactions - Key management compensation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Related Party [Abstract]
Cash and other compensation	$ 18.7	$ 19.3	$ 12.8
Post-employment benefits	0.9	0.9	1.1
Equity-based compensation	22.4	20.9	9.2
Total	$ 42	$ 41.1	$ 23.1

Commitments and contingencies -

Commitments and contingencies - Research and development payments (Details) $ in Millions	Dec. 31, 2022 USD ($)
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	$ 175
2023
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	6
2024
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	18
2025
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	24
2026
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	3
2027
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	41
Thereafter
Disclosure of contingent liabilities [line items]
Commitments to make payments under R&D arrangements	$ 83

Subsequent events - Additional

Subsequent events - Additional Details (Details) $ in Millions, ¥ in Billions				1 Months Ended
	Feb. 27, 2023 USD ($)	Feb. 27, 2023 SFr / shares	Feb. 14, 2023 USD ($)	Feb. 28, 2022	Feb. 14, 2023 JPY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Disclosure of non-adjusting events after reporting period [line items]
Borrowings						$ 4,648	$ 4,080
Local bilateral facilities, Japan
Disclosure of non-adjusting events after reporting period [line items]
Borrowings			$ 170			$ 69
Borrowings, term				1 year
Potential ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Dividends declared (per share) | SFr / shares		SFr 0.21
Dividends declared, amount	$ 113
Debt transactions
Disclosure of non-adjusting events after reporting period [line items]
Borrowings, term			2 years
Debt transactions | Local bilateral facilities, Japan
Disclosure of non-adjusting events after reporting period [line items]
Borrowings | ¥					¥ 22.5

Alcon subsidiaries - Equity int

Alcon subsidiaries - Equity interests (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Disclosure of subsidiaries [line items]
Total asset and net sales threshold	$ 5
Alcon Laboratorios Argentina S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (Australia) Pty Ltd
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Ophthalmika GmbH
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories Belgium BVBA
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon N.V.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Brasil Cuidados com a Saúde Ltda.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Canada Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratorios Chile Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon (China) Ophthalmic Product Co., Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Hong Kong Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Laboratorios Alcon de Colombia S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Pharmaceuticals (Czech Republic) s.r.o.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Nordic A/S
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
AlconLab Ecuador S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Laboratoires Alcon S.A.S.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Deutschland GmbH
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
CIBA Vision GmbH
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
WaveLight GmbH
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories Hellas- Single Member Commercial and Industrial S.A.C.I.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Hungary Pharmaceuticals Trading Limited Liability Company
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (India) Private Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
PT. CIBA Vision Batam
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories Ireland Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Aerie Pharmaceuticals Ireland Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Optonol Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Italia S.p.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Japan Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (Malaysia) Sdn. Bhd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
CIBA Vision Johor Sdn. Bhd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratorios, S.A. de C.V.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Finance B.V.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Nederland B.V.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (New Zealand) Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Centroamerica S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Pharmaceutical del Peru S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (Philippines), Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Polska Sp. z o.o.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon (Puerto Rico), Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Romania S.R.L.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Farmacevtika LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Pte Ltd
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Singapore Manufacturing Pte Ltd
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
CIBA Vision Asian Manufacturing and Logistics Pte Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (South Africa) (Pty) Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Korea Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Healthcare S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Grieshaber AG
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Management SA
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Pharmaceuticals Ltd.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Services AG
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Switzerland SA
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories (Thailand) Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratuvarlari Ticaret A.S.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Ukraine LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Eye Care UK Limited
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Aerie Distribution, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Aerie Pharmaceuticals, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Finance Corporation
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratories, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon RefractiveHorizons, LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Research, LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Vision, LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
CIBA Vision, LLC
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
WaveLight, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Ivantis, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
MDBackline, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
PowerVision, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Tear Film Innovations, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
TrueVision Systems, Inc.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%
Alcon Laboratorios Uruguay S.A.
Disclosure of subsidiaries [line items]
Proportion of voting rights held in subsidiary	100%